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ABSTRACT
This thesis described the development of a pragmatic, randomized clinical trial 
evaluating the safety and efficacy of antipsychotic treatment in schizophrenia. In the 
perspective of highlighting some critical issues of the trial design, the thesis focused on 
the trial's planning and conduct and on the preliminary analysis of the first followed-up 
subjects.
Having experienced significant problems in patient recruitment a survey on perceived 
inclusion barriers and antipsychotic preference was performed. Investigators mainly 
complained about system-related barriers, and believed in the superiority of second- 
generation antipsychotics. Taking the cue from these results, strategies were adopted 
in order to reach the planned target of 800 subjects. Remedial actions included study 
promotion activities, education initiatives and bursaries, and resulted in a significant 
improvement of the recruitment rate. Nevertheless, we had to reduce the sample to 
one third of the original size.
The second part of the thesis focused on the concept of endpoints using a secondary 
analysis of existing data and a preliminary analysis of GiSAS trial data. The assumption 
that differences in discontinuation rates reflect differences in effectiveness was 
reinforced by the results of a pharmaco-epidemiological study comparing the use of 
reboxetine and SSRIs in a large population sample. The established lack of efficacy of 
this antidepressant was mirrored by a higher proportion of treatment discontinuations. 
We explored the baseline characteristics of 114 included subjects and compared the 
baseline and follow-up variables between those who discontinued study drugs at 
follow-up and those who did not. Discontinues' worse outcome was mainly 
attributable to self reported side-effects.
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This thesis highlighted some critical issues on the execution of a pragmatic trial in 
schizophrenia. The feasibility of the trial design and the concept of endpoints were 
critically analyzed. The trial mechanism is now fully functional and most problems of its 
implementation have been identified and contained.
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CHAPTER I
GiSAS TRIAL: BACKGROUND, RATIONALE AND METHODS
1*. Background
Debate over old versus new antipsychotics
Schizophrenia is a serious and disabling mental illness characterized by positive 
symptoms (such as delusions and hallucinations) and negative symptoms (such as lack 
of motivation and social withdrawal). It  usually needs long-term therapy and can 
produce far-reaching effects on personality, cognition, global functioning and quality of 
life. Antipsychotic drugs are the cornerstone of the pharmacological treatment of 
schizophrenia. First Generation Antipsychotics (FGAs) are high-affinity antagonists of 
dopamine D2 receptors. Their short-term benefits in controlling positive psychotic 
symptoms, together with high rates of neurological side effects, such as 
parkinsonism, akathisia and tardive dyskinesia, are well documented. Flowever, 
long-term data are too few and there is no convincing evidence that FGAs exert 
any effect on the negative symptoms of schizophrenia [1-3].
The introduction of second generation antipsychotics (SGAs) promised enhanced 
efficacy and safety. While FGAs were characterized by predominant dopaminergic 
blockade, SGAs had significant affinity for a broader and somewhat diversified 
range of receptors, especially the serotonin 5-FIT2 receptor [4]. Clozapine, the 
first representative of this new class of drugs, was developed in the early 1960s 
as an antipsychotic with low affinity with D2 receptors and minimally associated 
extrapyramidal symptoms (EPS) [5]. Initial enthusiasm for the novelty of the 
mechanism of action of clozapine, which based on a more potent effect on the 
symptoms of schizophrenia, was seriously tempered by the occurrence of serious 
blood dyscrasias and patient deaths. Thus, clozapine was briefly marketed and 
quickly withdrawn before it recovered its reputation [5, 6] a decade later.
Nonetheless, the introduction of clozapine refuted the hypothesis that EPS and 
antipsychotic efficacy were linked and paved the way to the search for a new 
generation of antipsychotics that might be better tolerated and more effective 
than FGAs. The supposed superiority of SGAs over FGAs was questioned by early 
reviews [7, 8]. Studies indicated that SGAs are effective in reducing psychotic 
symptoms and produce few neurological effects. The evidence of their greater 
efficacy, however, resulted neither consistent nor robust [7, 8]. Moreover, 
although there is evidence of a lower risk of extrapyramidal side effects, they 
were reported to cause metabolic side effects like weight gain, dyslipidemia and 
impaired fasting glucose [9]. Only clozapine, after a bumpy road of withdrawal 
and review, was clearly more effective in patients whose symptoms do not 
respond to other antipsychotics, but severe side effects and the need for blood 
cell count monitoring limit its use in community settings [6, 10, 11].
In a recent meta-analysis, including 150 double-blind trials, some SGAs showed to 
be more efficacious than FGAs in terms of symptom relief, with small effect sizes 
for amisulpride, olanzapine and risperidone and with a medium effect size for 
clozapine [12]. However, most of the trials included in the analysis recruited 
highly selected samples adopting short-term follow-up and investigator-scored 
efficacy measures. These features limit the reliability, the external validity, and 
the generalizability of the results. Moreover, in another meta-analysis focusing on 
the metabolic side-effects of SGAs, olanzapine and clozapine had the worst profile 
[13].
Initial enthusiasm for the "atypical" effect of SGAs has gradually waned, while 
there has been a growing concern about the rapidly escalating costs of this class 
of medication [14, 15]. Public institutions and researchers have become 
increasingly suspicious about the evidence on antipsychotic medications, most of
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which comes from industry-sponsored trials [16 / 17]. Thus, there is need to 
further investigate the effectiveness of both FGAs and SGAs in pragmatic 
independent trials [18, 19].
Recent pragmatic findings on antipsychotics
Many worthwhile treatment effects on major outcomes in medicine are only of 
moderate size and their evaluation requires large-scale studies. RCTs need to be 
large to minimize systematic bias and random error and to measure treatment 
effects reliably and precisely. Moreover, they need to be simple to minimize the 
additional clinical workload and help to maximize widespread collaboration [18- 
20]. Recently, three landmark independent studies, CATIE, CUtLASS and EUFEST, 
casted further doubts on the effectiveness of SGAs vs. FGAs in schizophrenia. All 
those randomized clinical trials (RCTs) shared many features of so-called large 
and simple trials: sufficient power, few exclusion criteria, sound endpoints and 
simple study designs (See Table 1).
The US Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study 
was conducted between 2001 and 2004 at 57 clinical sites in the United States [21]. 
The trial included both a phase 1 and a phase 2. The phase 1 was a double-blind 
trial in which patients affected by chronic schizophrenia were randomized under 
double-blind conditions to one of the SGAs olanzapine, quetiapine, risperidone, 
ziprasidone or to the FGA perphenazine and followed-up for 18 months. The 
primary endpoint was time to treatment discontinuation for any cause, chosen to 
reflect clinical practice. Among the secondary outcomes there were the specific 
reasons for discontinuation of treatment (e.g. inefficacy or intolerability owing to side 
effects such as weight gain, extrapyramidal signs, or sedation as judged by the study 
doctor) [21].
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In a subsequent trial (phase 2) those participants who discontinued the first 
phase because of lack of efficacy were re-randomized to an open-label 
comparison between clozapine and the other SGAs [22].
In CATIE phase 1 a total of 1,493 patients were enrolled and randomly assigned to 
treatment and 1,432 (96%) were included in the analysis: olanzapine (n=330), 
quetiapine (n=329), risperidone (n=333), ziprasidone (n=183) or to the FGA 
perphenazine (n=257). Overall 74% of patients in the intention-to-treat analysis 
discontinued the assigned treatment before 18 months. The time to discontinuation of 
treatment for any reason was longer in the olanzapine group than in the quetiapine 
group and the risperidone group. By contrast, the difference between the olanzapine 
group and the perphenazine or the ziprasidone group was not significant. However, the 
time to discontinuation of treatment for lack of efficacy was longer in the olanzapine 
group than in the perphenazine group. Referring to antipsychotic safety profile, time 
until discontinuation owing to intolerable side effects was similar among the groups 
even with a trend toward statistical significance (P=0.054). However, rates were 
significantly different: olanzapine was associated with more discontinuation for weight 
gain or metabolic effects, and perphenezine was associated with more discontinuation 
for extrapyramidal effects [21].
The UK Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia (CUtLASS) 
study comprised a pair of smaller open-label trials comparing FGAs vs. SGAs in 
terms of quality of life (QLS) at one year [23, 24]. The authors considered as 
clinically meaningful a difference in the QLS scores between the 2 arms of 5 
points from baseline to 12 months. In CUtLASS-2, clozapine was compared with 
the other SGAs in 136 patients non-responders to antipsychotic drugs. In 
CUtLASS-1, 227 people with schizophrenia were randomized to either the class of 
FGAs (n=118) or the class of SGAs (n=109), with the exclusion of clozapine.
Contrary to the primary hypothesis, the estimate of 5 points in favor of SGAs was 
excluded and the apparent advantage for FGAs, an effect opposite to the 
hypothesis, did not reach statistical significance (P =0.24).
Both the CATIE and the CUtLASS study failed in finding clinically relevant 
differences between SGAs and FGAs in terms of effectiveness or tolerability [21, 
23]. On the other hand, they found clozapine to be more effective in refractory 
schizophrenia, and the prescription of FGAs to be associated with lower costs and 
higher quality-adjusted life-years [22, 24-26].
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The European First Episode Schizophrenia Trial (EUFEST) study was a pragmatic 
open randomized-controlled trial in which a wide group of European psychiatrists and 
researchers compared the effectiveness of low doses of haloperidol with SGAs in first- 
episode schizophrenia [27]. The study hypothesis was based on the conclusions of a 
meta-regression analysis by Geddes et al. (2000), suggesting that trials demonstrating 
the inferiority of first- versus second-generation antipsychotics used too high doses of 
haloperidol [8]. Like CATIE, the EUFEST study adopted all-cause treatment 
discontinuation at one year as primary endpoint, randomly assigning 498 subjects 
affected to haloperidol (n=103), amisulpride (n=104), olanzapine (n=105), quetiapine 
(n=104) or ziprasidone (n=82). The proportion of drug discontinuation was 72% for 
haloperidol, 40% for amisulpride, 33% for olanzapine and 53% for quetiapine. Thus, 
results showed that patients on low dose haloperidol had a greater treatment 
discontinuation at one year than patients on all of the second-generation 
antipsychotics. Moreover, global improvement as measured by CGI and GAF scale 
differed between treatment with most improvement recorded with amisulpride and 
least with quetiapine and haloperidol. On the other hand, symptom reductions, as 
measured by PANSS, and hospital admission rates did not show any difference. Those 
results led the authors to conclude that since discontinuation rates were not consistent 
with symptomatic improvement the superiority of second-generation antipsychotics 
versus haloperidol has not been confirmed [27].
Finally, two papers presenting data from CATIE and EUFEST reported no significant 
differences between FGAs and SGAs in terms of cognitive test performance [28, 29].
Clinical equipoise and the uncertainty principle
The concept of 'equipoise' holds that randomization is appropriate when there is 
substantial uncertainty as to which treatment is likely to provide greatest clinical 
benefit. This concept has been represented by many authors as a central ethical
15
principle of human experimentation [30-44]. As stated by Richard Ascroft: "It is widely 
maintained that a clinical trial is ethical only if some form of equipoise between th e . 
treatments being compared obtains. To be in equipoise between two treatments A and 
B is to be cognitively indifferent between the statement 'A is strictly more effective 
than B' and its negation ... Equipoise regarding A and B is necessary for randomized 
assignment to treatments A and B to be beneficent and non-maleficent and is sufficient 
for such an assignment to be fair" [30].
The ethical basis of equipoise has seldom been challenged. Surely physicians can 
ethically randomly assign patients to treatments if uncertainty exists. In this case, in 
fact, no trial participant would be given inferior treatment. However, some contrary 
considerations should be taken into account [45, 46]. Equipoise principle narrowly 
locates the ethical dilemma of human experimentation within the doctor-patient 
relationship [45]. In this framework, RCTs are subordinate to the delivery of optimal 
medical care and their value in developing new scientific knowledge is somewhat 
underrated. There is no definitive consensus on the boundaries of uncertainty, as its 
proponents have not yet clarified how to determine when it exists [45, 46]. An 
approximately 50-50 split in expert opinion is unlikely and, if literally interpreted, would 
substantially obstacle randomized clinical research. The reliance on expert opinion is 
another weak point of the classical formulation of the uncertainty principle [45]. The 
fact that the most rigorous approach to produce unbiased evidence should be allowed 
by mere expert opinion appears, in fact, somewhat contradictory.
These conflicting views suggest some caveats in the interpretation and application of 
the equipoise principle to RCTs. The reigning concept of equipoise makes no reference 
to the cost-effectiveness of treatments. Some new treatments could hardly justify their 
high costs in the light of their small advantages. On the other hand, the cost dimension 
could introduce significant levels of uncertainty in comparisons which otherwise would 
be considered unethical, thus generating rigorous knowledge to guide health policy
decisions [45]. Finally, equipoise promotes early discontinuation of RCTs based on 
interim data related to treatment benefit, and systematic reviews showed how the 
increasing incidence of these premature terminations could result in an overestimation 
of treatment benefits [47-49].
Clinical equipoise is a nuanced concept dependent on the existence of controversy 
about the relative value of two treatments being compared [50]. It  should therefore 
not be literally interpreted. One possible reformulation of the equipoise principle in the 
context of RCTs has been proposed by Djulbegovic et al. (2000): "participants will not 
suffer relative harm from random assignment to a particular treatment arm; the results 
of a study cannot be predicted consistently in advance; and over a number of RCTs 
those proving or failing to prove an hypothesis will be approximately equal in number" 
[37].
Clinical equipoise, generally requires a trial design that will compare two treatments 
under the conditions in which they would be applied in practice and answer the 
question of which treatment should we prefer [51]. The observance of this principle 
should therefore be an important starting point in planning a phase IV, unblinded., 
pragmatic RCT. The aim of a pragmatic or effectiveness trial is to compare 
interventions within everyday clinical practice, and in this context no patient could be 
given inferior treatment. Moreover, as those trials deal with well-known therapies the 
existence of a state of clinical equipoise can be more clearly defined. Finally, the 
parameter of cost-effectiveness is usually taken into account in pragmatically defining 
the advantages or disadvantages of already marketed drugs.
If  the ethical basis for planning a pragmatic trial should rely on equipoise, the ethical 
dilemma of whether to enter a patients in a randomized comparison refers to the so- 
called uncertainty principle [52]. This distinction has been made by some authors 
according to whom equipoise reflects a failure of general consensus within the clinical 
community whereas uncertainty reflects the personal belief of a single physician who
17
might be convinced that one treatment is better than another for a given patient. 
Uncertainty has been argued not to be a solid moral basis to opt for randomization. 
Under this subjective principle it would, in fact, be difficult to establish if a physician 
errs in excluding (or including) a patient from a trial [52]. However, uncertainty is an 
unavoidable prerequisite for randomization [53]. A responsible physician would hardly 
participate in an effectiveness trial if he or she is certain that one arm is superior to the 
others and that some of his or her patients will receive an inferior treatment by being 
randomized [52, 53].
Metabolic effects of new antipsychotics
Even if a better tolerability profile in terms of extrapyramidal side effects for SGAs has 
been recognized, an increasing number of reports concerning weight gain diabetes, 
ketoacidosis, hyperglycemia and lipid dysregulation in patients treated with SGAs have 
raised concerns about a possible association with metabolic effects [54, 55].
Metabolic syndrome is characterized by the combination of hyperinsulinaemia, low 
glucose tolerance, dyslipidaemia, hypertension, and abdominal obesity. This cluster has 
been recognized for many years, but the syndrome was not formally labelled until 
Reaven did so in 1988 and suggested that insulin resistance was its central 
characteristic [56]. Insulin resistance seems to be the main underlying factor leading to 
the increased risk of mortality from coronary heart disease among people with the 
syndrome. The clinical identification of metabolic syndrome is based on measures of 
abdominal obesity, atherogenic dyslipidaemia, hypertension, and glucose intolerance. 
The World Health Organization's definition of metabolic syndrome requires evidence of 
insulin resistance and measurement of fasting insulin or its surrogates as essential 
criteria [57]. The Adult Treatment Panel I I I  of the US National Cholesterol Education 
Program (NCEP) , however, proposed a simpler definition, developed for clinical use 
and not including any estimation of insulin resistance [58, 59]. People meeting three of
18
the following criteria qualify as having the metabolic syndrome: high blood pressure 
(>130/85 mm Hg), low serum concentration of HDL cholesterol (<40 mg/dl in men or 
<50 mg/dl in women), high serum triglyceride concentration (>150 mg/dl), high 
fasting plasma glucose concentration (>110 mg/dl), and abdominal obesity (waist 
circumference >102 cm/40 inches in men and >88 cm/35 inches in women). A new 
definition, recently proposed by the International Diabetes Federation, has central 
obesity as an essential criterion, with a range of cut-offs for waist circumference for 
people from different ethnic groups [60]. Metabolic syndrome tends to evolve gradually 
and the presence of one or two features of the syndrome was found to be associated 
with increased risk of mortality from coronary heart disease and cardiovascular disease 
[61].
The prevalence of metabolic syndrome in the general adult population in developed 
countries is 22-39% and varies depending on the definition used and on ethnicity [62, 
63]. Outcome data from the CATIE Schizophrenia Trial have provided important 
information on the metabolic and clinical impact of antipsychotic treatment for those 
subjects with metabolic syndrome and other medical comorbidities. Using baseline 
data, assessment of metabolic syndrome prevalence was performed based on NCEP 
criteria, and also using a fasting glucose threshold of 100 mg/dl (AHA) [64]. Among 
the 689 participants meeting inclusion criteria and applying both the NCEP and AHA 
derived criteria, the prevalence of metabolic syndrome was 40.9% and 42.7%  
respectively. In females it was 51.6% (NCEP) and 54.2% (AHA), compared to 36.0%  
(p=0.0002) and 36.6% (p=0.0003) in males respectively. 73.4% of all females 
(including non fasting subjects) met the waist circumference criterion compared to 
36.6% of males. Comparative analyses were performed using a randomly selected 
sample from national general population estimates (NHANES II I )  [65]. In a logistic 
regression model with age, race and ethnicity as covariates, CATIE males were 138% 
more likely to have metabolic syndrome than the matched sample, and CATIE females
19
251% more likely than their counterparts. Even when controlling for differences in 
body mass index, GATIE males were still 85% more likely to have metabolic syndrome 
than the matched male sample, and CATIE females 137% more likely to have 
metabolic syndrome than females in the comparison group. Similarly, using baseline 
data from the same CATIE Trial, metabolic syndrome was found to be strongly 
associated with a poor self-rating of physical health and increased somatic 
preoccupation. There were no significant differences between the two groups on 
measures of symptom severity, depression, quality of life, cognition, or self-rated 
mental health. Neither years of antipsychotic exposure nor alcohol usage were 
significant predictors of metabolic syndrome status when adjusted for age, gender, 
race, and ethnicity [65].
Mortality in schizophrenia
There are extensive data linking people affected by schizophrenia or related psychosis 
to an elevated mortality risk [66]. Schizophrenic patients do not only have higher 
suicide rates but are at increased risk for premature death due to somatic conditions 
too [67]. Best available evidence shows that the differential mortality gap between 
people with schizophrenia and the general population has worsened in recent decades, 
with an almost linear increase in the standardized mortality ratio (SMR) from 1.84 in 
the 70s to 3.20 in the '90s [68]. This is somewhat inconsistent with the increased 
focus on comprehensive care and increase availability of treatment options for people 
affected by serious mental illness, which would have involved an improvement of life 
expectancy. Explanations for this increased mortality risk are complex and of 
multifactorial origin. Weight gain, smoking, poor diet and physical activity certainly play 
a significant role. Those risk factors are directly associated with the psychotic illness 
itself, as schizophrenic negative symptoms could be common underlying causes of 
most of these unhealthy behaviours. However, life-style or disease-specific risk factors
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may not be sufficient to explain the entire differential mortality. In the last few years 
concern has grown about the well-known side-effects of antipsychotics and about the 
fact that they may have further contributed to shorten the lifespan of people with 
schizophrenia. Many FGAs and SGAs can cause significant weight gain, metabolic 
syndrome, diabetes mellitus, and cardiovascular disorders [54, 55, 66]. Moreover, 
evidence is accumulating linking antipsychotics to an increased risk of sudden cardiac 
death [69]. In fact, the prolongation of the QT interval induced by those drugs is 
advocated as one important causal mechanism for the ventricular tachyarrhythmias 
that often lead to sudden cardiac death. Weinmann et al. (2009) reviewed studies 
assessing the association between antipsychotic exposure and risk of death in 
schizophrenia concluding that although some evidence supports the hypothesis that 
long-term antipsychotic therapy may increase mortality, insufficient research attention 
has so far been devoted to this important issue [70].
All these results underline the need to take an active role in monitoring the physical 
health of patients with schizophrenia and to estimate the real impact of long term 
antipsychotic treatment on medical comorbidity and drug tolerability.
Indicators of cardiovascular risk
Cardiovascular diseases are among major threats to the future worldwide public health. 
Success in reducing cardiovascular mortality has been partially achieved. However, the 
aging of the population and the difficult reduction in risk factor prevalence will require 
more innovative approaches to predict and prevent major cardiovascular accidents. 
The metabolic syndrome is a constellation of closely related risk factors and represents 
a way of assimilating risk across the various pathogenetic pathways related to obesity 
[57-63]. Obesity is a major risk factor for cardiovascular disease, but the most 
predictive measure for different ethnic populations is still not clear. The World Health 
Organisation recognizes the body-mass index (BMI) as a universal criterion of
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overweight (>25) and obesity (>30); measures of waist circumference (WC) or waist- 
to-hip ratio (WHR) are also encouraged [71]. Some authors have promoted 
anthropometric measures as good indicators of cardiovascular risk. WHR showed a 
graded and highly significant association with myocardial infarction risk resulting as 
stronger indicator than BMI [72]. Whereas, in a recent study testing the accuracy of 
anthropometric measures as indicators of metabolic syndrome, dyslipidemia and type 2 
diabetes, WC and waist-to-height ratio (WHtR) were considered better predictors of 
cardiovascular risk [73]. In order to take into account the complexity of the 
pathogenesis of cardiovascular diseases some authors have created algorithms, scoring 
schemes and assessment tools to calculate individual risk. In particular, Sacco et al. 
(2009) proposed a global cardiovascular prediction tool incorporating traditional, 
anthropometric, and behavioural risk factors applicable to both white and non-white 
subjects which could improve primary prevention strategies [74].
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2. Rationale
Independent funding
All these conflicting views called for the production of more independent and 
pragmatic evidence to guide clinicians in antipsychotic prescription. Therefore, the 
members of the Italian Group for the Study of Second-generation Antipsychotics 
(GiSAS) decided to design a pragmatic, open-label RCT aimed at comparing old 
and new antipsychotics in people with schizophrenia treated in routine Italian 
clinical settings. The Italian Group for the Study of Second-generation 
Antipsychotics was formed as a loose association in 2006 under the aegis of the 
'Mario Negri' Institute for Pharmacological Research, a non-profit research 
institute dedicated to health sciences research. The group currently comprises 21 
members all of whom are part of the GiSAS trial steering board.
The GiSAS group started working on the protocol and the Mario Negri Institute 
accepted to act as sponsor for the study. As it was not possible obtaining economical 
support from national public agencies, funding was ensured through an unrestricted 
grant from the drug company Bristol-Myers Squibb. The grant was accepted by the 
Mario Negri Institute on the basis of a contract that guarantees full independence and 
data property. Bristol-Myers Squibb had no direct involvement in the study design, in 
the collection, analysis and interpretation of the data.
The GiSAS trial was acknowledged by all the ethics committees involved as an 
independent study aimed at improving clinical practice in health care, according to the 
definition of the Italian Ministerial Act 17 December 2004. This national law recognizes 
the public health value of not-for-profit studies on clinically relevant topics. If  certain 
specific and accountable criteria of independence are met, the National Health Service 
supports the study conduct, covering part of the expenses, like the costs of study
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drugs and insurance. This allowed us to not rely only on industrial funding and to 
conduct a large multicenter study on a relatively low budget.
An independent review board has been set up to examine ethical issues related to the 
trial. All study data belong to the GiSAS trial investigators' group who undertake to 
publish them as soon as possible. Data will be analyzed and filed by the Laboratory of 
Epidemiology and Social Psychiatry of the Mario Negri Institute. Following publication 
of study results, full data will be made entirely available to the scientific community 
through unrestricted access to the trial database [75].
Choice of study drugs
All the above findings fuelled disagreement among researchers and clinicians 
instead of resolving the controversy about the comparative effectiveness of 
antipsychotic medications. This may be partly due to the fact that SGAs are not a 
homogeneous category, as they differ in many properties and comprise both old 
drugs, like clozapine and amisulpride, and the newer ones, such as aripiprazole 
and ziprasidone. The same can be said for FGA that also combine drugs with 
diverse side-effect profiles. In a recent critical review Leucht and colleagues 
concluded that although atypical antipsychotics are not a breakthrough, the 
overall evidence in favor of some of them is consistent. Thus, the debate for or 
against SGAs seems to be influenced more by values than by data [76].
Adverse reactions like metabolic disturbances or extrapyramidal symptoms are 
extremely common and somewhat class-specific effects of antipsychotic treatment 
[7-9]. Since the latest pragmatic RCTs were unable to settle the controversy on 
the comparative efficacy of SGAs over FGAs, we proposed a trial focused on 
tolerability. The purpose of the GiSAS study was to compare FGAs and SGAs in 
terms of tolerability and effectiveness with the goal of detecting clinically 
meaningful differences. We conceived the present trial to find out whether the
prescription of one of the selected antipsychotics would be associated with better 
treatment retention and would produce less harm than the others. The choice of 
study drugs was made taking into account tolerability and current prescribing 
practice in Italy and fell on three antipsychotics with different backgrounds and 
completely different tolerability profiles. Clozapine was excluded for its peculiar side- 
effect profile and difficult management [5, 6, 11]. Thus, among the other available 
SGAs (i.e. amisulpride, risperidone, olanzapine, quetiapine, and aripiprazole) we 
selected aripiprazole and olanzapine.
At the time the trial was being planned (2006) aripiprazole was the latest and 
most promising antipsychotic with a good but only preliminary reputation for 
tolerability (i.e. infrequent metabolic and extrapyramidal side-effects) and a still 
questioned reputation for effectiveness. The drug was approved by the FDA (USA) 
on the 15th November 2002, for the treatment of schizophrenia, and was later 
licensed also in Brazil (April 2003), Australia (May 2003), Swiss (July 2004), Japan 
(June 2006) and many other countries. Date of issue of marketing authorization 
valid throughout the European Union was 4 June 2004.
Aripiprazole was assumed to exert its antipsychotic effects by acting as a partial 
agonist at D2 dopamine- and 5-HTla serotonin receptors, and as an antagonist at 
5-HT2 serotonin receptors. In particular, it was postulated that, through the 
above receptor site actions, and hence dopamine and serotonin system 
stabilization, a partial D2 agonist would be able to act as an antagonist in 
pathways where an abundance of dopamine produces psychosis, and as an 
agonist at sites in which low dopaminergic tone would produce side effects (e.g. 
areas mediating motor movement and prolactin release) [77, 78]. Nevertheless, 
aripiprazole also has an affinity to other receptors including D3, D4, 5-HT2c, 5- 
HT7, alpha-1 adrenergic and H I histamine receptors. This could explain adverse
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effects associated with this compound such as sleepiness, headache, 
gastrointestinal upset and light-headedness [79].
A Cochrane systematic review of RCTs, first published in 2004, evaluated the 
effects of aripiprazole for people with schizophrenia and schizophrenia-like 
psychoses [80]. The reviewers searched the Cochrane Schizophrenia Group's 
Register (up to August 2004) and contacted relevant pharmaceutical companies, 
the FDA and authors of trials for additional information. All clinical randomised 
trials comparing aripiprazole with placebo, FGAs or SGAs for schizophrenia and 
schizophrenia-like psychoses were included. Despite the fact that 4125 people 
participated in 10 randomized studies, there were no usable data on number of 
death, general functioning, behavior, cognitive functioning, engagement with 
services, satisfaction with treatment and economic outcomes. Study attrition was 
very high and data reporting poor. Compared with FGAs, there were no significant 
benefits for aripiprazole with regards to global state, mental state, quality of life 
or leaving the study early. Both groups reported similar rates of adverse effects, 
including akathisia and general extrapyramidal effects. Aripiprazole, however, 
caused more insomnia than perphenazine and less need for anti-parkinsonian 
drugs than 10-20 mg/day haloperidol. When compared with olanzapine and 
risperidone, aripiprazole was neither better nor worse on outcomes of global state 
and leaving the study early, and adverse effect rates were also similar. On the 
whole, aripiprazole was associated with a low likelihood of inducing EPS, sedation, 
QTc prolongation, weight gain and metabolic abnormalities. However, evidence on 
its effectiveness and tolerability was still scant and its hypothesized different 
profile of therapeutic and adverse effects was not demonstrated [80].
Olanzapine is a widely used SGA and in the last years has been the most 
prescribed antipsychotic in Italy [81]. In the CATIE trial subjects receiving 
olanzapine showed greater effectiveness than the other agents despite its
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association with significant metabolic disturbance, especially weight gain [82]; 
some commentators have-pointed out that the doses of olanzapine were often 
higher than the upper limit of 20mg that may account for this better efficacy in 
the trial. On the whole, olanzapine had an excellent reputation for efficacy, and 
was known to cause few extrapyramidal symptoms; its use, however, was 
associated to well-known adverse effects on glucose and lipid metabolism [9, 54, 
55].
Lastly, haloperidol was chosen being a highly potent and effective FGA and the 
most used comparator in clinical trials investigating the efficacy of antipsychotic 
drugs for schizophrenia [8, 14, 83-85]. In their review, Geddes and colleagues 
(2000) concluded that trials showing SGAs to be superior to haloperidol used too 
high doses of this drug [8]. It  has so been argued that haloperidors comparative 
effectiveness might improve with the adoption of a more prudent dosing 
approach, although this was not confirmed by most recent reviews [83, 85]. The 
use of haloperidol as control drug for randomized trials of new antipsychotics has 
been questioned for its propensity to cause extrapyramidal adverse-effects such 
as parkinsonism, akathisia and acute distonia [14, 83]. Movement disorders, 
however, were mostly associated with the prescription of high doses of 
haloperidol [14, 83, 84]. On the other hand, haloperidol has been associated with 
a low propensity to cause metabolic side effects, although this was never 
adequately investigated [84]. Haloperidol is the worldwide most prescribed FGA 
and is still widely prescribed in Italy, where a strong tradition of low-dosing may 
have led to a less critical view about its use [81].
In 2006 the above-mentioned Cochrane review on aripiprazole was updated by 
adding data of 2985 patients from 5 new papers but this did not significantly alter 
the main results or conclusions of the original review [80, 86]. Compared with 
FGAs there were no significant benefits for aripiprazole with regards to global
27
state, mental state, quality of life or leaving the study early. Both groups reported 
similar, rates of adverse effects, with the exception of akathisia (n= 955 RR 0.31 
Cl 0.2 to 0.6, NNT 20 Cl 17 to 32) and the need for antiparkinson medication 
(n=1854, 4 RCTs, RR 0.45 Cl 0.3 to 0.6, NNT 4 Cl 3 to 5) which were lower in 
those receiving aripiprazole. When compared with olanzapine and risperidone, 
aripiprazole was no better or worse on outcomes of global state and leaving the 
study early [86]. Two other recently published Cochrane reviews evaluated the 
effect of aripiprazole compared with FGAs [87] and SGAs [88]. Compared with 
typical antipsychotics, aripiprazole differed little in terms of efficacy but presented 
advantages in terms of tolerability [87]. I t  was associated with fewer 
extrapyramidal symptoms and hyperprolactinemia and with an advantage in terms 
of attrition rates. Compared with haloperidol, however, it did not show a 
significant advantage in terms of weight gain [87]. Compared with SGAs, 
aripiprazole resulted less efficacious than olanzapine, though only in terms of 
general mental state (PANSS score) and only in the short term [88]. It  was 
associated with fewer side-effects like cholesterol increase, weight gain, sedation 
and prolactin associated problems. However, no differences were found in terms 
of leaving the studies early, cardiac effects, EPS and glycemia [88]. These 
findings are consistent with the meta-analysis already mentioned on metabolic 
side-effects of SGAs [13]. That review, in fact, found that aripiprazole was 
tolerated better than olanzapine in terms of weight gain and glucose and 
cholesterol elevation. Both analyses, however, were based on only two industry- 
sponsored RCTs and were biased by selective reporting [89, 90]. Even in the light 
of new evidence we can conclude that the planned comparisons are well-balanced 
and should produce innovative and clinically meaningful results.
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Designing a trial within the pragmatic-explanatory continuum 
The GiSAS trial was conceived to be large enough to identify small to moderate 
treatment effects differences and simple enough to be introduced in non- 
academic community mental health services (CMHS).
Peto et al. (1995) introduced the definition of "large, simple trial" which should be 
applied to randomized studies sufficiently powered to identify modest but clinically 
relevant effects and simple enough to allow easy participation of non-selected 
patients and providers [91]. More recently different terms, like "pragmatic" or 
"practical", were introduced to describe large and simple randomized clinical trials 
which should adopt sound and meaningful outcomes and include a range of 
heterogeneous practice settings and representative participants [18, 92]. Many 
authors considered those terms to be interchangeable. We opted for the 
appellation "pragmatic trial" because it echoed the empirical philosophy of 
pragmatism originated by the scientist Charles Peirce who argued that the 
importance of ideas or actions lies in whether they make a difference in everyday 
life and not only in their attractiveness [93, 94].
March et al. (2005) argued the case for practical clinical trials in psychiatry 
outlining their characteristics and scope [95]. Practical trials were characterized 
by the following defining principles: they should be randomized and performed in 
clinical practice settings; their questions should be simple and of substantial 
public health importance; their questions should belong to an important area of 
uncertainty; their outcomes should be sound, simple and clinically relevant; their 
procedures should enact best clinical practices and should minimize adjunctive 
burden to participants [95]. In mental health outcomes research the distinction is 
frequently made between efficacy and effectiveness trials or between explanatory 
versus pragmatic trials. Efficacy trials should ask the question: "Will a treatment 
work under ideal conditions?". On the contrary, effectiveness trials should ask:
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"Will a treatment do more good than harm when implemented in everyday clinical 
practice?". Industry-funded registration trials represent the paradigmatic example 
of efficacy trials, whereas, quasi-experimental comparative research represents 
the far end of the effectiveness part of the spectrum [95].
The randomized clinical trial (RCT) has been developed as the gold standard for 
studies of treatment efficacy due to its potential for maximizing internal validity 
(i.e. the ability to attribute differential outcomes to the experimental manipulation 
of treatment rather than to other causes). Fundamental to this strength is the 
between-group equivalence produced by randomization, which permits the strong 
inference that alternative explanations can be eliminated [96]. Further, the 
rigorous controls and standardization characteristic of RCTs (i.e. blinding and 
concealment) reduce variability in both treatment delivery and outcome 
measurement, thereby enhancing the statistical power to detect treatment 
effects. From this point o f view, pragmatic trials represent an evolution in the 
direction of enhancing the external validity of experimental design (i.e. the 
generalizability of the results).
All the above mentioned definitions mostly refer to a trial's purpose. However, the 
degree to which the purpose is met depends on how the trial is specifically 
designed and conducted. Moreover, few trials are completely pragmatic or 
explanatory and most of them find their place on a continuum. Currently no 
validated definition of effectiveness studies exist. Therefore, standardized tools to 
assess and display the position of a given trial within the pragmatic-explanatory 
spectrum have been recently proposed [97, 98].
The GiSAS trial was designed to be conducted in a representative group of Italian 
CMHS which are the first care facilities available to the general population. The 
purpose was to develop a pragmatic randomized study to test the effectiveness 
and tolerability of three antipsychotic drugs in the medium and long-term
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treatment of schizophrenia. Therefore, the following pragmatic features have 
been adopted:,wide*eligibility criteria to promote participation of a wide range of 
subjects with the condition of interest; flexibility of experimental interventions 
and of follow-up assessments; objectively measured and clinically relevant 
outcomes; unobtrusive measurement of participant compliance to study 
intervention or practitioner adherence to study protocol; full intention-to-treat 
(ITT) analysis of primary outcome [98]. The study was planned to include an 
experimental treatment phase (randomized study) and an observational follow-up 
phase (cohort study).
31
3. Methods
Aim
Given the unsettled controversy on the comparative efficacy of first- over second- 
generation antipsychotics, clinicians should face a substantial uncertainty in the 
choice of the antipsychotic likely to provide greatest clinical benefit in adult patients 
with no specific counter-indications who responded insufficiently to antipsychotic 
medications. The aim of the trial was to compare the medium- and long-term 
tolerability and effectiveness of aripiprazole, olanzapine and haloperidol in 
schizophrenic patients without diabetes or metabolic syndrome and who had been 
already exposed to antipsychotic drugs. The onset of metabolic syndrome and the 
occurrence of drug discontinuation at one year were adopted as main outcome 
indicators.
Study design
The GiSAS trial is an open label, one-year randomized controlled trial firmly 
rooted in everyday clinical practice. To enhance representativeness, the inclusion 
criteria were wide and recruitment takes place in a broad array of clinical settings 
and across the various components of service provision. The sample was meant to 
be heterogeneous and to reflect the real population attending Italian community 
psychiatric services, recruiting a broad range of "real-world" patients, including 
those with comorbid conditions (i.e. substance use disorders, medical problems). 
In a non-selected sample of schizophrenic patients, it was hypothesized that there 
were significant differences in the overall safety, tolerability and acceptability of 
aripirazole, olanzapine and haloperidol and consequently in their effectiveness. 
Eligible subjects were randomly assigned to non-blind oral monotherapy with one 
of the study drugs. Principal investigators and data analysts were blinded, but
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clinicians and patients knew the allocated treatment. The study was not designed 
to replace any aspect of the usual clinical care. During follow-up, the participants 
were seen as often as usually clinically indicated. For each patient, all 
examinations were performed in the respective recruiting center by the designed 
clinician.
Patients were assessed:
• at baseline (all subjects);
• when monotherapy treatment is stopped or changed (those who stop);
• at 12 months (all subjects).
At the end of the 12-month follow-up period, all randomized patients entered a 2- 
years prospective observational study.
All the study procedures are described in the Manual of Procedures (see APPENDIX 1) 
and in the Monitoring Manual (available in Italian).
Sample selection 
Inclusion criteria:
• Age 18 years and over.
• DSM-IV diagnosis of schizophrenia, based on the Mini International
Neuropsychiatric Interview [99].
• patients entering the study should, according to their own judgment and in 
consultation with their doctor, have had a condition appropriate for changing current 
antipsychotic treatment.
The latter criterion represents the crucial starting point of the trial. Patients should 
have been included in the study only if the current medication is somehow 
unsatisfactory. However, subjects already taking one of the study drugs at study entry
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were not excluded. Thus, given the possibility not to change medication, staying on the 
same antipsychotic must have been considered a viable clinical option.
Exclusion criteria:
• Diagnosis of metabolic syndrome, defined as the fulfilling of at least three of
the diagnostic criteria for the metabolic syndrome derived from Adult Treatment 
Protocol I I I  (ATP I I I )  [59]:
1. Abdominal obesity (waist circumference >102 cm in men and >88 cm. in
women);
2. Fasting triglycerides (Tg) >150 mg/dl;
3. High Density Lipoprotein (HDL) <40 mg/dl in men or <50 mg/dl in women;
4. High blood pressure >130/85 mm Hg or on antihypertensive medication;
5. Fasting glucose >110 mg/dl or on insulin or hypoglycemic medication.
• Diagnosis of diabetes mellitus type II.
• Any organic condition clearly contraindicating treatment with one of the studied
drugs (e.g. pregnancy or breast-feeding).
• Known ineffectiveness or intolerance of one of the study drugs, which was 
consequently contraindicated.
• The patient had never been exposed to antipsychotic drugs.
• According to clinician's opinion, it was unlikely that the patient could have been
followed-up for the whole duration of the study (one year).
Recruitment
The principle of uncertainty, which has been proposed by many authors as the 
cornerstone of the credibility of a clinical trial, was adopted as the leading criterion for 
GiSAS recruitment [52, 53]. A subject should have been excluded from the trial if one 
of the three study drugs had already proven ineffective or intolerable or if the treating 
clinician had some definite idea of which antipsychotic would fit best.
34
Recruitment was conducted in a broad array of community settings: outpatient clinics, 
acute hospital units, residential facilities and day centers. Patients meeting the; 
inclusion criteria were asked to participate and, after giving informed consent, could 
access randomization (see APPENDIX 2: Recruitment Form). Once randomized, 
subjects were included in the study if they took at least one dose of the assigned 
medication. The recruitment forms of the excluded subjects were filed and periodically 
reconsidered for inclusion.
Baseline assessment
For those who consented to participate the following information were collected at 
baseline:
• clinical and demographic characteristics;
• vital signs (ECG, arterial pressure and pulse frequency);
• anthropometric measures (WC; WHR; WHtR);
• standard clinical laboratory test (hemochrome, electrolytes) and serum lipid 
profile, glycemia, prolactinemia;
• pharmacological treatments;
• psychiatric symptoms: Brief Psychiatric Rating Scale 4.0 [100];
• side effects induced by previous antipsychotic treatments;
• Patients' subjective reports of antipsychotic adverse effects, assessed by the 
Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) [101];
• global assessment of functioning (GAF) [102].
Psychopathology was measured by the Brief Psychiatric Rating Scale 4.0 (BPRS) [100]. 
The BPRS consists of 24 items rated on a seven-point Likert scale (l= n o  symptom; 
7=extremely severe symptom). Items cover four dimensions: anxiety/depression 
(constituted by six items: somatic concern, anxiety, depression, suicidality, guilt,
tension); positive symptoms (five items: grandiosity, suspiciousness, hallucinations, 
unusual thought content, conceptual disorganisation); negative symptoms (seven 
items: blunted affect, emotional withdrawal, motor retardation, uncooperativeness, 
self-neglect, disorientation, mannerisms); and mania (hostility, elevated mood, bizarre 
behaviour, self-neglect, uncooperativeness, excitement, distractibility, motor 
hyperactivity, mannerisms).
Patients' subjective reports of adverse antipsychotic effects were measured by the 
Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) [101]. The 
LUNSERS is a 51-item, self-rating scale. Respondent are required to indicate how much 
in the previous month they have experienced each of the adverse effects listed with 
regard to 41 known side effects and 10 "red herring" symptoms not known to be side 
effects of antipsychotic medication. Responses are scored on a five-point scale: 
0 = not at all; 1 = very little; 2 = a little; 3 = quite a lot; 4 = very much. Different 
subgroups of adverse effects could be obtained from the scale: extrapyramidal 
reactions (7 items), anticholinergic reactions (5 items), other autonomic reactions (5 
items), allergic reactions (5 items), physic reactions (10 items), endocrine reactions (6 
items), other reactions (4 items).
The Global Assessment of Functioning Scale (GAF) is a well known rating scale, scoring 
1-100, which can be found as Axis V of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR) [102]. It covers the range from exceptionally good mental 
health and functioning to severe psychopathology. It  measures the severity of mental 
illness taking into account psychological, social and occupational functioning as well as 
symptoms. It is a global and comprehensive measure of how patients are getting along 
in their current situation, and is intended to be a generic rather than a diagnosis- 
specific scoring system. The 100-point scales are divided into intervals, or sections, 
each with 10 points (for example 31-40 and 51-60). The scale is provided with 
examples of what should be scored in each 10-point interval. Written instructions
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describing hierarchies of relevant symptoms and functional impairment (anchor points) 
are provided. For interval 1-10 the anchor points describe the most severely ill, for 
interval 91-100 describe the healthiest. The finer grading within intervals provides the 
possibility of distinguishing between nuances, but there are no written instructions for 
this.
All baseline data were recorded in the Baseline Form (BF) (see APPENDIX 3). 
Randomization
Eligible patients were randomized to the three treatment arms following a 1:1:1 
procedure. Randomization was stratified by site. Although the number of criteria 
already satisfied in a patient at study entry could be a powerful predictor of developing 
metabolic syndrome at follow-up, the low number of subjects recruited per center 
made it impossible to stratify also for this variable. The analysis of the primary 
outcome will be adjusted for the number of criteria already met at study entry 
The allocation sequence (computer generated random-sequence) was registered 
before the trial's start. Investigators were unaware of the exact details of how the 
chosen randomization method was being implemented.
A central randomization by telephone with an interactive voice response system was 
adopted. Investigators assessed eligibility, gaint consent, and made the decision to 
enroll a patient at the participating site, then called the randomization service to get 
the treatment allocation and the subject's code. All records on the randomization 
database (e.g. failed calls, unregistered randomizations) were monitored to detect 
attempts to decipher allocation.
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Masking
Those who are directly involved in patients' care were not blinded. In blinded trials 
clinicians are not in condition to tune and adjust the optimal dose to the individual 
patients. The open-label nature of this trial enhances its feasibility, reflects real clinical 
practice, increases its external validity and consequently the generalizability of the 
results. However, knowing to which drug a subject has been assigned could 
theoretically influence outcome thus decreasing the internal validity of the comparison 
and the strength of the inference [96]. To explore the possible effect of clinicians 
expectations on outcome, investigators' attitude towards the study drugs has been 
surveyed (see below: GiSAS survey).
Post-randomization exclusion represents another critical issue related to the open 
nature of treatment allocation. To avoid this, adherence to the best possible standards 
of trial execution has been constantly supported by trial management. Through the 
weekly monitoring of the randomization database clinicians were actively prompted to 
prescribe the allocated drug. At this stage, dropping out of the trial was not an easy 
option for the clinician and was considered acceptable only if patients withdrew 
informed consent.
All people involved in GiSAS trial coordination, supervision, and data analysis were 
blinded.
Study medications
At study start-up all the study drugs were already licensed and marketed in Italy for 
the treatment of schizophrenia [103]. After randomization, the assigned daily oral 
doses of the assigned drugs was prescribed according to usual care practice and 
adjusted according to individual response and side effects
Although clinicians were not constrained to follow strict dose ranges, suggested doses 
are as follows:
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• Aripiprazole 10 mg/day starting dose and 10-30 mg/day dose range.
 • ..... Olanzapine 5 mg/day starting dose and 10-20 mg/day dose range.  ^ r
• Haloperidol 1-3 mg/day starting dose and 3-10 mg/day dose range.
For patients already taking an antipsychotic medication prior to study entry, tapering 
the previous medication over a period of at least four weeks was suggested. Guidelines 
have been provided in order to allow physicians to choose the switching strategy which 
is the best for the patients and with which they are most comfortable. The use of 
concomitant antipsychotic medication at the end of the switch period was considered 
as a discontinuation of the allocated drug.
Participation in another pharmacological trial is prohibited.
All these data were recorded in the Treatment Form (TF) (see APPENDIX 4).
Concomitant medications
After inclusion no limits have been imposed to the clinicians who were free to treat 
patients at their own discretion. The only exception was represented by mood 
stabilizers, being their use associated with the onset of metabolic disturbances [104]. 
The prescription of mood stabilizers is allowed only for subjects who were on these 
medications prior to study entry. On the contrary, the subsequent prescription of mood 
stabilizers is to be considered a protocol violation.
The prescription of concomitant antipsychotic therapy was allowed but considered 
treatment failure. The occasional occurring of parenteral antipsychotic drug 
administration (i.e., during emergency admission) was not allowed. A temporary stop 
of the assigned antipsychotic (no longer than 2 weeks in 6 months) was not considered 
as drug discontinuation, thus was not considered as a reason to perform a follow-up 
assessment.
39
The use of concomitant psychotropic medication (e.g. benzodiazepines, 
antidepressants) or of non-psychotropic drugs (e.g. anticholinergic drugs, beta- 
blockers, statins) was allowed and routinely recorded. Data on their prescription will be 
used in the secondary analyses.
All these data were recorded in the Treatment Form (TF) (see APPENDIX 4).
Primary outcomes
The onset of metabolic syndrome was adopted as primary negative endpoint. The 
study design and conduction, however, are focused on drug retention and the study 
power has been estimated for this endpoint too. Thus, the trial takes account of two 
primary endpoints: one for tolerability and one for effectiveness. Together, in fact, they 
must provide the most clinically relevant and convincing evidence directly related to 
the primary objective of the trial.
Do not develop metabolic syndrome after a one-year trial of antipsychotic was 
considered treatment success. The onset of metabolic syndrome, defined by meeting 
at least three of the above mentioned criteria, was considered as treatment failure 
even for patients with one or two clinical signs of metabolic syndrome at study entry. 
The onset of metabolic syndrome was recorded at the end of the trial or when the 
assigned monotherapy treatment was stopped/changed or a second antipsychotic was 
added. Analyses were centralized and assessment of metabolic syndrome parameters 
were performed in the same reference laboratory.
All-cause discontinuation of the allocated drug monotherapy during follow-up were 
considered treatment failure. Treatment discontinuation is a discrete measure of 
effectiveness that, being the result of intolerable side effects, insufficient clinical effect 
or inconstant acceptance or compliance, could reflect both tolerability and efficacy.
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Switching to another antipsychotic, adding a second antipsychotic or stopping the 
assigned drug was classified as study drug discontinuation. Reasons for discontinuing 
the assigned antipsychotic was registered in the TF but not considered in the primary 
outcome (see Figure 1).
Patients who meet the criteria for drug discontinuation were counted as treatment 
failures with regard to effectiveness but were followed-up for the rest of the one-year 
period as well.
In order to capture whether, when and why participants stopped the assigned 
treatment or added concomitant medication the patients' ongoing treatments was 
strictly monitored. The occasional occurring of parenteral antipsychotic drug 
administration (i.e. during emergency admission,) was allowed. A temporary stop of 
the assigned antipsychotic (no longer than two weeks in six months) was not 
considered as drug discontinuation.
The proportion of subjects who will discontinue treatment during the 12-months 
follow-up will be compared between the three study groups. Time to discontinuation 
will be taken into account in the secondary analysis.
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DISCONTINUATION MODULE
PLEASE MARK THE M AIN REASON FOR DRUG DISCONTINUATION
DISCONTINUATION date: I I I I I I I
dd mm yy
[q\ LACK OF EFFICACY ->  ©  clinician's decision
® patient's decision
© shared decision
Please specify:
a POOR TOLERABILITY © clinician's decision
© patient's decision
© shared decision
Please specify:
2 PATIENT'S OWN IN IT IA T IV E
Please specify.
3 CLINICAL REMISSION © clinician's decision
© patient's decision
© shared decision
Please specify:
Fig. 1. The study drug discontinuation module in the trial monitoring form.
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Secondary outcomes
The following secondary endpoints were taken into account:
• reasons for study drug discontinuation;
• Global Assessment of Functioning score [102];
• worsening of metabolic profile, defined as the new onset of at least one 
metabolic syndrome criterion;
• onset of serum lipids abnormalities (dyslipidemia);
•  waist-to-hip-ratio (WHR);
•  electrocardiographic abnormalities;
• hyperprolactinemia (reference ranges for prolactin are 3.57 to 12.78 ng/mL for 
men and 6.12 to 30.54 ng/mL for women);
• onset of extrapyramidal side effects, derived from from antiparkinson drugs 
use;
• Concurrent use of psychotropic medication, to pragmatically evaluate the 
occurrence of further psychiatric symptoms or changes in different dimensions of 
psychopathology;
• Patients' subjective assessment of adverse effects, assessed by LUNSERS [101]. 
Follow-up evaluations
Included subjects were assessed (a) at baseline, (b) when monotherapy treatment was 
stopped or changed and (c) at 12 months. Thus, at the end of the trial all subjects 
were re-assessed even if they have stopped or changed the assigned drug.
During the one-year follow-up period, the participants have been seen as often as 
usually clinically indicated (about once a month). On these occasions investigators 
were asked to fill a specific monitoring form to check if any change in the patient's 
medication has occurred (TF).
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With the exception of the centralized analyses, which were performed by 'Mario Negri' 
Institute to detect metabolic disturbances, for each patient all examinations were 
carried out by the designed clinician in the respective recruiting centre. Any 
psychosocial intervention provided by services all along the study period was 
monitored and recorded.
All follow-up data were recorded in the Follow-up Form (FF) (see APPENDIX 5).
Data analysis
All analyses will be by full intention-to-treat (ITT) including all randomized participants 
who will receive at least one dose of investigational drugs. Subjects already taking one 
of the study drugs at study entry could never be excluded from the ITT analysis. 
Analyses will be performed on both the full ITT population (i.e. all randomized 
participants) and the modified ITT population (i.e. randomized participants receiving at 
least one drug dose).
Collected data will be analyzed using a last-observation-carried-forward approach. 
Patients with no follow-up data available will be allocated to the outcome category of 
treatment failure.
The proportion of participants in each treatment arm who developed metabolic 
syndrome at follow-up was adopted as primary endpoint for tolerability. At baseline 
subjects could meet up to two metabolic syndrome criteria. A statistical analysis of the 
primary outcome will adjust for the number of criteria already met at study entry.
The proportion of patients who maintained the allocated antipsychotic treatment as a 
monotherapy in each treatment arm within a year was adopted as primary endpoint for 
effectiveness.
Mean GAF scores in each treatment arm will be compared. Covariance analysis and 
effect size calculation will be performed.
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Survival analysis of time to discontinuation due to treatment-related side effects will be 
carried out. Subgroup comparisons will be performed to analyze subjects who stopped 
treatment due to (a) extrapyramidal side effects, (b) onset of metabolic syndrome. 
Moreover, the proportion of patients whose metabolic profile worsened at follow-up 
will be taken into account. The proportion of normolipidemic/dislipidemic participants in 
each treatment arm at follow-up was evaluated. Participants will be divided into two 
groups according to their lipid profile at study entry and the two groups will be 
analyzed separately
Mean waist-to-hip-ratio in each treatment arm will be compared. Covariance analysis 
and effect size calculation will be performed.
Mean LUNSERS scores in each treatment arm will be compared. Covariance analysis 
and effect size calculation will be performed.
The proportion of patients developing electrocardiographic abnormalities in each 
treatment arm will be compared (see FF: APPENDIX 5).
The proportion of patients in each treatment arm who will take antiparkinson drugs or 
adjunctive psychotropic medication will be used to pragmatically evaluate the onset of 
extrapyramidal symptoms or the occurrence of further psychiatric symptoms.
Statistical analysis
The main goal of the trial is to test the null hypothesis that the proportion of cases 
developing metabolic syndrome is equivalent for all three drugs. The criterion for 
significance (alpha) has been set at 0.05 (2-tailed). Treatments will be compared by 
use of a logistic regression model taking into account the stratification criterion used 
(trial site).
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For all statistical analyses, sites with a small number of randomized patients will be 
pooled together. The analyses will be conducted on the intention-to-treat population: 
all subjects who take at least one dose of study medication will be included.
If  the null hypothesis of the three treatments being equal is rejected, subsequent 
analyses will be performed considering each pair of drugs.
Pairwise comparisons between the three treatments will be carried out ensuring that 
the overall Type I  error rate is maintained at 0.05 using a Hochberg adjustment for 
multiple comparisons. All three comparisons will be significant if the largest p-vaIue will 
be <0.05, the two strongest comparisons will be significant if the second smallest p- 
value will be <0.025, and only the strongest comparison will be significant if the 
smallest p-value will be <0.0167.
As secondary steps, survival analyses using Cox Proportional Hazards regression 
models and logistic regressions/analyses of covariance will be used on the secondary 
outcome measures. In survival analyses, subjects still on treatment one year after 
randomization will be censored.
The study power was calculated as follows. The criteria for significance were set at 
0.05 (2-tailed), corrected for multiple testing, wherever necessary.On the basis of data 
extrapolated from recent studies [16, 72-75], it was hypothesized that the percentage 
of patients who will develop metabolic syndrome within 12 months will be 25% in the 
group treated with olanzapine, 15% in the group treated with haloperidol and 5% in 
the aripiprazole group.
The first step of the primary analysis was an overall 2 degree of freedom test (using a 
2 df Chi square as an approximation for the logistic regression). The proposed total 
sample size of 750 subjects (see below for discussion of the number) had power 
exceeding 99% to yield a statistically significant result. If  a significant difference was 
found, pairwise comparisons between the study drugs were be evaluated. To detect
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significant differences within each single comparison, an increase of the statistical 
power was required.
Assuming that (a) the smallest detectable difference was to be found in the olanzapine 
vs. haloperidol comparison (to be found at p=0.05), (b) the second smallest difference 
would be found in the haloperidol versus aripiprazole (at p=0.025), and (c) the highest 
difference found in the aripiprazole and olanzapine comparison (at p=0.016), 250 
subjects per group were calculated to correspond to a power of, respectively, 80%, 
93% and more than 99%. I f  the percentage of patients on aripiprazole developing a 
metabolic syndrome were 7%, the power to detect a difference against a 15% on 
haloperidol was be 73%.
To protect against a possible drop-out rate of 5-10%, about 800 patients were 
required for the study.
On the basis of data extrapolated from the most recent and comparable study [16], it 
was hypothesised that retention at 12 months would be 45% in the group treated with 
olanzapine, and 30% in the group treated with haloperidol. We assumed a retention 
rate of 60% in the group treated with aripiprazole. Using the above calculated sample 
size (n=800), the measure of effectiveness adopted as secondary outcome (retention 
rate at one year) had a power >85% to detect significant differences 
(alpha=0.05/0.025/0.016, 2-tailed) between the three possible pairwise comparisons 
using a logistic regression.
As patient recruitment to the GiSAS trial was a serious problem (see below: Trial 
planning and conduct) the originally hypothesized sample size could not be achieved. 
Thus, we opted to downsize the sample to about one-third of the original size. 
Adjustment for multiple comparisons lowers statistical power. Therefore, to preserve 
the study power we chose to cut one of the planned comparisons and to focus on 
aripiprazole vs. olanzapine, and aripiprazole vs. haloperidol. The less original 
comparison between olanzapine and haloperidol was moved to the secondary analyses.
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We predicted to recruit about 250 subjects. Assuming that drop-out rate will be 
marginal (less than 5%) data from 240 subjects should be available for analyses.
The first step of the primary analysis is an overall 2 degree of freedom test (using a 2 
df Chi square as an approximation for the logistic regression). The proposed total 
sample size of 240 subjects will have a power of 89% to yield a statistically significant 
result. If  a significant difference is found, pairwise comparisons between the 
aripiprazole and the two other compounds will be performed. Assuming that (a) the 
smallest detectable difference is found in the aripiprazole (5% ) vs. haloperidol (20%) 
comparison (to be found at p=0.05), and (b) the largest difference is found in the 
aripiprazole (5%) vs. olanzapine (25%) (at p=0.025), 80 subjects per group will 
correspond to a power of, respectively, 77% and 87%.
Data ownership
All study data belong to the GISAS Trial investigators group. Data collected for this 
study will be analyzed by the Istituto di Ricerche Farmacologiche "Mario Negri" in 
Milan.
Following the publication of study results, data will made available for the scientific 
community.
Cohort study
At the end of the 12-month follow-up period, all randomized patients who gave their 
consent entered a prospective observational study. Participants were evaluated every 
six month for the subsequent 2 years using the above mentioned TF and FF.
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Pharmacogenetic study
All randomized patients who gave specific informed consent entered a 
pharmacogenetic ancillary study. Genetic samples were collected at each study site 
and processed at the study coordination centre (the Laboratory of Genetics, Galliera 
Hospital, Genova).
A candidate gene approach will be used. Thus, genes will be selected from current 
evidence and their association with drug response will be investigated. The same 
endpoints adopted in the present trial will be used to define treatment response. No 
further data will be collected.
Publications
The primary publication from GISAS Trial will be attributed to the GISAS Study Group. 
The names of all investigators who randomize patients within the trial will be listed 
with the Principal Investigators and Steering Group at the end of the primary 
publication. Subsequent publications will be permitted after approval from the GISAS 
Trial Scientific Advisory Board.
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4. Trial design considerations
Two primary endpoints?
The ICH E9 guideline on biostatistics in clinical trials states that safety/tolerability may 
sometimes be the primary variable, and will always be an important consideration 
[105]. As metabolic disturbances or EPS are extremely common negative 
consequences of antipsychotic treatment, Tyrer and Kendall (2008) wrote that serious 
adverse reactions should be adopted as important outcome measures [106], The 
decision to focus on tolerability and to adopt a harmful effect as primary -negative- 
outcome, although uncommon, could therefore be valuable for improving the 
pharmacological treatment of schizophrenia. Endpoints selected for clinical trials must 
strike a balance between their scientific validity and their practical and clinical 
importance. Since metabolic side-effects of SGAs (i.e. weight gain, dyslipidemia and 
impaired fasting glucose) were emerging issues and since aripiprazole showed an at 
least promising metabolic profile we chose as primary endpoint for tolerability the 
incidence of metabolic syndrome.
According to the ICH E9 guideline, we indicated one primary variable as primary 
endpoint [105]. However, as the study design and conduction focused on drug 
retention, we took also account of drug discontinuation as endpoint of primary 
importance. Both endpoints were used to estimate the sample size because together 
they should provide the most clinically important and convincing evidence directly 
related to the primary objective of the trial [107].
Previous antipsychotic medication
Patients who were on antipsychotic therapy at study entry should have had a condition 
appropriate for changing their treatment to be considered for inclusion. This criterion
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was the natural starting point of the trial: patients should have been randomized only if 
the current medication was somehow unsatisfactory. A trial recruiting subjects with 
severe, long-lasting disorders has to deal with previous and current pharmacological 
treatments. As in CATIE we decided to allow random assignment to the medication 
taken prior to study entry. Given the possibility of not changing medication, staying on 
the same antipsychotic had to be a viable clinical option. On the other hand, those who 
were completely satisfied with their medication would have not been entered into the 
study. Therefore, GiSAS participants who at baseline were already taking olanzapine, 
haloperidol or aripiprazole should have not been completely satisfied with their 
medication but did not need absolutely to change it. The use of the ITT principle 
allowed us to preserve randomization from any subsequent change of the allocated 
drug. Thus, if continuing previous medication turned out to be the wrong choice 
clinicians could easily intervene without affecting trial participation.
In CATIE phase I, 23% of subjects randomly assigned to olanzapine and 18% of 
subjects randomly assigned to risperidone did not change medication because they 
already were on those drugs at study entry. In a post-hoc study, Essock and 
colleagues (2006) found that those "stayers" had significantly longer times until 
discontinuation than those assigned to switch, and that, when these "stayers" were 
removed, differences seen in the original CATIE results were attenuated [108]. As 
exposure to treatment prior to the trial seemed to advantage "stayers", the authors 
concluded that future randomized comparisons should take into account whether 
medications being compared were newly initiated or not [108]. In a subsequent study 
a similar analysis addressing additional outcomes measures evaluating symptoms, 
neurocognition, quality of life, neurological side effects, weight, and health costs was 
performed [109]. Switching to a new medication yielded no advantage over staying on 
the previous medication. However, staying on olanzapine was associated with greater 
weight gain [109]. These analyses showed that, even in double-blind RCTs, there can
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be biases in treatment effect estimates related to differences in the study participants' 
previous exposures to treatment. Comparisons of medication effectiveness need to 
take into account whether medications being compared were each newly initiated. We 
will take into consideration this potential source of bias adjusting for being "stayers" 
both primary endpoints.
Potential sources of bias
Some characteristics of the study design might be sources of bias. Patients and their
treating psychiatrists were unmasked for the assigned treatment, since this better
reflects routine clinical practice increasing the trial's external validity. Knowledge of the
treatment allocation and drug prescribed, however, can influence the referring
clinician's and participant's assessment and interpretation of effectiveness and side-
effects, and this might in turn influence treatment decisions and patients' subsequent
use of the service and outcomes. The only strategy we could adopt to compensate this
bias was to survey clinicians' attitudes towards antipsychotics with the aim of using
these data to control for possible confounders (see below: GiSAS Survey). A secondary
statistical analysis of the primary outcomes will adjust for clinicians' expectations of the
effectiveness and tolerability of the various antipsychotic classes.
Post-randomization exclusion is another problematic issue related to the open nature of
the trial. We decided to include in the modified-ITT analysis only patients who had
taken at least one dose of study medication. Thus, since patients and their
psychiatrists were unblinded, they could choose to opt out of the trial if their treatment
did not turn out to be the one they wanted. To deal with this, investigators were
always prompted to adhere to the best possible standards of trial execution. All records
on the randomization database (e.g. failed calls, unregistered and registered
randomizations) are monitored by the study team on a weekly basis in order to detect
any attempts to decipher allocation and to actively prompt clinicians to prescribe the
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allocated drug. At this stage, dropping out of the trial is not an easy option for the 
clinician and is considered acceptable only if patients withdraw informed consent. 
Moreover, patients for whom the allocated treatment turns out to be the same cannot 
be excluded from the modified-ITT analysis since, by definition, they have already 
taken at least one dose of the investigational drug. I wish to clarify that the inclusion in 
the modified-ITT analysis was not only determined by the actual intake of the assigned 
drug. No specific way of controlling patients' compliance was prescribed, thus inclusion 
was not determined by treatment adherence. To fulfil our inclusion criteria the 
allocated drug should simply have been directly prescribed to the patient by the 
treating clinician in a face-to-face meeting. If  this has happened the patient qualifies 
for inclusion. The basic ITT principle is that participants should be analyzed in the 
groups to which they were randomized, regardless of whether they received or 
adhered to the allocated intervention and regardless of whether they withdrew from 
the trial. Nevertheless, we decided to link patients' inclusion to the prescription of the 
allocated treatment and not simply to randomization. This allowed us to maintain a 
certain control over the inclusion phase and to obtain that the allocated drugs were 
actually prescribed. Had we not done so, investigators would have probably considered 
randomization only as a feeble suggestion and many subjects would have been 
prescribed different treatments.
Conclusion
The protocol of a pragmatic clinical trial should be as simple as possible. Its design 
should attempt to mirror routine clinical practice, as in this context are the study 
hypotheses to be tested. This is aimed at increasing the trial's feasibility and the 
possibility that its results will have a significant impact on the clinical community.
The GiSAS trial was projected as a community effectiveness randomized controlled 
trial. Therefore, its procedures, while promoting best available practices without giving
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inferior treatment to any participant, had to match with the everyday clinical practice 
of Italian community mental health services. Some of the difficulties encountered in . -3 
the trial implementation (see below) might be interpreted as an effect of this 
compromise. The fact of allowing randomization only when the clinicians were really 
uncertain about the drug choice could have paved the way for a significant slowdown 
of recruitment. On the other hand, the attempt to mimic everyday clinical practice 
conflicted with the random assignment of medication or with the fixed prescription of 
blood and electrocardiographic examinations.
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CHAPTER I I
TRIAL PLANNING AND CONDUCT
5. Trial conduct and patient recruitment
The study protocol, the study manual, the information brochure and the informed 
consent form have been approved by the ethics research review board of the clinical 
coordinating center, the Local Health Agency of Genoa (n° 49549, March 2007). The 
trial has been approved as an independent study aimed at improving clinical practice in 
health care, according to the definition of the Italian Ministerial Act 17 December 2004, 
and has been registered in the National Monitoring Centre for Clinical Trials and the 
European Clinical Trial Database (EudraCT number 2007-000278-22) and in the 
ClinicalTrials.gov registry (number NCT01052389) [110, 111]. The approval was 
released on 15 March 2007 and transmitted to the principal investigator Dr. Luigi 
Ferrannini, director of the local Mental Health Department, to the study sponsor, the 
'Mario Negri' Institute for Pharmacological Research, and to the National Monitoring 
Centre for Clinical Trials (https://oss-sper-clin.aQenziafarmaco.it/index inol.htm). Local 
research ethics review boards approval has been obtained for each participating 
center.
In Italy, this is one of the first attempts to apply the model of "pragmatic trials" in the 
field of antipsychotic treatment. The study is coordinated by the Epidemiology and 
Social Psychiatry Unit of the Mario Negri Institute for Pharmacological Research in 
collaboration with the Department of Mental Health of the Local Health Agency of 
Genoa and the Department of Psychiatry of the University of L'Aquila.
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All study sites were monitored on a regular basis, case record forms checked and data 
entered in the central database, According to Good Clinical Practice, all necessary 
procedures to ensure the quality of every aspect of the trial are complied with. Patient 
information is only accessible to the research team and no identifying information is 
kept with raw data. Each study investigator keeps records of laboratory tests and ECG 
diagrams in the patient's file as original source documents for the study.
Two protocol amendments were submitted to all ethics committees and approved 
within the first three years of study implementation: a) the recruitment period, which 
was estimated at one year for each study center (see APPENDIX 1), was prolonged; b) 
the sample size was downsized to about one-third of the original size (see above: 
paragraph 3.14.1).
All phases of the GiSAS trial are recorded following the CONSORT statement [112].
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Recruitment initiatives
In the early phase of recruitment, conferences at each participating UnitS“haverbeen ^  
held to present the overall profile of the project.
Once the local ethics committees approved the protocol, further meetings were 
scheduled in order to give detailed information and practical advice on patients' 
screening and inclusion. Raising suitable and well-motivated clinicians became the 
focus of start-up phase of the study.
Participating centers and sampie recruitment (updated June 2011)
48 centres across Italy were initially involved. Three centres (6%) withdrew before 
ethics approval was complete. Three local research ethics review boards (6% ) did not 
approve the study. After participation agreement and ethical approval two centres 
(4% ) withdrew from the study for reasons of time constraints and work overload and 
five centres (10%) failed to recruit any patients.
The 35 participating centers, all belonging to the National Health Service (SSN) are 
listed in Table 2. Most of them have taken a long time before becoming operative and 
only 16 of them (46%) reached the original recruitment target of at least 10 subjects 
per center.
The study recruitment from October 2007 to June 2008 was very problematic. Patient 
inclusion was very low in the first nine months of recruitment: only 34 subjects had 
been randomized by June 2008 (see Figure 2 for details). Table 3 shows data on the 
screening and inclusion of patients carried out by GiSAS investigators between October 
2007 and June 2009 at 8 study sites (17 recruiting centers). Figure 3 shows CONSORT 
flow-chart of the first 34 recruited subjects (June 2008).There was a huge variation 
across the sites in the proportion between patients screened for eligibility and patients 
included in the study: from 0.02 in Piacenza to 1 in Rho or Savona. Screening
procedures had been applied differently despite all our efforts to uniform inclusion 
across the trial centres. Figure 4 shows reasons for exclusion of the first 337 excluded 
subjects. All of them were non-drug naive patients affected by schizophrenia. Patients 
entering the study must, according to their own judgment in consultation with their 
physician, have a condition appropriate for starting treatment with an oral 
antipsychotic medication or changing antipsychotic treatment. The change of the 
current antipsychotic medication was by far the most indicated reason for exclusion 
(59%).
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Table 2. Recruiting centers and ITT sample (n=300).
Center code Patients randomized (N0)
1. 41 26
2. 37 20
3. 28 21
4. 07 18
5. 49 15
6. 29 15
7. 44 17
8. 50 12
9. 34 15
10. 14 12
11. 15 11
12. 24 11
13. 31 12
14. 32 12
15. 11 11
16. 58 11
17. 09 7
18. 01 6
19. 46 6
20. 10 5
21. 12 4
22. 23 4
23. 38 4
24. 39 4
25. 05 3
26. 08 3
27. 20 3
28. 22 3
29. 13 2
30. 19 2
31. 02 1
32. 25 1
33. 33 1
34. 35 1
35. 57 1
Total 300
60
Fi
gu
re
 
2. 
Re
cr
ui
tm
en
t 
tre
nd
 
(u
pd
at
ed
 
Ju
ne
 
20
11
: 
30
1 
pa
tie
nt
s 
ra
nd
om
iz
ed
).
HOE-fO
m m
oioMr
nm-m
VlGZ*5Q
OlQZ'ffl
m m
oro^o
mz*n
600f* 10
soozr-iT
ttOMD
*oozHei
lOOMf
o^o^Hsr
oCN!: tft otHf o
Table 3. Recruitment and screening procedure in the eight actively recruiting study sites at June 
2008.
Recruiting center Patients screened - N0 Patients excluded - N0 Patients recruited - N0 ( % )
1. 01-07 (Genova Trust) 100 92 8 (8.0)
2. 08-10 (Como Trust) 78 72 6 (7.7)
3. 11 (Aosta Trust) 17 11 6 (35.3)
4. 12-13 (Milano-Niguarda Trust) 23 18 5 (21.7)
5. 14 (Piacenza Trust) 133 130 3 (2.3)
6. 15 (Milano-Policlinico Trust) 18 14 4 (22.2)
7. 19 (Savona Trust) 1 0 1 (100.0)
8. 22 (Milano-Rho Trust) 1 0 1 (100.0)
Total 371 337 34
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Figure 3. Consort Flow-chart at June 2008 (n=371).
RANDOMIZED
Excluded n= 337
Allocated drug A
Received at least one dose of 
study medication:
Yes
n= 12
n= 12
Allocated drug B
Received at least one dose of 
study medication:
Yes n= 13
n= 13
Allocated drug C
Received at least one dose of 
study medication:
Yes
n= 9
n= 9
Subjects to be screened for eligibility
Screened for eligibility 
n=371
>18 years
Diagnosis of schizophrenia
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Figure 4. Reasons for exclusion at June 2008 (n=337)
Reasons for exclusion
8%
5%
4%
4%
3%/
6%
59%
6%
5%
_  a Subject does not have a condition appropriate for
™  * changing the antipsychotic medication
§§ 2  Metabolic syndrome
□  3  Type I I  diabetes
. a Organic condition clearly contraindicating treatment
“  with one of the studied drugs
jgj ^  Aripiprazole positively known to be ineffective or 
not tolerable
m 6 Olanzapine positively known to be ineffective or
not tolerable
g | ~J Haloperidol positively known to be ineffective or 
not tolerable
|—I o Unlikely that the subject can be followed-up for
the whole study period (1 year)
H 9 No informed consent
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From June 2008 on we took a series of countermeasures to prevent failure to meet the 
recruitment target.
- We intensified efforts to recruit new study centres and to accelerate approval 
process. In June 2008, in fact, the study had been approved by the ethics committee 
of only 18 centres.
- We applied for the registration of the trial in the regional registry of education 
initiatives. In Italy, in fact, a number of professional profiles in the health sector must, 
by law, acquire an assigned number of formation credits in ECM (Continuous Education 
in Medicine) each year. Doctors of medicine, for instance, need to acquire at least 50 
credits per year. Participation to a clinical independent research "aimed at improving 
clinical practice in health care" (Italian Ministerial Act 17 December 2004) is considered 
equivalent to a full-time course or training program. The credits assigned to each 
specific course or educational activity are defined by the Italian Ministry of Health 
depending on their content and duration. On the basis of the education program we 
outlined, 20 credits were assigned for the GiSAS study participation. Thus, we were 
able to deliver 20 credits per years to compliant clinicians, nurses and clinical 
psychologists for all the study duration (at least three years).
- We assigned 16 annual cash awards (bursaries) to trainees attending the best 
performing centres using funds originally assigned to the reimbursement of the 
participating centres (400 Euro per patient with complete follow-up).
- We udertook a survey investigating clinicians' opinions on perceived inclusion 
barriers, GiSAS trial involvement and antipsychotic preference (see below: GiSAS 
Survey). The survey allowed us to get information on how to improve trial's 
participation. Consequently, we developed strategies to prompt clinicians to
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continuously monitor patients' eligibility, and we intensified efforts to involve other 
clinicians in the recruitment process.
- We accomplished the following activities:
• presentations to inpatients and outpatients clinical teams;
• seminar and research meetings;
• face to face meetings with consultants, psychiatrists and psychologists and nurses;
• regular phone contacts;
• flyer campaigns and poster editing.
In years 2008, 2009 and 2010 we gave more than 40 oral presentations to inpatients 
and outpatients clinical teams outlining the study background and rationale, the aims 
and hypotheses and the main features of the design. We held four annual investigators 
conferences to summarize the study progress, to prompt clinicians to adhere to the 
best possible standards of trial execution and to foster discussion on difficulties and 
barriers to trial's participation and to patients' inclusion and follow-up.
Education activities focused on two critical issues: the existence of equipoise or 
uncertainty around the choice of antipsychotic drugs and the reasons underlying 
treatment discontinuation or switch.
As shown in Figure 2, the study recruitment lasted 45 months, from October 2007 to 
June 2011, and the overall monthly recruitment rate was 6.7.
Successful implementation of the remedial actions described above resulted in a 
significant improvement of the recruitment rate. The monthly recruitment rate in the 
first nine-month recruitment period, from October 2007 to June 2008, was 3.8 and 
became 7.0, 5.0, 7.2, and 10.4 respectively in the following four nine-month periods, 
from July 2008 to June 2011. Nevertheless, at the end of 2009 we had recruited only 
133 patients and we were far away from the originally hypothesized sample of 800
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patients. As a consequence, in January 2010, we decided to downsize the sample to 
about one-third of the original size (see above: paragraph 3.14.1).
All analyses will be by full intention-to-treat (ITT) including all randomized participants 
who received at least one prescription of investigational drugs. Post-randomization 
exclusion is a critical issue related to the open nature of treatment allocation. Since we 
included only subjects who have taken at least one dose of study medication, some 
physicians and their patients could easily opt out of the trial if their allocated treatment 
turned not out to be the one they hoped for. To avoid this, adherence to the best 
possible standards of trial execution was constantly supported by trial management. In 
order to prevent late changes of mind we have actively prompted clinicians to 
prescribe the allocated drug as soon as patients were randomized. Among 301 
randomizations, only one (0.3%) was not taken into account and, thus, it is not 
reported in Table 2. It  was the first randomization (code num. 02901) of centre n° 29 
and was erroneously registered before asking the patient and the treating clinician 
about the trial participation. Presumably this happened due to the lack of experience of 
a local investigator. During our periodic check of the registered calls we identified the 
first registered randomization of center n° 29 and, as we had not received any 
confirmation about the patient inclusion, we contacted the principal investigator. We 
found out that a local investigator, who was not the treating clinician nor the principal 
investigator, called the randomization number and entered the patient's data without 
informing the patient about the trial and without verifying if he/she were actually a 
possible candidate. That local investigator did so apparently unaware of the fact that 
the randomization could not be cancelled nor ignored. We did not exactly understand 
why the investigator did so. Probably he/she simply entered the patient's data to test 
the randomization mechanism.
At that point, we prompted the principal investigator to find out whether there were 
the conditions to include the patient. However, the conditions for being included were 
not met and both the patient and the treating clinician refused to take part to the 
study (i.e. no need to change medication and unwilling to participate). The drug 
allocated by randomization was obviously never disclosed. We believe that, in this 
particular case, the m  principle should not be applied as the randomization was an 
error and there was no intention to include the subject in the study.
Out of the full ITT sample of 300 subjects, four patients (1.3%) were not prescribed 
the assigned antipsychotic and are therefore excluded from the modified-TIT 
population. Three of them withdrew the consent before the baseline visit; the name of 
the allocated drug was not disclosed and they did not change medication. These three 
patients were in stable conditions and there was no doubt about their capability to give 
or withdraw informed consent. For two of them randomization was not performed by 
the treating clinician. After having accurately looked into these withdrawals we 
concluded that there must have been some misunderstanding about trial participation. 
The last case (cod num. 00904) was a more tricky one. In fact, it was the only attempt 
to decipher randomization concealment discovered during the trial's recruitment. The 
investigator did the randomization in order to find out the assignment. To fill the 
recruitment schedule he/she used the data of a patient who had not yet given 
informed consent. Thankfully, the trick was discovered and the investigator received an 
official reprimand.
Also in this last case, the patient did not give informed consent. However, differently 
from case 02901 we opted to include him in the full ITT analysis. This decision is due 
to the fact that this patient was actually randomized, even if with a fraudulent intent. 
Moreover, the investigator, who was the treating clinician, confirmed that patient
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00904 was eligible. Case 02901, on the contrary, was randomized only by error and 
was not included because he/she was not eligible and not willing to participate.
Finally, 296 patients were randomized and included over 45 months and constitute 
therefore the modified-ITT sample.
Collected data will be analyzed using a last-observation-carried-forward approach. 
Patients with no follow-up data available will be allocated to the outcome category of 
treatment failure. At the end of recruitment (June 2011), 166 (56.1%) of the 300 
included subjects had completed the one year follow-up, 15 (5.1%) were lost to follow- 
up and 115 (38.8%) were still in active follow-up. All available baseline and follow-up 
data of the first 140 included patients had already been checked for accuracy and 
entered in the study database. Last twenty study subjects will be followed-up between 
May and June 2012. Study data are entered as soon as they are collected, so the first 
results will be available by end-2012.
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6. GiSAS Survey
Introduction
Patient recruitment is the universal rate-limiting factor for randomized controlled trials 
in all medical specialties, with most trials failing to recruit their original target by their 
deadline [113]. Barriers to participation in RCTs are the focus of three systematic 
reviews which looked at issues like time constraints, scarcity of resources, the 
importance of the research question, patients' preference for a particular treatment, 
worry about uncertainty of trials, and concerns about informed consent [114-116]. No 
clear conclusions could be drawn because of the poor quality of the studies included. 
The authors therefore called for more evidence on clinicians' commitment to 
participation in trials. Ross and colleagues suggested that studies exploring barriers to 
participation should be nested within ongoing trials [114].
Pharmaceutical companies spend around 23-30% of the actual cost of a drug on its 
promotion, basically directed to prescribing physicians [117], and doctors update their 
knowledge through information that is often produced and spread by companies 
themselves [118]. The need to guard against undue industry influence on preferences 
for antipsychotics was recently highlighted by the authors of a survey conducted 
among 431 U.S. psychiatrists [119]. Most of them believed in the superiority of SGAs 
and this optimism was related to pharmaceutical representatives' contacts and to 
familiarity with practice guidelines.
Both the concepts of clinical equipoise and uncertainty hold that randomization is 
appropriate when the clinician has substantial indecision as to which treatment is likely 
to provide greatest clinical benefit. In order to achieve commitment to RCTs from 
investigators and participants the uncertainty principle should be applied in trials' 
recruitment [53, 120]. This will, in fact, recognize and reinforce the value of clinical
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judgment and patients' autonomy and preferences and will protect the trial's internal 
validity regardless of whether clinicians' and patients' beliefs are correct or wrong 
[121]. However, the adoption of the uncertainty principle as a criterion for inclusion 
could introduce an excessive degree of discretion in the recruitment process thus 
hindering trial participation.
The inability of a human being to be objective is the ultimate source of this bias. Thus, 
in experimental science a variety of biases related to the awareness of treatment 
allocation have been described [122]. Open-label drug trials are subject to 
experimenter's bias which can occur in any stage of research: in specifying and 
selecting the study sample, in prescribing the study drugs, in measuring exposures and 
outcomes [123].
Davies et al. (2007) observed that only 20-37%  of possibly eligible patients (those 
with a diagnosis of schizophrenia whose drug treatment was being changed owing to 
poor response or intolerance) were randomised into the CUtLASS trial and that the 
remaining patients were either not referred or refused to participate [26]. As there was 
insufficient information to determine whether the patients who participated in the trial 
were representative of eligible patients, this relevant selection could reduce the 
generalisability of the trial's results to the population of interest [26]. As part of the 
CutLass trial, Lloyd et al. (2005) surveyed the clinicians' attitudes regarding the relative 
benefits and risks of conventional and atypical antipsychotic medication and found that 
90% of respondents believed that second-generation antipsychotics were associated 
with less severe side-effects than the conventional drugs and 38% believed that the 
former were superior in terms of clinical efficacy [122]. These results supported a lack 
of clinical equipoise in the CUtLASS trial investigators and led Davies et al. (2007) to 
hypothesize that the main reason for the low participation rate could be the belief in
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the superiority of second-generation antipsychotics. This explanation could reassure 
about the selection bias and the generalizability of the study results [26].
In the EUFEST trial, to control for biases that could have occurred in prescribing the 
study drugs and in measuring exposures, providers' expectation for outcome was 
assessed [27]. In contrast with the findings by Lloyd et al. (2005), the answers 
obtained by 32 (64%) of the 50 site coordinators did not support a lack of clinical 
equipoise [122]. Haloperidol, in fact, was expected to have the worst outcome by 11 
(34%) site coordinators, whereas 21 (66%) of them thought that there would be no 
difference between haloperidol and the SGAs [27]. To find whether expectations of 
psychiatrists could have led to haloperidol being discontinued more often, 
discontinuation rates for haloperidol were compared between patients from the sites at 
which haloperidol was expected to do worse and patients from the other sites. The 
analysis showed non-significant differences and the effect of expectations on outcome 
could not be proven [27].
Aim of the Survey
The uncertainty principle, which is one of the cornerstones of the credibility of clinical 
trials, was adopted as the leading criterion for GiSAS recruitment. Patients are 
assessed for eligibility only if they may benefit from changing their current antipsychotic 
treatment and if there is no clear indication or contraindication for any one of the three 
study drugs. The trial was planned to recruit 800 patients affected by schizophrenia. 
However, as is common in trials, patients’ inclusion was a problem, and at the end of 
June 2008, after nine months of recruitment, only 34 patients had been randomized.
The present survey was conducted among a group of clinicians involved in the GiSAS 
trial. The aim was to explore clinicians' views: (a) on the feasibility and utility of clinical 
trials in schizophrenia; (b) on RCT inclusion barriers; (c) on the degree of uncertainty
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underlying antipsychotic prescription, and (d) on the most important sources of 
informationrc>n antipsychotic effectiveness and tolerability.
Methods
As an ancillary study to the GiSAS trial, the present survey was addressed to all 
recruiting centers. These comprised 49 public facilities: 42 community mental health 
services, five university hospitals and two inpatient acute facilities.
An ad hoc anonymous questionnaire (see Appendix 6) was developed and posted to all 
clinicians working in these centers regardless of whether or not they were directly 
involved in the GiSAS trial. At each center, the collaboration of the trial principal 
investigator was obtained in order to prompt colleagues to complete and return the 
questionnaires. The questionnaire comprised 15 multiple-choice questions and 
consisted of two parts. The first collected clinicians' basic demographic and 
professional data (i.e. sex, age, years of clinical activity in psychiatry, main setting of 
clinical activity, use of official guidelines on schizophrenia, research experience). The 
second part was an opinion questionnaire about perceived inclusion barriers and 
objectives of clinical trials in schizophrenia, GiSAS trial involvement, opinions on 
efficacy and tolerability of antipsychotics, main factors influencing antipsychotic 
prescription, and sources of knowledge on. antipsychotic use.
Perceived inclusion barriers were identified from the literature [114-116, 121]. The 
pertinence of these barriers was checked taking account of the concerns raised by the 
investigators during the trial recruitment. To detect critical issues in recruitment, we 
reviewed all trial monitoring reports and interviewed the study coordination team. We 
made a list of statements reflecting GiSAS investigators' attitudes and potential 
inclusion barriers, and we selected 11 items. After items generation we adopted the 
classification of Fayter and colleagues to form three critical areas: "clinical barriers",
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including four items (i.e. difficulties in obtaining informed consent, poor cooperation, 
: fear of recurrence, fear of losing therapeutic alliance); "personal barriers" including 
four items (ill-disposed colleagues, ethical doubts about randomization, fear of legal 
consequences, time constraints); "trial related barriers", including three items 
(inclusion/exclusion criteria; forced change of current medication; limitations to clinical 
choice) [115]. For the purposes of the present analysis, respondents were then 
classified according to the critical area they rated as the most critical.
The perceived usefulness of pharmacological RCTs in schizophrenia was investigated 
by asking the clinician to express 1) a positive attitude (i.e. a way of improving 
scientific knowledge or clinical practice) or 2) a negative attitude (i.e. a way of 
promoting new drugs regardless of the results). Opinions on antipsychotics. included 
questions on the efficacy and tolerability of first-generation antipsychotics (FGAs) 
compared with second-generation antipsychotics (SGAs). Factors influencing 
antipsychotic prescription were explored by asking clinicians if they counted most on 
the efficacy or on the tolerability of these drugs. Finally, we explored clinicians' sources 
of knowledge about antipsychotics trying to understand the influence of scientific 
evidence, personal experience or industry-sponsored information.
Descriptive statistics for clinicians' characteristics were examined for each group. 
Multinomial logistic regression was used to examine the effect of psychiatrists' factors 
on perceived inclusion barriers, opinion about antipsychotics and GiSAS trial 
involvement after controlling for age, sex and work setting. Results are presented as 
adjusted odds ratios (OR) with associated 95% confidence intervals (Cl) using 
"uncertain" as the reference category for antipsychotic opinion and "personal" as the 
reference category for inclusion barriers.
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Results
The survey was conducted between June and, December 2008. A total of 465 clinicians 
(51 residents and 414 consultants) were involved. Of them, 278 (59.8%) returned the 
questionnaire (See Figure 5). Table 4 shows their main personal and professional 
information. Nearly half (47.5%) worked in hospital, 52.5% in community mental 
health centers. In line with Italian residency programs psychiatrists in training worked 
almost only in general hospital psychiatric units (93.8%). The majority of the 
respondents (89.9%) had a global positive attitude towards RCTs. Only half the sample 
reported using clinical practice guidelines. Personal experience was the main source of 
knowledge on antipsychotics for half the respondents, and efficacy the main factor 
influencing drug choices (79.5%). Comparisons of residents and consultants showed 
some significant differences. Consultants were older, worked more frequently in 
community settings, had more often taken part in at least one RCT, and relied less on 
tolerability for antipsychotic choice (p<0.01).
The same proportions of respondents (44.6%) indicated clinical and trial-related 
barriers as the most important, and personal barriers were reported much less 
(10.8%). Comparisons of respondents classified under the most problematic inclusion 
barrier showed two significant differences: clinicians working in general hospital 
psychiatric units appeared more worried about trial (OR 3.6, Cl 1.4-9.6) and clinical 
(OR 3.0, Cl 1.2-8.2) -related barriers than personal ones (p=0.02). Clinicians relying 
more on efficacy for prescription choices report a slight but still significant difference in 
barrier perception, with more reporting of trial (OR 3.1, Cl 1.3-7.8) and clinical (OR 
3.1, Cl 1.2-7.6) -related barriers than personal ones (p=0.04).
Comparisons of GiSAS investigators and those not involved in the trial showed three 
significant differences. As expected, GiSAS investigators were more likely to have had 
at least one previous experience in a RCT (48.5% vs. 32.4%, p=0.05), a positive
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attitude toward RCTs (95.6% vs. 84.5%, p=0.00) and used scientific publications as 
the main source of knowledge on antipsychotics (52.9% vs. 40.8%, p=0.02).
Table 5 reports respondents' rating on all the 11 barriers, regardless of the 
aforementioned classification. The barriers more often rated as the most relevant were 
in the clinical area "difficulties in obtaining informed consent" (18.0%) and "fear of 
recurrence" (10%), in the trial related area "limitation to clinical choices" (19%) and 
"inclusion/exclusion criteria" (13%), in the personal area "time constraints" (5%). On 
the other hand, "forced change of current medication" was indicated as one of the 
three most relevant inclusion barriers by 128 (46%) clinicians, "limitation to clinical 
choices" by 111 (39.9%) clinicians, and "inclusion/exclusion criteria" by 98 (35.3%) 
clinicians.
Clozapine was rated as the best antipsychotic drug by 75 clinicians (27.0%), followed 
by olanzapine (25.5%), haloperidol (19.4%) and risperidone (16.9%). Uncertainty on 
the efficacy and tolerability of antipsychotics was expressed by 85 clinicians (30.6%). 
The majority (62.9%) trusted in the superiority of SGAs, and only 18 (6.5%) favoured 
FGAs. These opinions on antipsychotics appeared to be unrelated to any other factor 
considered in the survey.
Among the sources of information on antipsychotic drugs, we investigated the role of 
information received from pharmaceutical companies: 111 subjects (39.9%) indicated 
industry representatives among their first three sources of information in order of 
importance, and 103 (37.0%) indicated this source as the main one. Clinicians in the 
first group were slightly older than the rest of the sample (47.0 vs. 44.1 yrs; p=0.01) 
and more frequently used clinical guidelines (OR 1.8, Cl 1.1-3.0; p=0.02). Clinicians in 
the second group preferred SGAs to clozapine (OR 2.1, Cl 1.1-3.9; p=0.01).
In question number 10, clinicians were asked to rate the three study drugs in order of 
better efficacy and tolerability. The results are reported in Table 6, the majority of the
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respondents rated the three drugs differently in terms of efficacy (n=215; 77%) and 
tolerability (n=223; 80%). For ten respondents (4%) all drugs were equally effective s 
and for only two (1%) all drugs were equally tolerable. Haloperidol was rated as the 
best effective antipsychotic by most of the responders (n=153; 71%), followed by 
olanzapine (n=55; 26%) and aripiprazole (n=7; 3%). On the other hand, most of the 
responders (n=144; 65%) rated aripiprazole as the best tolerable antipsychotic, 
followed by olanzapine (n=67; 30%) and haloperidol (n=12; 5%). For 27 of the 40 
clinicians who identified some similarities between the study drugs in terms of efficacy 
haloperidol and olanzapine were equally best effective. For 13 of the 37 clinicians who 
identified some similarities between the study drugs in terms of tolerability aripiprazole 
and olanzapine were equally best tolerable.
Discussion
This survey explored four critical areas: trial participation, recruitment barriers, 
antipsychotic preferences and sources of information on antipsychotic drug 
prescription. The results suggest that active involvement in the GiSAS trial was 
associated with a positive attitude towards RCTs and scientific evidence, and that 
clinical difficulties and trial-related barriers acted as important obstacles to 
randomization of patients, while personal barriers had less weight.
Recruitment barriers were largely related to the work setting. Clinicians working in 
community mental health services appeared to be more worried about personal 
barriers. The different clinical roles of the psychiatrists working in community teams 
could have influenced their perspective.
Drug choice appeared to be mostly influenced by respondents' beliefs about the 
efficacy of antipsychotics. Psychiatrists in training, however, seemed to give more 
attention to tolerability. The majority of respondents believed in the superiority of
SGAs, one-third indicating drug company representatives as the most important source 
of information on antipsychotics; this was associated withy familiarity with clinical 
guidelines for schizophrenia and further optimism towards SGAs. Our findings are 
therefore consistent with previous research, particularly the findings reported by 
Arbuckle et al. (2008) [119].
With regard to antipsychotic drug preference, we must specify that in the two 
questions investigating opinions on drug efficacy and tolerability clozapine was not 
considered. In a further question, respondents were asked to rate the best 
antipsychotic, without limitations, and a quarter of them indicated clozapine. Efficacy 
was indicated as the most important criterion for prescription and this may partly 
explain the choice of clozapine. However, those who considered industry 
representatives as the main source of information preferred all the other SGAs to 
clozapine. Thus, the influence of industry information on respondents' optimism about 
SGAs was evident.
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Table 5. Inclusion barriers indicated as the most relevant by the 278 respondents.
Inclusion barriers no. %
1. Study protocol limits clinical choices 53 19.1
2. Difficulties in obtaining patient's informed consent 50 18.0
3. Inclusion/exclusion criteria 35 12.6
4. Forced change of current medication 32 11.5
5. Fear of recurrence 29 10.4
6. Poor patient's cooperation 28 10.2
7. Time constraints 13 4.7
8. Fear of losing therapeutic alliance 13 4.7
9. Colleagues are not well disposed 10 3.6
10. Ethic doubts about randomization 6 2.2
11. Fear of legal consequences 0 0.0
Missing 9 3.2
Total 278 100.0
Table 6. Opinions on relative efficacy and tolerability of haloperidol, olanzapine and aripiprazole among responders 
who rated the three drugs differently (n=215 for efficacy; n=223 for tolerability).
Rank order Haloperidol Olanzapine Aripiprazole
Efficacy*, no. (%)
1 153 (71.2%) 55 (25.6%) 7 (3.3%)
2 53 (24.7%) 143 (66.5%) 19 (8.8%)
3 9 (4.0%) 17 (7.9%) 189 (87.9%)
Total 215 (100.0%) 215 (100.0%) 215 (100.0%)
Tolerability**, no. (%)
1 12 (5.4%) 67 (30.0%) 144 (64.6%)
2 38 (17.0%) 134 (60.1%) 51 (22.9%)
3 173 (77.6%) 22 (9.9%) 28 (12.6%)
Total 223 (100.0%) 223 (100.0%) 223 (100.0%)
* 1= best effective drug; 3= least effective drug
**1= best tolerated drug; 3= least tolerated drug
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As for the three study drugs, it seemed that most of the respondents had clear ideas 
about their relative efficacy and tolerability. Haloperidol was rated as the best 
antipsychotic in terms of efficacy and the worst in terms of tolerability. Aripiprazole, 
on the other hand, was rated as the best antipsychotic in terms of tolerability and the 
worst in terms of efficacy. The middle-ranking position of olanzapine was perhaps the 
best result. Only a scant minority of respondents, in fact, rated this drug as the worst 
in terms of efficacy or tolerability. Although not completely consistent with best 
available evidence, these results are not surprising or unreasonable. At the time the 
present survey was performed (2007) aripiprazole was the latest antipsychotic 
with a good reputation for tolerability and a still doubtful reputation for 
effectiveness. Haloperidol, a highly potent FGA, has been prescribed for many 
years in Italy and its use was frequently linked to clinically evident extrapyramidal 
symptoms [83-85]. Finally, olanzapine, a first-choice SGA, was the most ever 
prescribed antipsychotic in Italy and was positively known to cause very few 
extrapyramidal symptoms [81, 82].
Taking into account the threats to the validity of studies such as our that were set out 
by Fayter and colleagues we can highlight the strengths and limitations of the present 
study [115]. To our knowledge, this is the first survey of recruitment barriers nested in 
a large pragmatic trial on schizophrenia. However, this was both a strength and a 
limitation because there were no standardized instruments to rely on. As in other 
similar surveys the response rate was about 60%, and considering there was no 
reward and that it required some time we believe the response rate was acceptable 
[27, 119, 123]. We clearly described the survey design, data collection and analysis. To 
avoid selection bias, and because we believed that group attitudes can strongly 
influence the beliefs surveyed, we asked all the clinicians working in the trial centres to 
participate.
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The respondents’ opinions on best antipsychotic drugs partially mirrored the actual 
prescription patterns of Italian clinicians- Olanzapine and risperidone, in fact, were the 
two most prescribed antipsychotics in Italy at the time the survey was being conducted, 
and haloperidol was by far the most prescribed FGA [124]. The generalizability of the 
results, however, suffers some limitations. Although the survey was anonymous, social 
desirability might have affected responses. In fact, 46% of respondents indicated 
scientific information as their main source of knowledge on antipsychotics and this was 
much more than expected. Moreover, response patterns might have been influenced 
by the characteristics of responders since results were not adjusted for non-response. 
Other limitations pertain to the validity of the survey: we did not allow clinicians to 
make additional comments and focused only on the clinicians' perspective.
These findings pertain primarily to the routine clinical practice of Italian mental health 
services. The differences between community and hospital teams, for instance, are 
likely to be related to the specific Italian context. However, the findings on attitudes 
towards RCTs or on antipsychotic preference could hardly be explained as a peculiarity 
of our sample and are therefore generalizable to other settings or situations.
Identifying the most important recruitment barriers in a trial is crucial for attaining of 
the objectives.
The GiSAS investigators mainly complained about system-related barriers, and personal 
barriers were given less weight. The lack of uncertainty about the relative efficacy and 
tolerability of FGAs and SGAs, however, could have affected clinicians' attitude towards 
trial participation, de facto acting as a personal barrier. In turn, the influence of 
industry-mediated information could have had a role in affecting clinician's opinions on 
SGAs.
Further investigation on the relationship between the identified inclusion barriers and 
the actual recruitment rate could lead to a better understanding of the phenomenon.
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CHAPTER I I I
CONSIDERATIONS ON STUDY ENPOINTS
7, Drug discontinuation as an endpoint for effectiveness
Background
Treatment discontinuation is a widely accepted broad and composite measure of 
treatment efficacy, safety, and tolerability. The discontinuation of medium- long-term 
pharmacotherapy could, in fact, be related to the lack of efficacy, the development of 
adverse events, and the patients' unwillingness to continue treatment, which are all 
negative endpoints.
Treatment discontinuation in clinical trials has been used as a measure of treatment 
ineffectiveness in a variety of disorders [125, 126]. Time to all-cause treatment 
discontinuation has been adopted as primary outcome in a number of independent 
pragmatic RCTs on antipsychotic drug in schizophrenia [21-27, 127].
In order to understand the relative roles of efficacy and tolerability on treatment 
discontinuation in schizophrenia two similar post-hoc pooled analyses of clinical trials 
within the Eli Lilly and Company database were performed [128, 129]. Data from four 
double-blind and actively controlled RCTs including 1627 patients were pooled and 
analysed to assess the pattern and reasons for antipsychotic discontinuation regardless 
of the treatment groups. In the analysis by Liu-Seifert et al. (2005) only a slight 
majority of patients (53%) discontinued treatment within 24-28 weeks most of them 
stopping the assigned medication at an early stage. Poor response or worsening was 
the most frequent reason for stopping medications (36%), whereas poor tolerability 
accounted for a minority of discontinuations. Moreover, at each timepoint completers 
had significantly lower PANSS total scores than non completers. Discontinuation for 
poor response resulted to be more often linked to patient perception than to clinicians' 
conclusions alone (80% vs. 20%) and discontinuation due to patients' perception of
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poor response occurred early in the course of treatment [128]. The analysis by 
Dunayevich et al. (2007) focused on time to all-cause treatment discontinuation 
showing that longer treatment retention was associated with greater improvements in 
symptoms and in all assessed functional domains (p<0.05) [129]. In another post hoc 
pooled analysis of the same four RCTs from the Eli Lilly and Company database, Kinon 
et al. (2006) compared differential rates of treatment discontinuation in clinical trials as 
a measure of treatment effectiveness between olanzapine and other atypical 
antipsychotics [130]. The analysis, which included 822 olanzapine-treated and 805 
risperidone-, quetiapine-, or ziprasidone-treated patients, showed that the rates of 
discontinuation for poor response or symptom worsening were significantly lower for 
olanzapine (14.23%) than for the other atypical antipsychotics (24.60%; p<0.0001). 
No statistically significant differences in terms of discontinuation rates for intolerability 
were found by treatment groups (olanzapine, 5.60% vs. other antipsychotics, 7.45%; 
p=0.13) [130].
Continuous pharmacological treatment at therapeutic doses is essential for the care of 
people affected by schizophrenia, but it is also considered an important goal for the 
effective management of other psychiatric disorders such as major depression or 
bipolar disorder [131, 132]. Some studies suggests that the duration of antidepressant 
treatment might be influenced by medication choice and tolerability [133-136]. 
Evidence derived from observational studies indicated that patients treated with 
tricyclic antidepressants were more likely to early discontinue their treatment 
compared with patients treated with newer classes of antidepressants [137-139]. 
Treatment persistence has been adopted as an indicator of effectiveness in a number 
of pharmaco-epidemiological studies on antipsychotic or antidepressant prescription 
[140-143]. Kreyenbuhl et al. (2010) compared time to discontinuation of FGAs and 
SGAs in the treatment of schizophrenia [142]. Data on antipsychotic prescription in
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years 2004-2006 were drawn from the U.S. department of Veterans Affairs' pharmacy 
and health care utilization databases. The analysis, involving 2138 patients starting a 
new antipsychotic treatment, showed that the majority of the sample (84%) 
discontinued their index antipsychotic during the follow-up period. Only risperidone 
showed a lower cumulative proportion of persistent individuals if compared with 
olanzapine (adjusted hazard ratio=1.25, 95%; Cl: 1.02-1.30, p=0.25) [142]. Vlahiotis 
et al. (2011) identified in the U.S. Marketscan Commercial Claims database 16659 new 
antidepressant prescription episodes with the aim of comparing discontinuation rates at 
180 days between generic and brand SSRI or SNRI [143]. 47.8% initiated a brand- 
name antidepressant whereas 52.2% initiated a generic antidepressant. The study 
results showed no statistically significant differences in terms of adjusted odds of 
discontinuation between the two classes of products [143].
Further observational studies using larger samples in routine clinical practice may be 
useful in understanding differences in discontinuation rates across medications.
As mentioned above, the most indicated reason for the exclusion of patients from the 
GiSAS trial was the fact that the clinicians did not consider appropriate to change their 
antipsychotic medication. Therefore, education activities aimed at improving 
recruitment focused on two critical issues: a) the existence of equipoise/uncertainty 
around the choice of antipsychotic drugs and b) the reasons underlying treatment 
discontinuation or switch. A closer look was given to the concept of treatment 
discontinuation as an endpoint for effectiveness using a secondary analysis of existing 
data (see APPENDIX 7) and a preliminary analysis of GiSAS trial data (see Section 8).
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The secondary analysis of existing data focused on antidepressants’ dispensing trends 
in a large popujation sample of northern Italy (APPENDIX 7: reboxetine study). 
Drug-dispensing data were drawn from the regional drug administrative Lombardy 
database (Italy), they were managed and analyzed using an anonymous patient code, 
after obtaining the authorization by the Regional Health Ministry. The dataset 
contained all prescription records for 1 704 923 inhabitants of three administrative 
provinces from January 1, 2000 to December 31, 2007.
Taking the cue from a recently published meta-analysis we performed a
pharmacoepidemiological study comparing the use of reboxetine, fluoxetine, paroxetine
and mirtazapine in a large sample of adults in Lombardy (Italy) [144]. Although
reboxetine has been prescribed for many years in Europe for the treatment of
depression, Eyding et al (2010) concluded that it was ineffective and potentially harmful
[144]. We aimed, therefore, at confirming those results comparing the use of
reboxetine with that of other antidepressants in terms of prescription trends and rates
of prolonged and persistent use. The study was not only meant to possibly corroborate
recent experimental findings through naturalistic evidence. In our view, it represented a
unique occasion to find out whether the prescription patterns of a drug later found
ineffective by research evidence would have shown earlier its limits.
Prevalent and incident use of the study antidepressants were analysed. The proportion
of prolonged to occasional use and of persistence to non-persistence among
reboxetine, fluoxetine and paroxetine users were compared. A mean of 211 883
subjects per year were prescribed and dispensed one of the study drugs across the
study period. In years 2000-2006 the prescriptions of fluoxetine, paroxetine and
mirtazapine increased. On the contrary, the use of reboxetine progressively declined
and was associated with higher discontinuation rates. In particular, the rise in the
prescriptions of paroxetine and fluoxetine from 2000 to 2006 was dramatic: from
0.42% to 1.16% and from 0.18% to 0.39%, respectively. Also the prescripition rates of
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mirtazapine gradually increased all through the study period: from 0.07% in 2000 to 
0.13% in 2006. On the contrary, the prescription rates of reboxetine progressively 
decreased from 0.20% in 2000 to 0.04% in 2006. The overall proportion of prolonged 
to occasional use was significantly lower for reboxetine (42%) than for paroxetine 
(57%; OR 0.55, 95% IC 0.53-0.57, p<0.001) and fluoxetine (58%; OR 0.53, 95% IC 
0.51-0.55, p<0.001). Similarly, the overall proportion of persistence to non-persistence 
was significantly lower for reboxetine (23%) than for paroxetine (34%; OR 1.67, 95%  
IC 1.56-1.79, p<0.001) and fluoxetine (36%; OR 1.89, 95% IC 1.76-2.03).
To summarize, reboxetine showed a progressive decrease in prescription rates in years 
2000-2006 and was associated with worse treatment retention than paroxetine and 
fluoxetine. Our observational findings were consistent with recent experimental 
evidence. The higher discontinuation rates of reboxetine could have affected its 
perception as a poorly effective antidepressant and this could have resulted in the 
decline of its prescriptions.
Antipsychotic and antidepressant prescription patterns are obviously different. 
However, reasons for discontinuation are very similar across different classes of drugs 
[131, 132]. As mentioned above, we decided to focus on reboxetine because its case 
represented a unique occasion to test out if its lack of efficacy would have been 
translated into a higher proportion of treatment discontinuations. As a consequence, 
our results added validity to the assumption that differences in discontinuation rates 
reflect differences in effectiveness in actual clinical practice and were therefore used in 
trial related education activities.
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8. Prelim inary analysis o f the first 114 patients enrolled in the GiSAS trial.
Baseline characteristics of the sample
As on June 2010, 120 subjects completed their one year follow-up period. In October 
2010, all available baseline and follow-up data of those subjects had been checked for 
accuracy and entered in the study database. Six subjects (5% ) were excluded from the 
present analysis because of inconsistencies in the data.
Table 8 shows the sociodemographic characteristics of this sample of patients affected 
by schizophrenia. There were around 20 percent of missing data with respect to 
"marital status", "years of education" and "working status". The mean age of the 
sample was 40 years. They were mostly males (56%) and unmarried (70%). The 
majority lived at home (84%) and with their parents (76%).
Table 9 shows the clinical characteristics of the sample. They were mostly outpatients 
with a mean duration of contact with mental health services of eight years. Most of 
them (72%) were on antipsychotic oral medication at study entry, 16% were on long- 
acting medication or both, and 12% were not taking any antipsychotic medication. 
Although patients with comorbidities (with the exception of metabolic syndrome and 
diabetes type 2) were not excluded from the study, only 26 (23%) subjects had a 
medical disorder, 8 (7%) abused of alcohol or other substances, 14 (12%) were 
affected by medication-related problems and no one was affected by tardive 
dyskinesia. Overall, 82 (72%) subjects were free from any major medical comorbidity, 
from any medication-related problem, and from alcohol/substance abuse or 
dependence.
Psychiatrists were asked to rate compliance of subjects with at least one prior 
adequate antipsychotic trial on a four-point Likert scale on the basis of their clinical 
judgment. For the majority of them (63%) compliance was rated as satisfactory.
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Clinicians were also asked to collect patients' opinion on the efficacy and tolerability of 
antipsychotic drugs through statements that utilized a four-point Likert scale. Most of 
respondents rated those drugs positively: 68 (63%) subjects were satisfied in terms of 
efficacy, 69 (64%) in terms of tolerability. Among them, 52 (48%) were totally 
satisfied and 29 (27%) were satisfied in terms of efficacy but dissatisfied in terms of 
tolerability (or viceversa). Only 16 (15%) subjects were totally dissatisfied.
The mean GAF score was 46.85 with a standard deviation of 15.67. 89 (82%) patients 
scored below 61 which is a widely adopted cut-off point for moderate disability, 61 of 
them (68%) scored below 51 (severe disability). The mean BPRS score was 56.82 with 
a standard deviation of 17.99. We adopted a cut-off of 38 or greater for BPRS score, as 
in a previous paper it showed to be a reliable indicator of illness severity [145]. In the 
present sample, 97 (90%) patients scored above that cut-off score. Overall, 85 (78%) 
patients satisfied both GAF and BPRS criteria for at least moderate severity and 
disability.
Table 9 shows LUNSERS side-effect scores. Psychic and extrapyramidal reactions had 
the higher scores: 12.10 (SD=6.08) and 4.53 (SD=4.11) respectively. Psychic reactions 
were the most frequently reported adverse effects (98%), followed by extrapyramidal 
reactions (88%), anticholinergic reactions (76%) and autonomic reactions (71%). We 
adopted the cut-off scores proposed by the authors of the scale and we classified 
patients in terms of the overall side-effect burden and in terms of the reliability of their 
responses (red-herring items) [102] . Most of the sample (76%) reported a low burden 
of antipsychotic induced side-effects (total scores 0-40), and only 24% reported a 
medium burden (total scores 41-80). We discriminated between reliable and unreliable 
subjects adopting a cut-off of 20 points on the red-herring subscale (see paragraph 
3.5). Unreliable subjects (n=5) scored significantly higher in all the seven subscales of
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adverse effects and in the LUNSERS total score (Mann-Whitney, p<0.05 for all 
comparisons). ^
Data from clinical examination and electrocardiogram are shown in Table 10: clinical 
signs of prolactin dysregulation were evident in 14 (12%) subjects, extrapyramidal 
signs were evident in 9 (8% ) subjects, and ECG abnormalities were evident in 10 (9%) 
subjects with only 3 (3%) subjects showing a borderline or prolonged QTc.
Subjects with evidence of extrapyramidal symptoms had a higher mean extrapyramidal 
LUNSERS subscore (n=7; mean=9.00, SD=4.65) than those without (n=76; 
mean=4.31, SD=3.92; p=0.010, Mann-Whitney). Subjects with evidence of endocrine 
abnormalities had a higher mean endocrine LUNSERS subscore (n=10; mean=5.40, 
SD=4.22) than those without (n=74; mean=2.95, SD=3.13; p=0.054, Mann-Whitney). 
Table 11 shows baseline levels of prolactin and of metabolic syndrome variables and 
baseline anthropometric indicators of obesity. Due to missing data, a complete 
evaluation of metabolic syndrome was not possible for 45 (39%) subjects. Missing data 
were found for blood analysis parameters (n=37 subjects), for hypertension (n=8), 
and for abdominal obesity (n=13).
Among the subjects with complete data, 41% had hypertension, 42% had abdominal 
obesity, 48% had high fasting triglycerides, 5% had high fasting blood glucose, 53%  
had low fasting HDL.
Although all subjects had been screened negative for metabolic syndrome by the study 
investigators, 22 (19%) resulted positive after central blood tests. Anthropometric 
indicators of obesity had less missing data: 15 (13%) for waist-to-hip ratio (WHR) and 
13 (11%) for waist-to-height ratio (WHtR). Among the subjects with complete data, 
71% had a high WHR and 49% had a high WHtR.
Comparing males and females in terms of baseline metabolic syndrome variables and 
anthropometric measures we found three statistically significant differences: more
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males had high triglycerides (59% vs. 33%; p=0.022, Chi-Square), more females were 
affected by abdominal obesity (57% vs. 30%; p<0.006, Chi-Square), and males had 
higher mean WHR (n=56; mean=0.98, SD=0.07) than females (n=43; mean=0.91, 
SD=0.13; p=0.000, Mann-Whitney).
Ten-year cardiac risk estimates including behavioural and anthropometric factors 
Schizophrenia has been associated to increased mortality rates compared with the 
general population [66]. Many well-established cardiac risk factors could contribute to 
an elevated incidence of cardiac events in schizophrenic patients [67]. Moreover, some 
evidence supports the hypothesis that long-term antipsychotic therapy may play a role 
in their increased cardiovascular mortality [70].
Various tools to predict adverse cardiovascular events have been developed. Most of 
them are based on the Framingham model and have been devised from longitudinal 
community-based cohort studies [146, 147]. However, the Framingham-based models 
do not include anthropometric indicators and lifestyle variables like waist 
circumference, physical activity, smoking or alcohol consumption, which could play an 
important role in the increased mortality of schizophrenia.
In a recent study a global cardiovascular prediction tool incorporating traditional, 
anthropometric, and behavioural risk factors was applied by Sacco et al. (2009) to the 
results of the Northern Manhattan Cohort Study (NOMAS) in order to improve primary 
prevention strategies [74]. Subjects were enrolled if they were at least 40 years of age, 
lived in a pre-defined area of Northern Manhattan, and did not have a history of 
stroke. A global vascular risk score (GVRS) of 9.0 implied a 10-year probability of 
developing cardiovascular events of 20%, a GVRS of 8.2 implied a 10-year probability 
of 10%, a GVRS of 6.6 implied a 10-year probability of 2%. The authors showed a 
significant improvement in the prediction of global vascular risk by adding behavioural
risk factors and waist circumference to the traditional cardiovascular profile. Waist 
circumference, for instance, which has never been included in prior models was a 
better predictor than body mass index in the study cohort [74]. Moreover, rather than 
use multiple risk factor tables, a model adaptable to Internet-based or handheld 
programmable devices was implemented. Simple online entry of the basic variables is 
available to permit calculation of GVRS [148]. The GVRS tool uses continuous variables 
rather than categorical classifications (fasting blood sugar instead of diabetes, blood 
pressure instead of hypertension), and this may provide more precise risk assessments 
[74].
94
Sociodemographic variables ^
Gender
Male 64 (56.1)
(missing n=0)
Marital status
Single 63 (70.0)
Married or cohabiting 20 (22.2)
Legally separated/divorced 7 (7.8)
Widowed 0 (0.0)
(Missing n=24)
Living status
Home 92 (84.4)
Residential facility 17 (15.6)
(Missing n=5)
Living condition
Alone 8 (7.4)
With family 82 (75.9)
With others 18 (16.7)
(Missing n=6)
Years of education, mean (SD) 10.94 (2.94)
(missing n=22)
Working status
Competitive employment 30 (33.7)
Supported employment 7 (7.9)
Retired 2 (2.2)
Housewife 5 (5.6)
Student 2 (2.2)
Unemployed 16 (18.0)
Disability pension 27 (30.3)
(missing n=25)
Age yrs, mean (sd) 40.27 (12.08)
Values are presented as n (%) unless otherwise indicated.
Table 8. Sociodemographic characteristics of the sample (n=114).
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Clinical variables
Years since first psychiatric contact, mean (SD) 
, v, .First-ever.contact 13.64 (11.97)
First contact with the study centre 8.36 (8.89)
Inpatient, yes
(missing n=10) 
21 (18.4)
Alcohol or substance abuse, yes 8 (7.0)
Past suicide attempts, yes 17 (14.9)
Number of suicide attempts, median (min, max) 1.00 (1, 15)
Tardive dyskinesia, yes
(missing n=6) 
0 (0.0)
Other medication-related problems 14 (12.3)
Neurological disorders 3 (2.6)
Cardiovascular disorders 7(6.1)
Other disorders 16 (14.0)
Previous antipsychotic treatments*,** (n=108) 
Compliance
Unsatisfactory 8 (7.0)
Uncertain 26 (22.8)
Satisfactory 72 (63.2)
Not assessable 8 (7.0)
Patient evaluation on efficacy
Absolutely negative 2 (1.9)
Partially negative 32 (29.6)
Positive enough 52 (48.1)
Absolutely positive 16 (14.8)
Not assessable 6 (10.6)
Patient evaluation on tolerability
Absolutely negative 3 (2.8)
Partially negative 28 (25.9)
Positive enough 55 (50.9)
Absolutely positive 14 (13.0)
Not assessable 8 (7.4)
Current antipsychotic treatment
Oral medication 82 (71.9)
Long-acting medication 9 (7.9)
Both 9 (7.9)
No medication 14 (12.3)
GAF score, mean (SD) 46.85 (15.67)
BPRS total score, mean (SD)
(missing n=5) 
56,82 (17.99)
LUNSERS*** (n=86)
Extrapyramidal reactions, mean (SD)
(missing n=6) 
4.53 (4.11)
Indicator of Parkinsonism, mean (SD) 0.55 (0.91)
Indicator of akathisia, mean (SD) 5.18 (2.97)
Psychic reactions, mean (SD) 12.10 (6.08)
Allergic reactions, mean (SD) 1.42 (1.96)
Anticholinergic reactions, mean (SD) 2.76 (2.87)
Other autonomic reactions, mean (SD) 2.48 (2.70)
Endocrine reactions, mean (SD) 3.07 (3.28)
Others adverse reactions, mean (SD) 2.45 (2.00)
Red herring items, mean (SD) 3.23 (3.64)
Total score, mean (SD) 28.82 (17.54)
Values are presented as n (%) unless otherwise indicated. GAF=Global Assessment of Functioning; 
BPRS=Brief Psychiatric Rating Scale; LUNSERS=Liverpool University Neuroleptic Rating Scale.
*in the previous 2-year period; ♦♦Subject with no past adequate antipsychotics trials were excluded; 
♦♦♦Subjects not on antipsychotic medication at study entry were excluded.
Table 9. Clinical characteristics of the sample at baseline (n=114).
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Clinical and instrumental exams
Endocrine signs and symptoms 14 (12.3)
Galactorrea 2 (1.8)
Gynecomastia 2 (1.8)
Dysmenorrhea 6 (5.3)
Menstrual irregularities 11 (9.6)
Extrapyramidal signs and symptoms 9 (7.9)
Akathisia 5 (4.4)
Tardive dyskinesia 0 (0.0)
Parkinsonism 5 (4.4)
Dystonia 1 (0.9)
Heart rate, mean (SD) 76.55 (13.1)
ECG abnormalities 10 (8.8)
QTc, mean (SD) 394.89 (30.9)
Normal* 98 97.0)
Borderline** 1 (1.0)
Prolonged*** 2 (2.0)
(missing n=13)
Values are presented as n (%)
unless otherwise indicated.
♦Normal: <430 msec (males), <450 msec (females); **Borderline: 431-450 (males),
451-470 (females); ***Prolonged: >450 (males), >470 (females)
Table 10. Data on baseline electrocardiographic and clinical examination (n=114).
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Males Females Total
Diastolic blood pressure5, mean (SD) 74.45 (20.67) (missing n=0)
73.00 (23.14) 
(missing n=0)
73.82 (21.70) 
(missing n=0)
Systolic blood pressure5, mean (SD) 117.19 (33.06) (missing n=0)
112.10 (36.83) 
(missing n=0)
114.96 (34.69) 
(missing n=0)
Antihypertensive medication9, yes 2 (3.1) 3 (6.0) 5 (4.4)
Hypertension, yes 24 (40.0) 
(missing n=4)
19 (41.3) 
(missing n=4)
43 (40.6) 
(missing n=8)
Waist circumference5, mean (SD) 97.30 (14.43) 92.75 (16.50) 95.32 (15.45)
Abdominal obesity, yes 17 (29.8) 
(missing n=7)
25 (56.8) *  
(missing n=6)
42 (41.6) 
(missing n=13)
Metabolic syndrome5, yes 0(0.0) 0 (0.0) 0 (0.0)
Fasting TG55, mean (SD) 163.84 (94.53) 139.09 (83.63) 153.23 (90.29)
High TG, yes 26 (59.1) 
(missing n=20)
11 (33.3) * 
(missing n=17)
37 (48.1) 
(missing n=37)
Fasting HDL55, mean (SD) 25.72 (18.86) 30.78 (24.97) 27.94 (21.80)
Low HDL, yes 23 (52.3) 
(missing n=20)
18 (54.5) 
(missing n=17)
41 (53.2) 
(missing n=37)
Fasting glucose55, mean (SD) 61.67 (44.10) 57.52 (43.26) 59.85 (43.60)
High glucose, yes
Number of risk factors55,
0
1
2
3
4
5
Missing
Total
3 (6.8) 1 
(missing n=20)
6 (9.4)
10 (15.6)
11 (17.2)
8 (12.5)
3 (4.7)
2 (3.1)
24 (37.5)
64 (100.0)
(3.0) (missing 
n=17)
4 (8.0) 
6 (12.0) 
10 (20.0) 
8 (16.0) 
1 (2.0) 
0 (0.0) 
21 (42.0) 
50 (100.0)
4 (5.2) 
(missing n=37)
10 (8.8) 
16 (14.0) 
21 (18.4) 
16 (14.0) 
4 3.5) 
2 (1.8) 
45 (39.5) 
114 (100.0)
Metabolic syndrome55, yes 13 (20.3) 9 (18.0) 22 (19.3)
Prolactin55, mean (SD) 17.55 (16.20) 26.89 (28.07) 21.55 (22.40)
High prolactin, yes 19 (44.2) 
(missing n=20)
9 (27.3) 
(missing n=17)
28 (36.8) 
(missing n=37)
WHR, mean (SD) 0.98 (0.07) 0.91 (0.13) * 0.95 (0.10)
High WHR, yes 41 (73.2) 
(missing n=8)
29 (67.4) 
(missing n=7)
70 (70.7) 
(missing n=15)
WHtR, mean (SD) 0.58 (0.11) 0.57 (0.11) 0.57 (0.11)
High WHtR, yes 26 (45.6) 
(missing n=7)
24 (54.5) 
(missing n=6)
50 (49.5) 
(missing n=13)
Values are presented as n (%) unless otherwise indicated. TG= triglycerides; HDL=high-density lipoproteins; 
WHR=waist-to-hip ratio; WHtR=waist-to-height ratio; §local blood analysis; §§central blood analysis; *p<0.05;
**p<0.01.
Table 11. Gender differences in baseline levels of metabolic syndrome variables and of 
prolactin and in baseline anthropometric indicators of obesity (n=114; Chi-Square or 
Mann-Whitney test where appropriate).
As all the risk factors and indicators included in the NOMAS model were already 
collected for the GiSAS, trial, we could apply the model to our sample. Among the first 
114 recruited subjects, 74 (65%) were at least 40 years of age and were therefore 
eligible for the GVRS calculation. As requested by the trial inclusion criteria, none of 
them was diabetic or diagnosed as having metabolic syndrome. However, when the 
results of the centralized analyses were taken into account, 18 of them fulfilled at least 
three criteria of metabolic syndrome. None of them had an history of stroke (as in the 
NOMAS cohort) or was affected by peripheral vascular disease. For 27 subjects (36%) 
some variables of the model were missing. Thus, we were able to calculate GVRS for 
only 47 subjects (41%).
The variables of the NOMAS global vascular risk model are shown in Table 12 and the 
results of the GVRS calculation are reported in Table 13. Most of the subjects of our 
sample had a low cardiovascular risk. In particular, the majority of the sample (55%) 
had both a 5- and a 10-year risk below 5%. Moreover, only one subject had a 5-year 
risk, and only 7 subjects a 10-year risk above or equal to 10% (min 10%, max 45%). 
No differences in terms of GVRS were found between those who discontinued the 
study drug during follow-up (n=24; mean=7.13, SD=0.93) and those who did not 
(n=23; mean=7.30, SD=0.88; p=0.406, Mann-Whitney).
Comparison of baseline variables between continuers and discontinues.
Of the 114 subjects included in the present report, 61 (53.51%) were still on the 
allocated antipsychotic at 12 months, whereas 53 (46.49%) discontinued study drug. 
As shown in Figure 8, 33 (62%) discontinued for lack of efficacy, 12 (23% ) chose to 
discontinue on their own initiative, and eight (15%) discontinued for poor tolerability. 
For 16 (49%) of those who experienced lack of efficacy discontinuing was a clinician's 
decision, for four (12%) of them it was their own decision, and for 13 (39% ) of them it
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was a shared decision. For two (25%) of those who experienced poor tolerability it was 
their-own decision, for five (62%) of them it was a shared decision, and for one. (13%) 
of them it was a clinician's decision. Overall, treatment discontinuation was a patient's 
decision in 18 (34%) cases, a clinician's decision in 17 (32%) cases, and a shared 
decision in 18 (34%) cases.
All baseline variables displayed in Tables 8, 9, 10 and 11 were compared between 
those who were still on study drug at one year ("continuers", n=61) and those who did 
not ("discontinues", n=53). No differences in terms of sociodemographic or clinical 
characteristics were found, and illness severity, as measured by GAF and BPRS, was 
similar between the two groups. Statistical analyses showed no significant differences 
in any comparison (Mann-Whitney, p>0.05 for all comparisons).
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Subjects not on antipsychotic medication at study entry (n=14) were excluded from 
the analysis on the antipsychotic-induced side effects assessed through the LUNSERS. 
Only one difference of borderline statistical significance was found. Discontinuers had 
higher scores than continuers in the extrapyramidal symptom subgroup (mean=5.50, 
SD=4.52 vs. mean=3.69, SD=3.56; Mann-Whitney, p=0.049). Comparisons showed no 
statistically significant differences in any other subgroup of adverse effects (Mann- 
Whitney, p>0.05 for all comparisons).
Comparisons between the two groups in terms of baseline levels of metabolic 
syndrome variables or prolactin and of anthropometric indicators of obesity were 
performed. Only one statistically significant difference was found. Discontinuers had 
lower levels of fasting HDL (mean=23.40, SD=20.21) if compared with continuers 
(mean=31.89, SD=22.51; Mann-Whitney, p=0.024). No other comparison showed 
statistical significance (Mann-Whitney, p>0.05 for all comparisons).
Data from physical examination and ECG were compared between the two groups, as 
well. No significant differences in terms of electrocardiographic abnormalities, 
extrapyramidal symptoms or clinical signs of hyperprolactinemia were found (Chi- 
Square, p>0.05 for all comparisons).
Comparison of follow-up variables between continuers and discontinuers.
For 39 subjects (34%) follow-up LUNSERS and GAF scores were missing. Thus, they 
were not included in the present analysis. No differences in terms of baseline variables 
were found between subjects with missing data (n=39) and the rest of the sample 
(n=75) (Mann-Whitney, p>0.05 for all comparisons). Eight (20.5%) of the excluded 
subjects and 14 (18.7%) of the included subjects fulfilled at least three criteria of 
metabolic syndrome at baseline (centralized analyses).
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33 subjects (44.0%) discontinued study drug at follow-up, whereas 42 (56%) did not. 
Tables 14 and 15 show the mean LUNSERS and GAF scores, with the mean differences 
and effect sizes (ES), at three time points: at baseline (BL, all subjects: n=75), when 
the assigned medication is stopped or changed (FU1, only discontinuers: n=33), and at 
12 months (FU2, all subjects: n=75).
Both continuers and discontinuers showed statistically significant improvements in GAF 
scores at 12 months (Wilcoxon, p<0.01). Although there was no statistically significant 
difference between continuers and discontinuers in terms of 12-month GAF ratings 
(Mann-Whitney, p>0.05), a significant difference in terms of magnitude of change was 
found, continuers showing greater improvement at FU2 (Mann-Whitney, p=0.037) with 
a moderate and statistically significant effect size (0.62, 95% IC 0.18/1.06).
For discontinuers the size of change before and after treatment discontinuation 
differed. The change in mean GAF scores from BL to FU1 showed an effect size of 0.15 
(95% IC -0.33/0.64), whereas the change from FU1 to FU2 showed an effect size of 
0.27 (95% IC -0.21/0.76). Moreover, only the improvement registered from FU1 to 
FU2 reached statistical significance (Wilcoxon, p=0.050).
At 12 months (FU2-BL) continuers showed a statistically significant reduction of 
LUNSERS total score (Wilcoxon, p<0.0001). Moreover, they showed significant 
reductions in the mean ratings of the following LUNSERS subgroups of adverse effects: 
psychic symptoms (p<0.0001, ES: -0.64, 95% IC -1.08/-0.20), autonomic symptoms 
(p=0.014), and endocrine symptoms (p=0.011). On the contrary, discontinuers did 
not show any significant improvement in self-reported side effects (Wilcoxon, p>0.05 
for all comparisons).
Comparisons between continuers and discontinuers at 12 months showed statistically 
significant differences in LUNSERS total score (Mann-Whitney, p=0.026) and in the 
following subgroups of adverse effects: extrapyramidal symptoms (p=0.047), psychic
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symptoms (p=0.034), autonomic symptoms (p=0.028), and endocrine symptoms 
(p=0.020). However, no statistically significant differences were found in terms of 
magnitude of change (Mann-Whitney, p>0.05 for all comparisons).
Figure 9 shows a list of evidence-based interventions for promoting compliance with 
the assigned treatment (see APPENDIX 5). Table 16 shows the percentages of 
continuers and discontinuers who received those interventions during the one-year 
follow-up. Most of the sample received interventions specifically aimed at improving 
therapeutic alliance (91%), behavioural interventions (95%) and social or family 
support strategies (69%). Few subjects received specific psychotherapy (15%) and 
individual psycho-education (19%) and no one received group psycho-education. Less 
than half of the sample was involved in organisational strategies aimed at improving 
adherence to treatment prescriptions (45%) and, among them, no one received an 
integrated treatment for schizophrenia and substance abuse. Continuers and 
discontinuers were compared in terms of the types of intervention received. No 
statistically significant differences emerged (Chi Square, p>0.05 for all comparisons).
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LUNSERS subgroups of adverse effects Mean BL (SD)* Mean FU1 (S D )** Mean FU2 (SD)*
Extrapyramidal 4.64 (4.24) 5.39 (4.06) 4.15 (3.81)
Muscle stiffness 0.64(0.99) 0.94(1.06) 0.72 (1.06)
Slowing of movements 0.97 (1.21) 1.03 (1.02) 1.07 (1.08)
Muscle spasm w- -isi-s-- 0.47(0.74) 0.39(0.70) 0.29 (0.59)
Restlessness 1.24 (1.1) 1.42 (1.25) 1.00 (0.97)
Shakiness 0.59 (0.95) 0.70 (0.98) 0.48 (0.78)
Involuntary movements 0.33 (0.68) 0.39 (0.83) 0.23 (0.45)
Drooling mouth 0.40 (0.79) 0.52 (0.79) 0.36 (0.73)
Psychic 12.33 (5.78) 11.39 (5.96) 9.55 (5.83)
Difficulty staying awake 1.01 (0.98) 0.79 (0.86) 0.69 (0.82)
Increased dreaming 0.65 (0.92) 0.55 (0.87) 0.41 (0.749
Difficulty in concentrating 1.61 (1.08) 1.45 (0.97) 1.35 (0.98)
Tension 1.40 (1.01) 1.33 (1.19) 1.03 (0.96)
Tiredness 1.60 (0.88) 1.52 (0.91) 1.33 (0.93)
Difficulty in remembering 1.37 (1.09) 1.36(0.96) 1.21 (1.03)
Lack of emotions 1.04 (1.10) 0.91 (1.01) 0.91 (1.04)
Depression 1.32 (1.02) 1.27 (1.01) 0.93 (1.02)
Sleeping too much 1.25 (1.05) 1.15 (1.06) 0.95 (0.90)
Difficulty getting to sleep 1.07 (0.92) 1.06 (1.09) 0.73 (0.88)
Allergic 1.44 (2.02) 1.03 (1.62) 1.18 (1.94)
Rash 0.28 (0.63) 0.30 (0.64) 0.23 (0.53)
Sensitivity to sun 0.57 (0.92) 0.30 (0.68) 0.40 (0.77)
Unusual skin marks 0.15 (0.46) 0.18 (0.77) 0.21 (0.70)
Itchy skin 0.44 (0.81) 0.39 (0.70) 0.40 (0.73)
Anticholinergic 2.68 (2.91) 2.18 (2.42) 2.25 (2.38)
Dry mouth 0.77 (0.99) 0.85 (1.18) 0.67 (1.02)
Constipation 0.88 (1.15) 0.79 (1.14) 0.76 (1.01)
Difficulty passing water 0.20 (0.59) 0.09 (0.29) 0.19 (0.46)
Blurred vision 0.51 (0.91) 0.24 (0.50) 0.39 (0.68)
Passing a lot of water 0.32 (0.77) 0.21(0.54) 0.25 (0.57)
Other autonomic 2.63 (2.64) 3.00 (3.06) 2.24 (2.95)
Dizziness 0.47 (0.70) 0.48 (0.87) 0.44 (0.83)
Feeling sick 0.39 (0.69) 0.58 (0.87) 0.31 (0.66)
Palpitations 0.80 (0.91) 0.79 (0.93) 0.57 (0.82)
Increased sweating 0.76 (1.08) 1.00 (1.12) 0.63 (1.06)
Diarrhea 0.21 (0.47) 0.15 (0.36) 0.29 (0.71)
Endocrine 3.00 (3.34) 2.70 (3.21) 2.13 (3.12)
Swollen or tender chest 0.25 (0.62) 0.27 (0.63) 0.11 (0.42)
Period problems 0.44 (0.92) 0.45 (0.90) 0.33 (0.83)
Increased sex drive 0.41 (0.89) 0.52 (0.91) 0.33 (0.66)
Difficulty achieving climax 0.83 (1.29) 0.39 (1.00) 0.48 (1.04)
Reduced sex drive 0.73 (1.20) 0.79 (1.22) 0.67 (1.14)
Periods less frequent 0.33 (0.87) 0.27 (0.67) 0.21 (0.70)
Others reactions 2.59 (2.12) 2.88 (2.07) 2.2 (1.92)
Headaches 0.73 (0.89) 0.73 (0.91) 0.57 (0.81)
Loosing weight 0.43(0.77) 0.52 (0.83) 0.28 (0.63)
Putting on weight 1.11 (1.20) 1.30 (1.55) 0.99 (1.22)
Pins and needles 0.32 (0.57) 0.33 (0.54) 0.36 (0.56)
"Red herring" items 3.28 (3.80) 3.33 (4.40) 2.92 (4.21)
Total score 29.31 (12.27) 28.73 (18.67) 23.76 (18.40)
*n=75; **n=33
Table 14. Mean change in LUNSERS scores of those who discontinued study drug (n=33) and 
those who did not (n=42).
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Figure 9. Activities for promoting compliance with the assigned treatment.
1. STRATEGIES FOR IMPROVING THE THERAPEUTIC ALLIANCE
A) Has the patient's personal experience and his/her subjective perception of both the 
beneficial and undesired effects of the AP treatment been investigated? I y e s I fNOl
B) Have the goals of the AP treatment been shared with the patient? | y e s | fNOl
C) Has the patient been involved in planning and monitoring the AP therapy? | y e s | fNOl
2. BEHAVIOURAL INTERVENTIONS
A) for improving attendance of follow-up examinations
A l)  Has the patient received regular telephone or mailed reminders? | y e s | Fno]
A2) Has the patient been permitted to come for visits even without an appointment? | y e s | l~NOl
A3) Has the patient been provided with guidance brochures? I YES | f~NOl
A4) Have the procedures for accessing the service been negotiated with the patient? 
(e.g. appointments always at the same time and on the same day of the week)
1 y e s | f~NOl
B) for improving daily compliance with the prescribed treatment
B l)  Has the dosage been optimised and the manner of taking the doses simplified? | YES | Fno!
B2) Has the treatment been delivered to the patient in a loose form or in a customised pack? I y e s I 1 NO 1
B3) Has the treatment been administered directly to the patient by a staff member? I y e s I l~NOl
B4) Has administration of the treatment been entrusted to a family member? I y e s I [ no]
3. PSYCHO-EDUCATIONAL INTERVENTIONS
Has a psycho-educational activity been conducted with regard to compliance with AP treatment?
3A) Individual I y e s I [ no]
3B) Group | YES | l~NQl
4. PSYCHOTHERAPY
Has a psychotherapeutic activity been conducted to improve the patient's motivation and insight?
4A) cognitive | y e s | [no ]
4B) short psychodynamic Ly e s ] [ n o !
4C) motivational therapy | YES | fNOl
5. SOCIAL AND FAMILY SUPPORT STRATEGIES
A) Have the patient's family been involved in planning and monitoring the AP treatment? I y e s I fNOl
B) Have the goals of the pharmacological treatment been shared with the patient's family? I y e s I I n o I
C) Has a family psycho-educational activity been conducted? I y e s I [ n o ]
D) Have specific activities been conducted to improve the patient's social network? 1 y e s | [ n o ]
6. ORGANISATIONAL STRATEGIES
A) When the patient was discharged from hospital or residential facility, was he/she placed in contact with 
the community mental health team?
B) Has an integrated treatment fo r both schizophrenia and substance abuse been 
implemented?
| y e s |
1 YES I
11
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Discussion
We performed the present analysis to explore the baseline characteristics of the first 
114 subjects included into the trial and to identify differences between those who 
discontinued study drugs at follow-up and those who did not. The purpose of this 
preliminary analysis was to test the convergent validity of all-cause treatment 
discontinuation as an endpoint for effectiveness. Thus, the assumption that 
discontinuers were on worse clinical conditions at the time they stopped the assigned 
antipsychotic was put under scrutiny.
Most of the first 114 subjects included into the trial were relatively young schizophrenic 
outpatients and had a moderate-to-severe illness severity and few medical 
comorbidities. The majority showed an enough positive attitude towards antipsychotic 
therapy, with 76% of the sample reporting a low burden of antipsychotic induced side- 
effects as measured by LUNSERS scale, and only 15% reporting a complete 
dissatisfaction with past antipsychotic medication. Compliance with previous 
antipsychotic prescriptions was rated as satisfactory by the treating psychiatrists in 
most of the patients (63%).
For 47 subjects of the sample, who were at least 40 years of age, we were able to 
calculate ten-year cardiovascular risk adopting a model which included behavioural and 
anthropometric factors. The results of this calculation are consistent with the other 
findings presented here. Most of the subjects had a low cardiovascular risk, with 55%  
of the sample showing both a 5- and a 10-year risk below 5%. The inclusion of 
anthropometric and behavioural risk factors in this prediction model opened up the 
doors to the cardiovascular risk assessment of relatively young subjects [74]. However, 
the lower age limit (>40 years) for risk calculation represents a major obstacle to the 
adoption of the GVRS as an outcome indicator in people affected by schizophrenia.
I l l
46% of the subjects included in the present report discontinued the allocated 
antipsychotic during the one-year follow-up. Most of them (62%) discontinued for lack 
of efficacy. In about one third of them discontinuation was a patient's decision, in 
another third it was a clinician's decision, and it was a shared decision in the last third. 
No statistically significant differences were found between continuers and discontinuers 
in terms of baseline clinical and sociodemographic variables. There were, however, 
some significant differences between the two groups in terms of outcome variables. 
Even if both groups showed statistically significant improvements in GAF scores at 12 
months, continuers showed a greater magnitude of improvement with a moderate and 
statistically significant effect size. Moreover, only continuers showed statistically 
significant improvements in self-reported side effects with a moderate and statistically 
significant effect size for psychic symptoms.
There are some limitations which should be taken into account in the interpretation of 
these results. This analysis is based on observational data and is therefore potentially 
subject to bias. Noteworthy is the substantial amount of missing data. We assumed 
that all missing data were missing completely at random thus we opted for case 
deletion [149]. The validity of this assumption, however, could not be properly 
evaluated. Owing to missing data and to the difficulties encountered in trial's 
recruitment we could perform the analysis of follow-up variables for only 75 subjects. 
The small sample did not allow us to identify factors associated to treatment 
discontinuation through a more complex multivariate statistical analysis. Finally, as only 
discontinuers had an intermediate follow-up (FU1), we were not able to compare their 
condition at drug discontinuation with that of a reference or control group.
The sample population for a pragmatic trial must be representative of the type of 
patients who might be offered the treatment in real-world conditions. We have made 
all efforts to avoid selecting unrepresentative patients, and, in fact, the
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sociodemographic and clinical characteristics of our sample are very similar to those of 
observed in other naturalistic samples of patients attending Italian community mental 
health services [150]. However, since the study focused on antipsychotic side-effects 
and since it recruited only subjects without metabolic syndrome and diabetes, a 
selection of particularly healthy subjects could have occurred.
Although all subjects had been screened negative for metabolic syndrome by the study 
investigators, 22 (19%) of them, recruited in 11 study centres, showed positive results 
to central blood tests. For seven of those subjects we were able to retrieve the results 
of the screening tests performed at the respective study centers, and we found them 
negative. As the study investigators had to rely on their own tests and examinations to 
opt for inclusion, we concluded that the screening of those subjects had been done 
properly. Discordance between local and central laboratory tests can be attributed to 
methodological factors or to the fact that blood samples for local and central analyses 
had been taken at different times. Future efforts will focus on carefully checking out 
these discrepancies in order to identify errors in patient inclusion.
In our study premature treatment discontinuation was mostly due to lack of efficacy, 
which is consistent with previous findings [128, 129, 151]. Perkins et al. (2008) 
conducted a study aimed at evaluating predictors of treatment discontinuation among 
400 first-episode patients randomly assigned to olanzapine, quetiapine, or risperidone 
as part of a 52-week, randomized, double-blind, flexible-dose, multicenter study (the 
CAFE study) [151, 152]. 115 patients who discontinued treatment against medical 
advice were compared with 119 patients who completed the study. Poor treatment 
response and low medication adherence were independent and significant predictors of 
discontinuation against medical advice. Ongoing substance abuse, ongoing depression, 
and treatment response failure significantly predicted poor medication compliance. 
Higher cognitive performance at baseline and black ethnicity were associated with
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lower medication compliance. The study demonstrated the importance of treatment 
response in predicting discontinuation against medical advice and poor adherence to 
medication, and supported interventions to improve behaviours linked with adherence, 
particularly by targeting substance use disorders and depressive symptoms [151]. 
One-year treatment discontinuation rate (46.49%) in our sample was lower than those 
reported in similar RCTs like the CATIE (74%) and the CAFE study (70.25%), but it 
was consistent with that reported in the EUFEST trial (41.57%) [21, 27, 152] . The 
agreement between our discontinuation rate and that reported by Kahn et al. (2008) 
could be explained by the fact that both studies were conducted in Europe, whereas 
CAFE and CATIE were conducted in the United States. Thus, we can hypothesize that 
the psychosocial interventions received by people involved in GiSAS and in EUFEST 
trial, and especially those linked with treatment adherence, were similar and differed 
from those received by people recruited in CAFE and CATIE trial.
No significant differences between continuers and discontinuers were found in terms of 
baseline burden of antipsychotic induced side-effects, in terms of compliance with 
previous antipsychotic prescriptions or in terms of the interventions for promoting 
treatment adherence received during follow-up. Therefore, treatment discontinuation 
cannot be attributed to predisposing factors or to a worse quality of treatment.
The fact that no subject received a targeted intervention for alcohol or substance 
abuse is consistent with the fact that none was affected by those disorders. On the 
other hand, the fact that 31% of those who were discharged from hospital during the 
study period were not placed in contact with community mental health teams can be 
interpreted as an indicator of low treatment quality. Immediate delivery of community 
care should, in fact, represent a key goal of any mental health care system in which 
hospital stay is generally short, as is the case in Italy. This finding, however, is not 
surprising. In a recent study we estimated the symptomatic outcome of a
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representative sample of 206 patients admitted for short treatment to 64 general 
hospital psychiatric-units in Italy [145]. The majority of the sample (71%, N=147^was 
discharged home and this was considered for most patients the best option by the 
treating clinician. Nevertheless, discharge and aftercare planning were discussed and 
agreed with the community teams only for about half the sample (55%, n=113) [145]. 
The assumption that discontinuers were on worse clinical conditions at the time they 
stopped the assigned antipsychotic is only partially supported by our results. 
Discontinuers had a worse outcome than those who were on the assigned medication 
at follow-up. Overall, however, the differences between these two groups were not 
striking. Moreover, differences in outcome were mainly due to self reported side- 
effects and less to efficacy. One interesting finding is, in fact, that not only continuers 
but also discontinuers significantly improved at follow-up in terms of GAF scores. For 
discontinuers, however, the size of change differed before and after treatment 
discontinuation and only the improvement registered from F ill to FU2 reached 
statistical significance. One possible explanation is that the change of medication which 
followed treatment discontinuation accounted for this improvement. I f  this 
interpretation were correct it would support the assumption that treatment 
discontinuation coincided with a perceived failure of the allocated monotherapy.
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CHAPTER IV  
CONCLUSIONS
The thesis specifically focused on the background, rationale and design of the GiSAS 
trial, on its planning and conduct, and on the preliminary analysis of the first 114 
followed-up subjects.
The trial encountered significant problems in patients recruitment which caused a big 
delay in the project deadline. We originally planned to recruit about 800 patients over 
a two-year period but we ended up recruiting 300 patients over 45 months. Evidently, 
we planned to recruit an unrealistically large number of patients in an unrealistically 
tight time frame. Also the involvement of the study centers took much more time than 
expected. We originally aimed at recruiting 50 participating centres but, as time 
passed, the target appeared beyond reach. The delay in this process was mainly due 
to clerical reasons as ethics boards approval had to be obtained for each participating 
center separately. Finally, in fact, only 35 Italian mental health services participated. 
The investigators' lack of commitment to study recruitment and conduct was another 
major problem which has been only partially tackled by the remedial actions previously 
described. Their passive attitude towards every aspect of study implementation proved 
to be hardly modifiable and more pervasive than expected.
The second part of the thesis delved into the concept of outcomes using a secondary 
analysis of existing data and a preliminary analysis of GiSAS trial data.
In a secondary analysis of pharmaco-epidemiological data, persistence was adopted as 
an endpoint for effectiveness to check out whether the established lack of efficacy of 
reboxetine would have been translated into a higher proportion of treatment 
discontinuations for any cause if compared to SSRIs. The results added validity to the 
assumption that differences in discontinuation rates reflect differences in effectiveness 
in actual clinical practice.
In the preliminary analysis of the first 114 included subjects we investigated some 
aspects of the validity of the two primary endpoints of the trial: metabolic syndrome
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and treatment discontinuation. As we were still blinded and we did not know the drug 
to which each subjects^was randomized we were not able to compare intervention 
groups. We calculated patients' cardiovascular risk adopting a model which included 
behavioural and anthropometric factors. Most of the subjects showed a low 
cardiovascular risk, and this result was consistent with the aim of recruiting subjects 
without metabolic abnormalities. The GVRS showed to be a promising outcome 
indicator. However, its use in people affected by schizophrenia is questionable because 
of its lower age limit (40 years). We compared continuers and discontinuers both in 
terms of baseline and follow-up data. Results showed that discontinuers had a worse 
outcome than those who were on the assigned medication at follow-up. Overall, 
however, the differences between these two groups were mainly attributable to self 
reported side-effects. Thus, the assumption that discontinuers were on worse clinical 
conditions at the time they stopped the assigned antipsychotic was only partially 
supported by our results.
Some critical issues of the trial design have to be highlighted. In chapter 2, page 57, 
the trial's recruitment flow was described. In the first nine months of the study patient 
inclusion was very low: out of 371 screened subjects only 34 (9%) were randomized. 
Thus, there was a significant degree of participants' selection. Figure 4 (page 63) 
shows reasons for exclusion of the first 337 excluded subjects. The change of the 
current antipsychotic medication was by far the most indicated reason for exclusion 
(59%). Notwithstanding the attempts to move towards pragmatic inclusion, many 
people were screened not eligible and this could have repercussions on how 
generalizable the findings are or are not. However, clinical reasons such as "not having 
a condition appropriate for changing medication" (Reason 1), or "one of the study 
drugs is known to be ineffective or intolerable" (Reasons 5, 6, 7) or "it is unlikely that 
the subject can be followed-up for the whole study period" (Reason 8) accounted for
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75% of the exclusions (see Figure 4, page 63). I f  those exclusions were not taken into 
account, 71% of the eligible subjects would be excluded and 29% of them , would be 
included. In this regard, I  can cite the following example: Davies et al. (2007) 
observed that only 20-37%  of possibly eligible patients (those with a diagnosis of 
schizophrenia whose drug treatment was being changed owing to poor response or 
intolerance) were randomised into the CUtLASS trial and that the remaining patients 
were either not referred or refused to participate [26]. Again, if we had considered for 
legibility, like CUtLASS investigators did, only those with a diagnosis of schizophrenia 
whose drug treatment was being changed, 80% of the eligible subjects would have 
been excluded and 20% of them would have been included (see Figure 4, page 63).
We have extended the screening for elegibility to all subjects above age with a clinical 
diagnosis of schizophrenia attending one of the participant centers. The 
hyperinclusivity of our screening might therefore have contributed to the observed 
significant degree of participants' selection. However, the above cited revisited 
proportions of included subjects (20-29%) might reassure about the inclusivity of our 
study and about the representativeness and the applicability of our findings.
Given the controversy on the comparative efficacy of FGAs over SGAs, we had 
hypothesized that clinicians would have faced substantial uncertainty in the choice of 
the antipsychotic likely to provide greatest clinical benefit in adult patients who had 
responded inadequately to previous antipsychotic medication. This hypothesis however 
was not confirmed by the results of the GiSAS survey which showed a preference for 
SGAs. This lack of uncertainty might have had a negative impact on trial's 
implementation, especially because, through the introduction of a specific inclusion 
criterion, uncertainty had been adopted as the leading criterion for recruitment.
In chapter 1, page 15, the concepts of equipoise and uncertainty have been presented 
and discussed. Notwithstanding some criticisms [45, 46] most of the cited authors
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believed that the ethical basis for planning a pragmatic trial should rely on equipoise. 
Equipoise has both been described as the ethical basis of randomized clinical trials and 
as a way to make principles of care compatible with those of clinical research [30-44]. 
However, most of the clinical trials being conducted are industry-sponsored and 
commercial support is obviously not dependant on equipoise. Fries and Krishnan 
(2004) formulated an interesting concept that accounted for the surplus of positive 
industry-sponsored RCTs evaluating new drugs [46]. They reported that all 45 of the 
industry sponsored RCTs presented over one year at the meetings of the American 
College of Rheumatology favoured the drug of the sponsor and postulated that the 
most important reason for these results was 'design bias' [46]. From an industrial 
perspective the drug development process must necessarily involve 'designing for 
success'. This is possible given all prior information and the extensive preliminary 
scientific work and investments, including preliminary trials to evaluate efficacy [46]. If  
equipoise was the only ethical principle we can lean upon, we were brought to believe 
that most of the available scientific evidence is unethical. It  follows that other 
principles are involved in randomized clinical research and that there must be room for 
considering ethical at least some of them. For Fries and Krishnan (2004), for instance, 
'design bias' was not necessarily a bad thing. As they considered violation of equipoise 
essential to efficient medical progress they rejected the principle itself. They suggested 
that the paternalistic and outdated concept of equipoise should be replaced by better 
alternatives such as the 'positive expected value of participation'. This concept holds 
that the principle of 'equal uncertainty' should be replaced by the principle of a 
reasonable 'expected value' for the participants after pooling the expected results of 
the trial's arms. For example, if a new drug expected to yield a response rate around 
40% is compared to a standard treatment known to have a response rate of 20%, 
each participant before randomization should have a pooled expected value of 30%.
This expected value is better than standard treatment. Therefore, it can be assumed as 
ethical justification for planning a clinical trial and it gives reasons for trial participation 
[46]. The concept of 'positive expected value of participation' overcomes the internal 
contradictions of equipoise and the paradox that it generates. Moreover, it is more 
consistent with the settled practice of formulating study hypotheses. Trialists, in fact, 
are usually required to formulate a prediction about the relative efficacy of the tested 
interventions and this would again be in some contradiction with the principle of 
equipoise. The positive value of participation to the GiSAS trial was mainly expected in 
terms of tolerability. As tolerablity was not reported to be the leading criterion for 
antipsychotic prescription or for changing medication (see GiSAS Survey) even from 
this perspective we can account for the difficulties encountered in trial's recruitment. 
Another critical aspect of trial's implementation was represented by the baseline 
diagnosis of metabolic syndrome. There were, in fact, some discrepancies between the 
evaluation performed at inclusion by the investigators and the one performed by the 
study group after central blood tests. These discrepancies could be attributed to errors 
in patients recruitment. However, a specific characteristic of the trial design could also 
be implicated. As stated above (see page 30), the present trial was designed within 
the pragmatic-explanatory continuum. Thus, its protocol combined features 
belonging to both extremes of the spectrum. The fact that the investigators were 
completely in charge of patient inclusion was a 'pragmatic' characteristic of the 
trial. On the other hand, the choice of diagnosing metabolic syndrome through 
central blood analyses was motivated by an 'explanatory' need. These two 
aspects, belonging to different clinical research conceptions, evidently conflicted. 
As written on page 44, all analyses will be by full intention-to-treat (ITT) including all 
randomized participants who will receive at least one dose of investigational drugs. 
Subjects already taking one of the study drugs at study entry could never be excluded
121
from the m  analysis. As clarified further on page 53, inclusion was not determined by 
the actual intake of the assigned drug. To fulfil our criteria the drug should simply have 
been prescribed to the patient by the treating clinician in a face-to-face meeting. No 
specific means of controlling patients' compliance were introduced, thus inclusion was 
not determined by treatment adherence. The basic ITT principle is that participants 
should be analyzed in the groups to which they were randomized, regardless of 
whether they received or adhered to the allocated intervention and regardless of 
whether they withdrew from the trial. We decided to link patients' inclusion not only to 
randomization but also to the prescription of the allocated treatment and this is not 
perfectly in line with the ITT principle. However, this allowed us to maintain a certain 
control over the inclusion phase. Through the weekly monitoring of the randomization 
database we actively prompted clinicians to prescribe the allocated drug. At this stage, 
dropping out of the trial has not been an easy option for the clinician and it has been 
considered acceptable only if the patient has withdrawn his/her informed consent. Had 
we not done so, investigators would have probably not considered randomization as a 
strong indication but only as a feeble suggestion and many subjects would have 
received different prescriptions.
Abraha et al. (2010) recently reviewed RCTs that reported using a 'modified' IIT  [153]. 
They identified 475 RCTs and found that the incidence of such trials significantly 
increased for 1982 to 2002. The descriptions of the modified IIT  approaches were 
found to be ambiguous and covering any type of descriptions for exclusion, such as 
missing data and deviation from protocol. They classified types of ITT deviations into 
six categories, the first of which was treatment- related and concerned the fact of 
having received or not at least one dose of study drug. The authors concluded that 
explicit statements about post-randomization exclusions should replace the ambiguous 
terminology of modified ITT [154]. We excluded from the full ITT sample four
subjects, three of which because they withdrew their informed consent before the 
i  baseline visit and thus they were not prescribed the assigned medication, and' one 
because he/she was involved in an attempt to decipher allocation by the treating 
clinician (see page 67 for further details). We are aware of the fact that excluding 
participants is a deviation from the ITT principle, that it might bias results and that 
even a few exclusions could become relevant when the trial will be considered for 
meta-analyses. For this reason we plan to perform both a modified (n=296) and a full 
ITT analysis (n=300).
At page 52 the open nature of the study was only discussed as it was a weakness or a 
potential source of bias. However, apart from the already mentioned vulnerabilities 
there are some strengths that deserve to be discussed. What was randomized, after 
all, was the 'intention to treat' and, in particular, the 'intention to openly treat' with 
these drugs. The methodological and clinical advantages of this approach should be 
taken into account.
For RCTs the concept of 'internal validity' refers to the validity of the study results in 
terms of whether differences in outcomes are related to the allocated treatment. On 
the other hand, the concept of 'external validity' refers to the transferability of the 
study results to other populations and settings. A blinded RCT is regarded by most 
authors as being less subject to bias than an open trial because it minimizes the impact 
of knowledge of treatment allocation on post-randomized treatment decisions and on 
outcomes' rating and reporting. As a consequence the internal validity of the findings is 
considered to be increased. However, a blinded trial is not always feasible and often 
not appropriate. Moreover, as Beyer-Westendorf and Buller (2011) pointed out, double 
blinding does not completely prevent from risk of bias in internal validity [154]. 
Selection bias, for instance, which mainly affects external validity needs to be 
considered also for internal validity because it might lead to exclude from double-blind
trials subjects who would be considered for participation in open-label trials [154]. The 
allocation to an open-label medication allows to more closelyvresemble routine clinical 
practice increasing the external validity of trial's results. Thus, in some respects, the 
two trial designs offer complementary strengths and weaknesses [154].
As written above (page 30) pragmatic trials represent an evolution in the direction of 
enhancing the external validity of experimental design (i.e. the generalizability of the 
results). The choice to randomize to the intention to 'openly treat* moved our trial 
toward the pragmatic side of the pragmatic-explanatory spectrum, which was our 
intent.
In the last four years, the GiSAS study group has been working for the implementation 
of this multicenter randomized clinical trial. The trial mechanism is now fully functional 
and working and most of the problems and critical aspects of its implementation have 
been faced. The trial will finish by mid-2012. As study data are entered as soon as they 
are collected the first results will be available by end-2012.
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1. REQUISITES AND TASKS OF EACH SITE TAKING 
PART
The 'M ario Negri' In s titu te  for Pharmacological Research is the sole and 
independent sponsor of this study. Scientific co-ordination of the study will be 
managed entirely by the Institute's Unit o f Epidemiology and Social Psychiatry.
Each site taking part in the study must be found suitable for taking part in 
pharmacological clinical studies. It must therefore be a healthcare facility 
belonging to a Local Health Unit or Hospital, to a University, to a public or private 
"IRCSS" (scientific institute for in-patient and out-patient care) or to a privately 
owned centre recognised by and linked by special arrangements to the Italian 
National Health Service (SSN). It  must be considered suitable by the Health 
Ministry for holding clinical trials with drugs, in accordance with the provisions 
contained in Ministry Decree dated 19th March 1998.
Each site taking part must be a specialised clinical centre operating in the field of 
mental health and dealing with the treatment of patients with schizophrenia.
A recruitm ent centre is defined as the functional unit of the participating site, at 
which it is expected to recruit a t least 10 patients.
Each participating site may have more than one recruitment centre at its disposal, 
depending on the agreements reached with Istituto 'Mario Negri'. A code 
(recru itm ent centre code) will be assigned to each recruitment centre.
Patient recruitm ent at each centre is planned to last for one year, after 
which each patient must be followed up for one year. The study will therefore last 
for approximately two years.
The psychiatrist appointed as Principal Investigator is responsible for  
performing the activities that, according to the protocol and to this M anual, 
are to be carried out by the recruitment centre. He/she may delegate the various 
activities to other personnel of the service, subject to prior notification of the 
Scientific Secretariat.
Each patient included in the study must have a treating  psychiatrist, who will be 
responsible for the treatment assigned to him/her.
The Principal Investigator must monitor progress of the trial for its whole duration. 
To this end, he/she must create an Excluded Patients Register, make sure that a 
Study Chart is completed for each patient and complete the CONSORT chart. It is 
important that, if these three tasks are delegated to someone else, they should all 
be entrusted to the same person.
The group of GiSAS investigators consists of:
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• The Principal Investigators and the persons delegated by them;
• the treating  psychiatrists or recruiting psychiatrists;
• other personnel a t the sites taking part.
Those patients who are enrolled in the study must be taken into care in accordance 
with the participating site's usual practice.
The following forms will have to be completed:
(a) Recruitment Forms (at the time of recruitment);
(b) Randomization Forms (at the time of randomization);
(c) Baseline Forms (after randomization);
(d) Treatment Forms (whenever the treatment assigned is altered and in any case at least 
once a month’):
(e) Treatment and Follow-Up Forms (upon discontinuing treatment);
(f) Treatment and Follow-Up Forms (at month 12, also for those who have already 
stopped taking the drug).
GiSAS Investigators must follow their patients and monitor the pharmacological 
treatment throughout the duration of the study. They are responsible for carrying 
out all the tests envisaged, for scheduling the assessments and for completing the 
scales and forms.
The study calls for some blood samples to be taken from the subjects recruited 
(see Study Protocol). These samples will be analysed centrally by Istituto 'Mario 
Negri'. It is, however, necessary for them to be prepared and stored by the 
recruitment centres in order for a certain number of samples to be accumulated 
before they are collected by Istituto 'Mario Negri'.
Each recruitment centre must therefore have a reference laboratory and must take 
care of ensuring that the blood samples reach it.
Each reference laboratory must, in turn , take care of centrifuging, freezing  
and storing the samples at -3 0 /-7 0 °C . Subsequent transport of the samples to 
the centralised laboratory and testing of all the samples will be taken care of by 
Istituto 'Mario Negri'.
The instructions for taking the samples and for preparing them are attached to this 
manual (Attachm ent 1).
The clinical tria l drugs must be prescribed by the clinicians in accordance 
w ith the habitual procedures used at the participating sites and with the rules of 
Good Clinical Practice, observing in particular the contraindications, the special 
warnings and the precautions associated with use indicated on the technical data 
sheets of the drugs contained in the Investigator's Brochure.
Flexible dosages adapted to the needs of each single patient must be used, within 
the framework of the following doses based on the international guidelines: 
aripiprazole 10-30 mg/day, olanzapine 10-20 mg/day, haloperidol 3-10 mg/day. 
Based on the contents of sub-section 1 of Article 2 of the Ministry Decree dated
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17th December 2004, since these drugs are being used for indications specified in 
the authorisation to place them on the market, they are for account of the  
Ita lian  National Health Service.
It is recalled here that patients for whom even only one of the clinical trial drugs is 
specifically contraindicated cannot be included in the study.
2. PATIENT RECRUITMENT
SCREENING
All patients of age being followed by the service With a diagnosis of 
schizophrenia can access this stage, and will therefore be evaluated for eligibility 
to take part in the study.
It is important to take into account also patients whose current diagnosis is not 
schizophrenia. Thus, it is advisable to evaluate the eligibility also of patients who do 
not appear to be schizophrenic but who are in any case receiving antipsychotic 
treatment, as systematic use of Module M of the M IN I can contribute towards a 
revision of some diagnoses and is in any case useful for achieving greater 
uniformity of diagnosis among the participating sites.
Starting from the date on which recruitment begins, the recruiting psychiatrist 
must screen his/her patients, completing a Recruitm ent Form for each potentially 
eligible subject. To do this, in the last week of each month (GiSAS w eek) he/she 
shall evaluate systematically the eligibility of all the patients he/she sees.
The Recruitment Form of each patient admitted to the trial must be initialled and 
marked with the patient code to be assigned at the time of automatic 
randomization. It shall then be kept in a special blue folder for each patient, 
known as the GiSAS Folder or Case Report Form (CRF).
The Recruitment Forms of the excluded patients (to whom no patient code has been 
assigned) must, on the other hand, be kept in a green folder, called the Excluded 
Patients Register.
During the recruitment stage, each treating psychiatrist shall create his/her own 
Excluded Patients Register. During the GiSAS w eek, eligibility of all the previously 
excluded patients shall be re-assessed, taking into account the fact that some 
elig ibility criteria m ay change during the course of the recru itm ent year.
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INCLUSION AND EXCLUSION CRITERIA
The assessment of eligibility of patients to take part in the study calls for three  
levels.
1 -  Prelim inary assessments by the Investigator:
• check of the diagnosis (M IN I, module M);
• absence of type I I  diabetes and of metabolic syndrome: patients must be
screened for any such conditions by their treating psychiatrists;
• absence of contraindications for the treatment assigned;
• evaluation of the patient's willingness, informed consent.
Each patient admitted to random ization will be assigned a number (patient code) 
and go on to the TRIAL STAGE.
2 -  Clinical investigation and blood sampling for centralised testing:
N.B. These must be carried out BEFORE the clinical trial drug is taken.
3 - Assessment by Is titu to  'M ario Negri':
• Check of the absence of diabetes and or metabolic syndrome, based on an 
assessment of the results of the centralised laboratory tests.
If a patient who was initially assessed as negative with regard to the criteria of 
m etabolic syndrome or of diabetes were to be found positive on the basis of the 
results of the centralised tests, this would be sufficient reason for h is /h e r  
exclusion from  the study. Such a patient would, therefore, have to be excluded 
and replaced with another. Istituto 'Mario Negri' undertakes to notify the results as 
soon as the data concerning the tests are available.
INFORMED CONSENT
Informed consent is the procedure by means of which a subject agrees voluntarily 
to take part in a clinical study. I t  is the duty of the treating  psychiatrist to  
obtain the subject's informed consent.
Sufficient time must be devoted to the process of informing the patient, which must 
be done in a suitable place and using suitable language. The Patient In fo rm ation  
Sheet provided by Istituto "Mario Negri" is in addition to and does not replace the 
doctor-patient interview. The tim e of providing the inform ation m ust be 
officially recorded in the patient's clinical records.
The rules of Good Clinical Practice (Ministry Decree dated 15th July 1997) state that 
a subject taking part in a clinical trial must give h is /h e r w ritten  consent 
beforehand, and th a t such consent m ay be w ithdraw n a t any tim e. Said 
written informed consent is provided as a special form that has to be signed and 
dated personally by the subject and by the treating psychiatrist in two copies.
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One copy w ill be handed over to the patient w hile the other w ill be kept in 
h is /h e r GiSAS Folder.
In  the event of hospitalisation, a copy of the informed consent form  must 
be attached to the patient's clinical records.
If  a patient is of unsound mind, his/her tutor will sign the informed consent form. If 
said unsound condition is of a temporary nature, the consent form can be signed on 
an interim basis by the patient's closest relative and, at a later time, by the patient 
him/herself.
CONSORT DIAGRAM
A CONSORT diagram is a flow chart describing progress of the subjects through the 
various stages of a clinical study.
It is up to the Principal Investigator to complete the CONSORT Diagram. A single 
diagram must be prepared for each site taking part, and will be collected at the end 
of the study.
The diagram will therefore take all the subjects assessed during the screening stage 
and all the subjects recruited at that site into account.
The information used to prepare the diagram will be based on the Recruitm ent 
Forms completed for all eligible patients.
The Recruitment Forms of the patients included in the trial must be initialled and 
marked with the patient code and kept in special blue folders known as the GiSAS 
Folders. The Recruitment Forms of the excluded patients (with no patient codes) 
must, on the other hand, be kept in a green fo lder called the Excluded Patients  
Register.
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Figure 2. CONSORT Diagram
E LIG IB IL ITY  ASSESSMENT
(thorough assessment of indusion/exdusion 
criteria)
1° -  Assessment by the  Investiga tor:
• Check of diagnosis (MINI);
■ Absence of diabetes and of metabolic 
syndrome;
■ Absence of contraindications with regard to 
indicated treatment;
■ Advisability of taking part in a drug trial;
■ Assessment of patient's willingness, informed 
consent;
2 ° -  Clinical investigation and blood sampling  
3 °  -  Evaluation by th e  sponsor:
• Evaluation of the results of the centralised 
laboratory tests;
■ Check of the absence of a diagnosis of diabetes 
or metabolic syndrome.
Patient to be assessed for eligibility
>18 years of age 
• Diagnosis of 
schizophrenia
Assessed fo r  e lig ib ility
n = .................
Excluded n = ..................
□ Patients not meeting the inclusion 
criteria
n = .................
□ Patients refusing to take part
RANDOMIZED
Assigned A Assigned B Assigned C
n_
Have they received at least one dose Have they received at least one dose Have they received at least one dose
of the drug? of the drug? of the drug?
[ I f  not, state the reasons] [ If  not, state the reasons] [ I f  not, state the reasons]
1 1 1
Lost to  fo llow -up Lost to  fo llow -up Lost to  fo llow -up
State reasons: State reasons: State reasons:
□ Consent withdrawn n = ...... □ Consent withdrawn n = ...... □ Consent withdrawn n = ......
□ Deceased n = ...... □ Deceased n = ...... □ Deceased n = ......
□ Untraceable n = ...... □ Untraceable n = ...... □ Untraceable n = ......
□ Others n = ...... 0 Others n = ...... □ Others n = ......
[I f  Others, state reasons] [ If  Others, state reasons] [ If  Others, state reasons]
1 1 1
Included in the analysis Included in the analysis Included in the analysis
n _
Excluded from the analysis Excluded from the analysis Excluded from the analysis
n - n_
[ I f  Excluded, state reasons] [ If  Excluded, state reasons] [ I f  Excluded, state reasons]
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3. CONDUCTING THE TRIAL
A Baseline Form must be completed at the earliest opportunity for all patients 
included in the trial and randomised. As soon as this has been done, the patient may 
start to take the drug assigned to him/her.
During the 12 months for which the study will last, the antipsychotic therapy and any 
concomitant therapy must be carefully monitored. This monitoring will be certified by 
completing a Treatm ent Form, which must be done at least once a month and 
whenever the antipsychotic therapy is altered (each Treatment Form must be 
sent to Istituto 'Mario Negri' by telefax).
I f  the treatm ent is DISCONTINUED, another Treatm ent Form must be completed, 
taking care to indicate clearly the date on which it was discontinued and the
reason (Drug Discontinuation Form). This completed form must then be sent in by fax 
and the follow-up medical examination and blood sampling scheduled. It is important 
that not more than 3 weeks should pass between the time of discontinuing the 
treatment and the follow-up assessment.
Follow-up assessments must be carried out if and when treatm ent is 
discontinued, and at the deadline of 12 months from the date of randomization.
In both cases, both the Treatment Form and the Follow-up Form must be completed.
STUDY CHART
This chart must be filed in by the treating psychiatrist. The Principal Investigator must 
check that it has been completed.
SCREENING PHASE: The yellow part, concerning selection of the patients, has to 
be completed at the time of inclusion.
TRIAL PHASE. the single items of the part concerning the actual trial (in green in 
the diagram) must be filled in after each activity has been completed. 
OBSERVATION PHASE: All those patients who have completed month 12 follow- 
up assessment will be candidates for the observation stage. It is planned to assess the 
patients included in this stage every six months for the following two years, completing 
the Treatment Form and the Follow-up Form.
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This stage will constitute a separate study, the protocol for which will be notified to the 
Ethics Committees of the participating sites. It  is therefore planned to include only 
those patients who give their specific informed consent.
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Figure 1. Study Diagram
1 2  months
A C T I V I T Y S c r e e n i n g T o
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S T O P P E D
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years following completion of 
the trial)
Recruitment Form (RF)
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RANDOMIZATION
Randomization is an automatic procedure and the service is therefore active 
every day, 24 hours a day, phone number +390239014915 .
A recorded voice asks the necessary questions for: (a) identifying the recruitm ent 
centre; (b) checking the inclusion and exclusion criteria.
The Investigator must follow the instructions, replying by pressing the appropriate 
numerical keys. If the key corresponding to the expected answer is not pressed, the 
randomization procedure will be broken off. If this occurs simply due to a mistake in 
making the entries, it is necessary to ring off and start the procedure from the 
beginning again.
The randomization date will be considered as the date of starting the study. If it 
is not possible to adm inister the drug assigned to the patient on the same day, it 
must be administered as soon as possible and in any case w ithin 7 days.
The fact that the randomised patient has taken at least one dose of the drug, which 
is the criterion for actual inclusion in the study, must be confirmed by the  
Investigator by faxing the Randomization Form to Istituto 'Mario Negri'.
This means that the Randomization Form should not be sent in before the  
patient has actually started taking the treatm ent.
If the patient has not yet taken the drug assigned to him/her within the seven-day 
deadline, please contact immediately Istituto 'Mario Negri'.
DRUG SWITCHES
Attached to the Manual are drug switching guidelines, for the purpose of providing tips 
for replacing antipsychotic treatment being taken at the time of recruitment with that 
assigned by the randomization procedure (Attachm ent 2).
The switch must be achieved w ithin one month from the tim e of taking the first 
dose of the drug.
DISCONTINUATION OF TREATMENT
The assigned antipsychotic treatm ent will be said to have been discontinued:
(a) when the patient and/or the treating psychiatrist decide to stop using the assigned 
drug;
Or
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(b) when another antipsychotic drug is added to the one assigned.
Cases of tem p o rary  an d  occasional d iscontinuation  (so-called drug holidays) are  
exceptions to point (a). This means that it is possible for the patient to stop taking 
the treatment provided (1) this does not happen more than once over a period of six 
months and that (2) the holiday lasts less than two weeks.
If , for example, it is found that a patient has stopped taking the drug assigned to him /her for a week, this 
does not entail the obligation to report that the treatment has been discontinued, unless the patient has 
already stopped taking the drug on a t least one other occasion in the previous six months. I f  he/she stops 
taking the drug for two weeks or more, on the other hand, it will be compulsory to report that the treatment 
was discontinued.
An exception to point (b) is occasional parenteral antipsychotic treatm ent. In
this latter case, no operational definition of the term occasional is provided since non­
depot intramuscular antipsychotic treatment is usually administered in emergency 
situations.
After stopping the treatment, it may happen that the patient starts taking the drug 
assigned by the randomization procedure again, either on its own or associated with 
another antipsychotic drug.
In  any case, once the assigned drug has been discontinued, it is no longer 
necessary to monitor the drug treatm ent (Treatm ent Form).
For patients who stop taking the treatment and therefore are no longer being 
monitored, the information on the drugs taken up to the time of the one-year follow-up 
must in any case be acquired, completing on that occasion only the Treatment Form.
MEDICAL CHECK-UP AND TESTS
The treating psychiatrist has the task of carrying out a medical check-up, at which 
time the following parameters must be measured: height, weight, blood pressure, 
abdominal circumference and hips.
The treating psychiatrist also has the task of scheduling the blood chemistry and 
instrumental tests for account of the service (haemochrome and ECG) and of 
arranging for the blood samples to be sent to the reference laboratory for 
centrifuging and freezing.
The check-up, the tests and the sampling are carried out:
(a) after inclusion in the study 
baseline, to
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(b) upon stopping the treatment assigned 
Follow-up 1, t i
(c) in month 12 from randomization 
Follow-up 2, t 2
ABDOMINAL CIRCUMFERENCE
The abdominal circumference, also known as waist circumference, is an indirect 
measurement of intra-abdominal visceral fat. It has to be measured and rounded off to 
the first decimal place (0.1 cm).
Istituto 'Mario Negri' will provide special measuring tapes made of flexible and 
undeformable material.
Each measuring tape is connected to a spring-operated device that will allow it to be 
tightened around the abdomen with a force of 750 grams.
The waist must be measured at its narrowest point, in the area between the superior 
iliac spine and the lower margin of the rib cage (usually at the height of the navel). 
With the patient standing up straight, the measuring tape must be applied to the bare 
skin, holding it parallel to the ground. While the measurement is being carried out, the 
patient must be relaxed and must breathe freely, with his/her arms hanging loosely at 
his/her sides.
HIP CIRCUMFERENCE
The hip circumference must be measured and rounded off to the first decimal place 
(0.1 cm). The same measuring tapes used to measure the abdominal circumference 
will be used. Each measuring tape is connected to a spring-operated device enabling it 
to be tightened around the hips with a force of 750 grams.
The circumference must be measured around the buttocks, at the height of the femoral 
head, in the place where the hips are at their widest.
With the patient standing upright, the tape must be placed over his/her underwear and 
held parallel to the ground.
WAIST-TO-HIP RATIO
This is the ratio of the abdominal circumference to that of the hips.
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ECG
The ECG must be carried out by the participating sites. Copies of the 
electrocardiogram and report must be attached to the CRF and the information 
contained in the report must be copied onto the CRF by the treating psychiatrist.
SAMPLING PROCEDURE
The treating psychiatrist must arrange for the samples to be taken according to the 
standard procedures and to send them to the reference laboratory, where they will be 
centrifuged and frozen at a tem perature between -30  and -70°C . Istituto 'Mario 
Negri' will make arrangements with the reference laboratory for collecting the samples 
and sending them to the centralised laboratory. Instructions for taking and collecting 
the blood samples are attached to this manual (Attachment 1).
HAEMOCHROME
Flaemochromocytometric testing and testing of the leukocyte formula and electrolytes 
must be carried out by the participating site. Copies of the reports must be 
attached to the CRF and the results be copied onto the CRF by the Investigator.
OTHER TESTS
Patients who, at the time of their follow-up tests, have fasting biood-sugar values 
exceeding 126 m g/d l must be tested by their participating site in order to exclude or 
confirm the diagnosis of diabetes.
Istituto 'Mario Negri' undertakes to notify the codes of those patients who have high 
blood-sugar values as soon as the results of the tests are available.
Patients who are reported as above will have to repeat the test for assessing their 
fasting blood-sugar levels and must undergo testing for their glycaemic loads. 
These tests must be carried out by the participating site and are for the  
latter's account, since they are part of a routine in-depth diagnostic procedure 
indicated specifically in standard guidelines.
The treating psychiatrists undertake to inform Is titu to  'Mario Negri' of the  
results of the tests, attaching copies of the results to the patient's Follow-up Form.
Appendix 1 -  page 16
ASSESSMENT SCALES
MINI
The Mini International Neuropsychiatric Interview1 (MINI) is a short structured 
interview enabling formulation of 14 Axis I  diagnoses according to the criteria of 
DSM IV , formulation of an Axis I I  diagnosis (Antisocial Personality Disorder) and 
evaluation of the risk of suicide. The authors referred to the CIDI (Composite 
International Diagnostic Interview), trying to simplify the diagnostic procedures for 
easier and faster use in clinical practice.
This tool has a modular structure, each module corresponding to a diagnostic area. 
Each area includes one or two preliminary questions requiring dichotomous answers 
(YES/NO). A reply in the negative to these questions indicates the absence of the 
related diagnosis and the need to go on to the next module. A reply in the affirmative, 
on the other hand, implies the possible presence of the diagnosis being investigated 
and therefore the need to go into the criteria to be met in further depth.
The period of time to be assessed is specified for each diagnosis and may span from 
the length of the interview to the interviewee's whole life, depending on what is 
specifically required for each diagnosis.
In this study, reference is made solely to module M of the MINI, which concerns the 
schizophrenia diagnostic area.
BPRS
The Brief Psychiatric Rating Scale2 (BPRS) is a m ulti-factor psychopathological 
rating scale developed with the intention of providing a minimum set of 
phenomenological characteristics capable of characterising the psychopathological 
state of the patient.
In the GiSAS study, the version extended to 24 items is used, together with the related 
instruction manual (BPRS 4.0)3. The manual is a sort of semi-structured interview 
providing detailed instructions on how to detect the presence of the symptoms and on 
assessing how serious they are. Each item refers to a specific symptom. The score for
1
Sheehan DV, LecrublerY etal. M IN I International Neuropsychiatric Interview (M .I.N .I.) . University of South Florida Institute for Research in 
Psychiatry,
Tampa, Florida and INSERM -  H$pital de la Salp^triere, Paris, France, 1994.
2
Lukoff D„ Nuechterlein K & Ventura J. Manual for the expanded Brief Psychiatric Rating Scale. Schizophrenia Bulletin 12 :594 -602 , 1986.
3
Ventura J„ Green MF, .Shaner A & Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale: "The drift busters". 
International Journal of Methods in Psychiatry Research 3 :221 -6 , 1993
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each item is assigned by means of a 7-point Likert-type scale (1 = absent to 7 = very 
serious).
In assigning the score, the treating psychiatrist must keep a hierarchical criterion in 
mind, referring to the highest level of seriousness of the symptoms in the period of 
time considered and must consider the aspect for which the prejudice appears to be at 
its greatest (frequency or gravity). The reference period of time is the month 
preceding the interview.
For each symptom the manual indicates an operational definition of the various levels 
of seriousness (anchor points): a score of 1 refers to a sub-clinical situation, a score of 
2 to 3 to a mild symptom, a score of 4 to 5 to a moderate symptom and a score of 6 to 
7 to a serious symptom. It is necessary, initially, to anchor oneself to one of these 
levels of seriousness and, only subsequently, to choose an intermediate score (e.g. 4 
or 5).
The symptoms must be identified and their seriousness be defined through the clinical 
interview, direct observation and the use of other sources (e. family members and 
friends, other staff members, clinical records).
The manual specifies which sources should be used to complete each item (see Table 
1).
In the GiSAS study, the BPRS is used to evaluate how serious the patients are at 
the baseline. The scale must therefore be applied to the patients only at the time of 
their inclusion. The overall score, consisting of the sum of the scores for the 24 items 
has to be entered on the Recruitment Form.
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Table 1. Reference sources for the BPRS
BPRS 4.0________
1. Somatic concern
14. Disorientation
1*3
h
2. Anxiety
3. Depression
4. Suicidality
5. Guilt
6. Hostility
8. Grandiosity
9. Suspiciousness
10. Hallucinations
11. Unusual thought content
□  Items 1-6, 8-11: Take the patient's own statements (clinical interview) or what he has said to others (other sources) 
into account.
§§f Items 7+12+13: ALSO take the behaviour observed (direct observation + clinical interview /  other sources)
into account
|  Items 15-24: Take ONLY observed behaviour or the type of language used into account (direct observation).
GAF
The Global Assessment of Functioning scale4 (GAF) is an assessment scale of the  
global type. It was developed in order to assess the overall seriousness of a patient 
on the basis of a pre-defined scale, regardless of the psychopathological complexity 
and of the nature of the psychiatric disorder. It was originally included in DSM-III-R 
and in DSM-IV as Axis V of the multi-axis classification.
The period of time that the treating psychiatrist has to consider is the month preceding 
the interview. The assessment of the seriousness refers both to the psychopathological 
aspects and to psychosocial and job-related functioning in a hypothetical continuum 
calling for assignment of a score of 100 for a situation of full mental health or ideal 
functioning and a score of 1 to a dysfunction serious enough to prejudice the very 
survival of the person.
The numerical scale is split up into 10 anchor points, each of which defines a level of 
seriousness. For each level, a reference description is provided which should match the 
patient's situation. Each anchor point is in turn further divided up into 10 points.
4
DSM-IV (1995) Washington DC: A.P.A. Press.
Appendix 1 -  page 19
The range from 81 to 100 refers to conditions of absence of mental disease and good 
functioning, characterised by the presence of positive features (richness of interests 
and social relations, warmth, positive attitude towards life). The range from 71 to 80  
indicates a marginal presence of mental illness or difficulty of functioning, and the 
range from 1 to 70 indicates the presence of mental disease or problems in 
functioning of different degrees of seriousness. Within this range, the cut-off level of 
50 should be kept in mind. Scores below this level (^ 5 0 ) refer to situations varying 
from moderately to extremely serious (Severely Mentally III, SMI).
Lastly, in assigning the score, the psychiatrist must keep a hierarchical criterion in 
mind, referring to the lowest level of functioning reached by the patient in the period of 
time considered (approximately one month) and considering the score in the area 
which appears to be most severely prejudiced (symptoms or social functioning).
In the GiSAS study, the GAF is used to assess the overall effectiveness of the drug 
assigned to the patient. The score must be entered on the CRF both at the baseline 
and at the time of the follow-up.
LUNSERS
The Liverpool University Neuroleptic Side-Effect Rating Scale5 (LUNSERS) is a 51-item 
self-rating scale to be used by the patient, indicating the conditions affecting him/her 
and their intensity. The patient must be asked explicitly to indicate the symptoms that 
he/she feels are side effects of the antipsychotic treatment he/she is taking. Those 
patients who at the time of recruitment have not been taking any antipsychotic 
treatment for over one month and who do not exhibit any residual side effects (e.g. 
obesity, tardive dyskinesia) need not complete the LUNSERS. In these cases the 
treating psychiatrist shall indicate the reason for not doing so on the Recruitment Form 
in the area next to that provided for indicating the LUNSERS score.
The score for each symptom is assigned using a 5-point Likert-type scale (1= not at all 
to 5 = very much). The reference period of time is the month preceding the interview. 
The questionnaire contains 41 questions referring to specific and proven side effects of 
neuroleptic drugs.
The remaining 10 questions, scattered at random throughout the list, are, on the other 
hand, "red herring" items having the purpose of drawing attention to unreliable side
5
*Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. 
British
Journal of Psychiatry 166 :650-3 , 1995.
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effects. That is to say, these symptoms, such as hair loss and chilblains, have nothing 
to do with the effects of the antipsychotic drugs and might be indicated by patients 
who tend to overestimate the negative effects of the drugs.
In the intentions of the authors, the total score of the "red herring" items (numbers 3, 
8, 11, 12, 25, 28, 30, 33, 42 and 45) would identify those subjects who tend to give 
imprecise answers, thus providing an index of the reliability of the results.
The psychiatrist is required simply to calculate the overall score, consisting of 
the sum of all fifty-one answers, to be entered on the CRF, both at the baseline and at 
the time of the follow-up. The score referred to the "red herring" and the difference 
between the two scores, on the other hand, will be calculated by Istituto 'Mario Negri".
USING THE ASSESSMENT SCALES
Use of the assessment scales and the manner in which they are to be completed are 
summarised in Table 3.
Table 3. Using the assessment scales
Which? Why? When? Where?
MINI To oonfirm or formulate the diagnosis of schizophrenia Screening Recruitment Form
BPRS To assess the severity of the symptoms Baseline Baseline Form
GAF To assess the overall severity and psychosocial functioning Baseline and Follow-up Baseline Form and Follow-up Form
LUNSERS To assess the side effects from the patient's point of view Baseline and Follow-up Baseline Form and Follow-up Form
ASSESSMENT FORMS
GENERAL PROCEDURE FOR COMPLETING THE FORMS
All the forms for acquiring data for the study are supplied by Istituto 'Mario Negri". If a 
recruitment centre has none left, it must request a supply.
The Randomization Forms, Treatment Forms and Adverse Drug Reaction Forms are 
simple paper forms.
The Baseline Form and the Follow-up Form, on the other hand, are self-copying
forms. They are grouped in sets containing on Baseline Form and two Follow-up
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Forms. To make entries on them use only blue or black ball-point pens, NOT fountain- 
pens or pencils.
Answer the questions, from time to time, by marking the appropriate reply with an 'X' 
or writing in the space provided, in block capitals.
For all questions w ith YES or NO replies, one of the two possible replies must 
always be marked with an 'X".
To correct an incorrect entry, cross it out and make the correct entry next to it, 
initialling and dating the correction. DO NOT use correcting fluid.
MONITOR
Each recruitment centre will be visited at least three times during the course of the 
study by a monitor (research assistant) who will have the role of supporting conducting 
of the study and the task of checking that the forms are properly completed.
The Investigator will be contacted to arrange an appointment, and all the necessary 
tim e must be devoted to it.
The monitor must be able to meet all the recruiting psychiatrists of the site during a 
single visit. To make this simpler, it is advisable to arrange the visits at time when it is 
easier to trace all the psychiatrists concerned will be present, e.g. on days on which 
regular meetings of the service are to be held.
FILING AND DESPATCH OF THE FORMS
The Recruitment Forms of the subjects included in the studied must be filed in their 
respective folders until the end of the study.
The Recruitment Forms of the excluded subjects must be filed by each treating 
psychiatrist in the special green folder (Excluded Patients Register). At the end of the 
year of recruitment, they shall be collected by the Principal Investigator, who will 
create the Excluded Patients Register of the participating site.
The Randomization Forms, Treatment Forms and ADR Report Form must be faxed to 
Istituto 'Mario Negri" (+39 02 39014300). The originals of the forms and sheets must, 
on the other hand, be kept at the recruitment centre in their respective folders. At the 
end of the trial stage and after being reviewed by the monitor, they will be collected by 
Istituto 'Mario Negri".
Special care must be taken with regard to the Treatm ent Forms reporting 
discontinuation of the treatm ent and the reasons for stopping, which must 
faxed immediately to Istituto 'Mario Negri".
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As far as concerns the sets of Baseline and Follow-up Forms, the coloured copies 
(originals) of each self-copying set must be sent to Istituto 'Mario Negri" immediately 
after completion in a pre-stamped envelope, while the white copies must be kept by 
the participating site in the GiSAS Folder until the end of the study. The same 
procedure must be adopted for the sheets for rating the BPRS and LUNSERS 
tests.
The clinical documentation (results of blood chemistry tests, electrocardiograms 
and ECG reports) must be photocopied and made anonymous. They must then be 
kept in the GiSAS Folder, taking care to mark each form w ith the patient code.
One copy of all the documentation should be kept in the GiSAS Folder until the end of 
the study.
The procedures to be used by the GiSAS investigators for sending the forms and 
sheets to Istituto 'Mario Negri" are summarised in Table 2.
After the final visit by the monitor, all the documentation w ill be collected by 
Is titu to  'Mario Negri".
RECRUITMENT FORM
A Recruitment Form must be initiated for each patient entering the screening stage. 
The Recruitment Form of each patient to be included in the trial must be completed, 
initialled and marked with the patient code (obtained by means of the telephone 
randomization procedure) and kept in the GiSAS Folder.
The Recruitment Forms of those who cannot be included, with no patient codes, must 
be kept in a special green folder (the Excluded Patients Register).
RANDOMIZATION FORM
A Randomization Form has to be completed for each patient included.
The Randomization Form is not self-copying. The first side contains the patient's 
main details and the randomization code, and must be faxed to Is titu to  'Mario  
Negri" (+39 02 39014300) after the patient has taken the first dose of the drug 
assigned to him/her. The second side, containing confidential data, must not be 
sent to Is titu to  'Mario Negri".
Table 2. Procedures for sending in the forms
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Fax Randomization Form Treatment Forms 
ADR Report Form
After the first dose of the drug
Approximately once a month circa and whenever the treatment is altered 
At the onset of any adverse drug reaction
Mail
Baseline Form (original) 
Follow-up Form (original) 
Coding form (original)
After the baseline assessments (to)
After the follow-up assessments ( t i  t2)
After the baseline and follow-up assessments ( t0 t i  t2)
BASELINE FORM
The Baseline Form and two copies of the Follow-up Form make up a single set of self­
copying sheets (set of Baseline and Follow-up Forms).
A Baseline Form must be completed by the treating psychiatrist for each patient who is 
randomised.
The randomization number (patient code) and the date of completion of the form
must be shown clearly on it.
It contains information concerning (a) the patient's lifestyle, (b) his/her case history,
(c) the drugs he/she was taking at the time of inclusion and (c) other clinically 
significant information.
The following must be copied onto it:
- the requested laboratory values (haemochrome, leukocyte formula and electrolytes);
- the patient's anthropometric and ECG data;
- the patient's GAF, BPRS and LUNSERS scores.
Lab and instrumental tests: The date on which the tests were carried out will have 
to be indicated, together with the values of all the parameters required, using the units 
of measurement indicated.
The date on which the tests w ere carried out:
(a ) shall be prior to that of taking the first dose of the drug;
(b ) shall NOT be more than 21 days earlier than the date of randomization.
The blood samples for the centralised laboratory must be identified by sticking 
one of the labels provided to the form.
First of all, the date of sampling must be entered. Then the two loose labels contained 
in each sampling kit and identical to those already attached to the test tubes must be 
put into place. One of the labels must be stuck to the coloured sheet (original to be 
sent to Istituto 'Mario Negri') and the other to the white sheet (copy to be kept at the 
site).
The date of sampling:
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(a )  shall be prior to  th a t o f tak ing  th e  firs t dose o f th e  drug;
(b ) shall NOT be m ore than  21 days ea rlie r than  the  date  of random ization.
TREATMENT FORM
A Treatment Form m ust be com pleted:
(a )  w h en ever a change is m ade in th e  antipsychotic tre a tm e n t assigned  
and
(b ) a t least once a m onth.
The randomization number (patient code) and the date of completion must be shown 
clearly on the form.
All the  T reatm en t Forms must be faxed to  Is titu to  'M ario  N egri' (+39 02 
39014300), taking care to send both the first and the second side.
To complete the Treatment Form correctly, it is necessary to refer to the M onitoring  
Chart (A ttachm ent 3 ). This flow chart illustrates the decision-making process to be 
followed by the treating psychiatrist in order either to confirm the treatment assigned 
to the patient or to state that it has been stopped.
The Treatment Form is divided up into four sections (points 1, 2, 3 and 4): Section 
One investigates any changes in the antipsychotic treatment assigned, Section Two 
documents confirmation by the treating physician of the antipsychotic treatment 
assigned, Section Three investigates the presence of other drug treatment and Section 
Four records the reasons, if any, for discontinuing the antipsychotic treatment assigned 
(D iscontinuation Form ).
If the antipsychotic treatment assigned is found to be unchanged, it will be sufficient to 
answer the preliminary question by marking the YES box with a cross. It will not be 
necessary to complete the second section (point 1), and it will be possible to go 
directly to the next ones (points 2 and 3).
The Discontinuation Form (point 4) must be completed only if th e  antipsychotic  
tre a tm en t assigned is stopped once and fo r all. The date  and th e  reason fo r  
stopping tre a tm en t must be indicated and a fo llow -up  exam ination  must be 
scheduled as soon as possible. A deadline o f 21  days has been set within which to 
carry out the follow-up assessment, instrumental tests and the blood sampling.
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FOLLOW-UP FORM
The Baseline Form and two copies of the Follow-up form make a single set o f self­
copying sheets (set of baseline and follow-up assessment forms).
A Follow-up Form must be completed by the treating psychiatrist for each patient 
randomised.
The random ization num ber (patient code) and the date o f com pletion of th e  form
must be shown clearly on it.
It contains information concerning (a) the patient's lifestyle, (b) the taking over of 
psychiatric care of the patient, and (c) the activities carried out in order to promote 
compliance with the prescribed treatment. Reference m ust be m ade solely to  th e  
period fo llow ing recru itm ent.
Careful viewing of the information required at the time of the follow-up is 
recommended.
This is because although such information is acquired retrospectively, it will be 
necessary to  keep track  of the  data required throughout the  duration  o f th e  
study, so as to avoid a reconstruction that might be too imprecise.
The following must be copied onto the form:
- the requested laboratory values (haemochrome, leukocyte formula and electrolytes);
- the patient's anthropometric and ECG data;
- the patient's GAF, BPRS and LUNSERS scores.
Lastly, taking of the blood samples for the centralised laboratory must be documented 
by sticking the special label to the form.
Lab and instrum ental tests: The date on which the tests were carried out will have 
to be indicated, together with the values of all the parameters required, using the units 
of measurement indicated.
Taking of the blood sam ples fo r th e  centralised laboratory  must be documented 
by sticking the special label to the form.
First of all, the date of sampling must be entered. Then the two loose labels contained 
in each sampling kit and identical to those already attached to the test tubes must be 
put into place. One of the labels must be stuck to the coloured sheet (original to be 
sent to Istituto 'Mario Negri') and the other to the white sheet (copy to be kept at the 
site).
Follow-up examination and the required tests must be scheduled on tw o  occasions:
(a) at the time, if any, of discontinuing th e  assigned antipsychotic tre a tm e n t  
(fo llow -up  I ,  t i ) ;
(b) in m onth 12 fo llow ing random ization (fo llo w -u p  I I ,  t 2 ).
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In the first case, the examination, the tests and taking of the samples for the 
centralised laboratory must be scheduled at a distance of 21 days a t the  most a fte r  
discontinuing th e  tre a tm en t. In the second case, on the other hand, the follow-up 
may be scheduled at any time betw een 7 days prior to  th e  date  set fo r the  
exam ination  to  21 days a fte r  it.
ADR REPORT FORM
Any detrimental or undesired reaction to medication during a trial, regardless of the 
dose administered is defined an adverse drug reaction (A D R ).
Any adverse reaction that, regardless of the dose, has a fatal outcome, endangers the 
life of the subject, entails hospitalisation or lengthens an existing stay in hospital, or 
which leads to an disability or a serious or long-term incompetence or to a congenital 
anomaly or malformation or a defect at birth is defined a SERIOUS ADR. 
Spontaneous reporting of an ADR consists of notification concerning the onset of a 
symptom or of an upset suspected of having occurred after taking a drug.
All such occurrences must be reported by completing an ADR Report Form and faxing it 
to Istituto 'Mario Negri' (+39 02 39014300).
In accordance with Law Decree no. 211 of 24th June 2003, Istituto 'Mario Negri' has to 
take care of recording in detail all adverse events notified by the investigators and of 
reporting same to the Ethics Committee concerned and to the Ministry of Health.
In the event that the death of a subject is notified, the Investigator must inform both 
Istituto 'Mario Negri' and, directly, the Ethics Committee concerned, completing and 
sending them the ADR Report Form of the study and providing any additional 
information required.
In  th e  event o f serious Adverse Drug Reactions (AD R's):
An ADR Report Form must be faxed (to 39 02 39014300) w ith in  24  hours from 
becoming aware of the event.
The up-dated form must be faxed w ith in  4  days from gaining knowledge of the event, 
attaching the necessary documentation for validating the event (e.g. letter of 
discharge, instrumental or laboratory tests).
If the event lasts for over 4 days, please fax the up-dated form, attaching any 
additional documentation, w ith in  4  days from  solution of th e  event.
The originals of the form and of the documentation must be sent to Istituto 'Mario 
Negri' using a pre-stamped envelope.
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In  the  event o f several ADR's affecting th e  sam e patien t, a separate form must 
be completed for each of these.
In the event of a serious ADR, one form must be completed for each event occurring 
until 30  days a fte r  discontinuing th e  assigned trea tm en t.
PUBLICATION OF THE RESULTS
The data relating to the study are the sole property  o f Is t itu to  di Ricerche
Farm acologiche 'M ario  Negri'. Access to the data in their entirely by the 
participating sites will be guaranteed.
Following approval by the Scientific Committee, Istituto 'Mario Negri' undertakes to 
publish a final report on the main results of the study.
The overall results will be made available to the single Investigators, who may use 
them in the name of the group of GiSAS investigators for teaching purposes, for 
presentations at congresses and scientific publications, subject to the prior consent of 
the Scientific Committee.
Istituto 'Mario Negri' and the Scientific Committee will schedule publication of a series 
of scientific papers on the main aspects of the trial. The investigators at the 
participating sites will be included among the authors of the main scientific paper in 
the form of a collective signature. Following publication of the results, the scientific 
data in their entirety will be made available to the scientific community.
GiSAS Investigators are encouraged to promote ancillary studies having the following 
characteristics: (a) they must be conducted on patients included in the GiSAS study;
(b) they must involve or concern staff members involved in the GiSAS study; (C) they 
must not entail an excessive burden for the staff.
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MARIO NEGRI
ISTITUTO DI RICERCHE 
FARMACOLOGICHE - PLEASE COMPLETE USING BLOCK CAPITALS - Q S ^ S  trial
S ite  code
RECRUITMENT FORM (RF)
{Please answer the following questions by marking the appropriate reply with a cross)
PLACE OF RECRUITMENT: ® Mental Healthcare Centre/out-patient ® Hospital w ard/in-patient
® Day Hospital © Day Centre
© Residential facility © At home
AG E SEX C LIN IC A L D IA G N O S IS
YEARS AT SCHOOL:
M ARITAL STATUS: ©  Never married 
®  Married
Separated/divorced
Widow/widower
EMPLOYMENT ©  Employed 
(D Protected employment ©  Student 
©  Retired
Housewife/husband ©  Disabled
STATUS:
Unemployed
M IN I D IA G N O S IS  ( NOTE: The diagnosis is made by the clinician using the checklist of psychotic disorders of the
Mini In ternatio na l Neuropsychiatric In terv iew , based on th e  c r ite r ia  o f D S M -IV )
Axis I ______________________________________________________
Axis I I  _______________________________________________________
Axis I I I
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RECRUITMENT CHECKLIST
(Please answer the following questions by marking the appropriate reply with a cross)
a )  IS THE PATIENT OF AGE?
b ) Does the patient have s c h iz o p h r e n ia ?
c) Is THE PATIENT TAKING AP TREATMENT?
YES NO
Is  he/she taking any of the proposed AP drugs? Has he/she already 
taken AP drugs in the 
past?
YESYES NO
Do the conditions enabling 
the AP drug to be 
changed exist?
Do the conditions for 
prescriving an AP drug
exist?
Do the conditions exist for 
including him/her in the 
study in any case, leaving 
the choice whether to 
change the AP drug to 
chance?
NOYES YES YES
YES
THE PATIENT IS TAKEN INTO CONSIDERATION FOR INCLUSION IN THE STUDY
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I .  Does the patient have m e ta b o lic  syndrom e?
I I .  Does the patient have ty p e  2 d ia b e tes ?
I I I .  Are there p a r t ic u la r  p h y s ic a l c o n d it io n s  o f  th e
PATIENT CONTRAINDICATING HIS/HER INCLUSION IN THE STUDY?
IV . Are there any clear c o n tra in d ic a tio n s  t o  th e  use o f
ARIPIPRAZOLE?
V. Are there any clear c o n tra in d ic a tio n s  t o  th e  use o f
OLANZAPINE?
V I . Are there any clear c o n tra in d ic a tio n s  t o  th e  use o f
HALOPERIDOL?
NO
NO
NO
NO
NO
NO
( I f  the re  are  any  co n tra in d ica tio ns  to  use o f  a n y  o f  the  p ropo sed  drugs,
spec ify  th e m ______________  )
V I I .  IS IT NOT THOUGHT POSSIBLE TO FOLLOW THE PATIENT FOR THE NEXT 12 MONTHS?
NO
IF  EVEN ONLY ONE OF THE QUESTIONS HAS BEEN ANSWERED W ITH A 
THE PATIENT CAN N O T BE IN C LU D E D  IN  THE STU D Y
DOES THE PATIENT AGREE TO TAKE PART IN  THE STUDY? y e s
t
IF  SO, THE PA TIEN T IS  INCLUDED IN  THE STUDY
Proceed to  com p le te  the  R andom isa tion  Form
C om pleted on J I l_
mm yy
Patient code
TREATING PSYCHIATRIST SIGNATURE
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Site code I I I I Patient code
BASELINE FORM (BF)
(Please answer the following questions by marking the appropriate reply with a
Where does the @ At home ©  Other, specify:
patient live? ®  in a residential facility
With whom does the ©  On his/her own ©  With other people. Specify:
patient live? ~
CP With family members
f N.B. Refer to the last year)
DOES THE PATIENT:
D R IN K  ALCOHOL [y|s] m \ SMOKE \m \ [Hal D R IN K  COFFEE [yes] M \
I f  SO, ind ica te  h is /h e r  average  d a ily  co n su m p tio n :
wine (125-m l glasses) n° |___ |__ | Cigarettes n°_|__ |__ | coffee-cups n° |___|___|
beer (33-cl cans) n° |___ |_|
hard drinks (small glass) n° |___ |_|
PHYSICAL A C T IV IT Y
AT W ORK IN FREE T IM E
[2 Sedentary (e.g. derical worker, student) a Little exercise, sedentary (e.g. reading, watching TV)
m Standing (e.g. shop assistant, housewife, teacher) CO Mild exercise (e.g. short walks, yoga, riding a bicycle)
s Average (e.g. maid /  manservant; cleaning) a Moderate exercise (e.g. regular sports or open-air activity)
a Heavy (e.g.. gardener, farmer, industrial worker) Intense activity (e.g. intense sports)
0 Very heavy (eg. builder, demolition worker, sports)
a Not workin
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Site code Patient code
SIGNIFICANT CLINICAL ASPECTS
Year of first psychiatric contact 
Taken on by this service in the year
J__ I_ l_
I I I
□  Unknow n
□  U nknow n
Is the patient currently hospitalised in a psychiatric ward? YES NO
Is the patient currently addicted to substances or alcohol, or does he/she  
exhibit abuse thereof? YES NO
Has the patient ever attempted suicide in his/her lifetime? YES NO
I f  so, how many times? 
Year of last episode I I I □  U nknow n
Does the patient have tardive dyskinesia? YES NO
Does the patient have other complaints traceable to drugs taken?
YES NO
I f  so, what complaints?
Drug Type of complaint (diagnosis, if any) Drug Type of complaint (diagnosis, if any)
CASE HISTORY
MAJOR DISEASES: CARDIOVASCULAR Iyes I [ n o !
NEUROLOGICAL Iyes I [ n o !
OTHERS | YES | [ n o !
I f  S O , specify th e  diagnosis:
GiSAS -  Baseline Form 3 of 5
G S ^ S  trial
Site code Patient code
PHARMACOLOGICAL TREATMENT
How long is it since the patient took an AP drug for the first time? | i 11 i
PREVIOUS ANTIPSYCHOTIC TREATMENT
years months
{re fer to the last two years)
P atien t's  com pliance: ® ® 
unsatisfactory uncertain satisfactory not assessable
P atien t's  overall opinion o f e a rlie r  AP tre a tm e n t
a) efficacy: ®
veiy
negative
®
fairly
negative
©
fairly
positive
©
very
positive
b) side effects: ®
V e ry
negative
®
fairly
negative
©
fairly
positive
©
very
positive
not
assessable
not
assessable
CURRENT PHARMACOLOGICAL TREATMENT {refer to time o f inclusion in the study)
YES NOIs the patient receiving oral an tipsychotic  trea tm en t?
I f  so, what drugs is he/she receiving?
M olecule Dose D ate o f s ta rtin g  tre a tm e n t
1  . ____________________________ I___ I___| m g/day I i I i I
2. I i
mm yy
m g/day
mm  yy
Is the patient receiving depot antipsychotic  trea tm e n t?  YES
I f  so, what drugs is he/she receiving?
NO
M olecule Dose
 I I mg
In te rv a l
every |___
D ate  o f las t in jection
weeks
mm yy
Is the patient receiving any other pharmacological treatment*? |yes[ |no
(consider any and all classes and categories of drugs, not only psvchoactive drugs)
I f  so, what drugs is he/she receiving?
Molecule Date of starting treatment Molecule Date of starting treatment
1 .  I I I I I 3 . I I I I I
2. I I I I I 4. I I I I I
*  The use of L IT H IU M  or other mood stabilisers is permitted only if it was started a t  least 3  m onths p rio r to 
recruitm ent.
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Site code I I I I Patient code
CLINICAL EXAMINATION
H eigh t | i i | cm Body w e ig h t I i i 1 kg
A bdom inal c ircum ference | i i U | cm
Hip c ircum ference 1 i i I J | cm
BP | i | I / I I | mmHq
Report the presence of any of the fo llo w in g  disorders:
Akathisia iV E g  [ n o I Gynaecomastia [ y | | ] l~NOl
Parkinsonian state 11 Galactorrhea I y e s I [ n o ]
Dystonia I Y E S | | N O | Dysmenorrhea {yes} [ n o ]
Tardive dsykinesia [ y H  [ n o ] Irregular menstruation [ y e s ] [ n o ]
I  ECG FIN D IN G * | Date 1 1 1 1 1 1 1
dd mm  yy
HR 1 i l 1 bpm QTC 1 1 1 1 msec
A ssessm ent o f ECG: 0 ABNORMAL [7 ]  NORMAL
I f  ABNORMAL, specify:
Atrial fibrillation/flutter I y e s I  I n o  I Right BBB [ye_s| [ n o ]
PM-induced rate I y e s I  I n o  I Left BBB |yesJ [ n o ]
Pathological Q waves I y e s I | n o LEFT v e n tr ic u la r h yp ertro p h y  [ y e s ] [ n o !
□  Other. Specify:
BPRS 4 .0  s c o re **  | i 1 GAF s c o re **  | i i
LUNSERS s c o re **  |___ |___ i___ |
I f  NOT com pleted , state the reason:
*  Keep copies of the electrocardiogram and of the finding in the GiSAS folder.
* *  Indicate the overall score of the scales and keep copies of them in the GiSAS folder.
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Site code |___|___ |___ | Patient code
BLOOD SAMPLES FOR THE C EN TR A LISED  LABORATORY
(glucose, triglycerides, HDL cholesterol, prolactin)
Taken on |__| |__|__|__|_
da mm yy
BLOOD TESTS
HAEMOCHROME W IT H  FO R M U LA * Sampling date | I | I | 1 |
dd mm  yy
Haemochromocytometric tests Leukocyte formula
While blood cells (/m m 3) 1 1 1 1 1
| Neutrophils (% ) I I I I
Red blood cells (/m m 3) | [ , | | million 
Platelets (/m m 3) 1 1 1 1 1 
Haemoglobin (g /dl) | | | , | | 
Haematocrit (%) | | |
Lymphocytes (% ) 1 1 1 1 
1 Electrolytes
Na+ (m Eq/l) 1 1 1 1 
K+ (m Eq/l) I I I I 
Mg++ (m g/dl) 1 1 1 1
Completed on 1 1 1 1 1 1 1
aa m m  yy
By Signature
Stick the adhesive label from 
the sampling kit here
*  Keep a copy of the report in the GiSAS folder. 6 di 5
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Site code I I I I Patient code
TREATMENT FORM (TF)
(Please answer the following questions by marking the appropriate reply with a cross)
WAS THE ASSIGNED DRUG TAKEN REGULARLY WITHOUT ADDING OF ANY OTHER ANTIPSYCHOTTCS? 
N.B. I f  so, skip the next Section and go to POINT 2.
IS  THE PATIENT CURRENTLY TAKING THE ASSIGNED ANTIPSYCHOTIC (AP) DRUG?
(See TREATMENT DIAGRAM)
□  YES, he/she is taking it □  NO, he/she is not taking it
_________________________v ________________________________ 4/ ____________
HAVE THERE BEEN PERIODS SINCE THE LAST CHECK-UP 
IN  WHICH HE/ SHE DID NOT TAKE THE AP?
□  NO □  YES
If  so, was it a temporary and occasional suspension *?
WAS IT  A TEMPORARY AND OCCASIONAL DISCONTINUATION? *  
□  YES □  I f f l lr
□  YES □  Iffll -> 1 1  Ml]
IS  THE PATIENT CURRENTLY TAKING ANY OTHER AP's**? □  NO □
I f  so, which?___________________ / __ |__ mg/day Start of treatment:
YES ^^DISCONTINUED
dd mm  yy
/ __ |__ mg/day Start of treatment: |__|_| | |__|_
dd mm  yy
If the patient IS  NOT TAKING ANY AP DRUG, state why:
□ Clinical, remission □ Temporary and occasional discontinuation*
□ Non-compliance □ All AP's contraindicated (specify:________
DURING TODAY'S CHECK-UP, WAS THE AP DRUG CONFIRMED AS MONOTHERAPY ***?
CURRENT DOSE: |___ |___ | mg/day
YES NO
The patient will C O N T I N U E  
to take the assigned AP drug
The patient will S T O P  
tak in g  th e  assigned AP drug
FIX A FOLLOW-UP APPOINTMENT AS SOON AS POSSIBLE, 
COMPLETE TH E DRUG D IS C O N T IN U A TIO N  FORM 
AN D FAX T H IS  FORM TO 
ISTITUTO'MARIO NEGRI' (Fax: +39 02 39014300)
*  Discontinuation is 'tem pora ry ’ i f  i t  lasts less than 2 weeks and ' occasional’  when i t  occurs only once in 6 months.
* *  Do no t consider overlaps during titra tion (4 weeks from  randomisation) o r occasional parenteral therapy in case o f need.
* * *  The AP drug can be confirmed only i f  the treatm ent DISCO NTINUATIO N criteria have NO T been met.
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HAVE ANY OTHER DRUGS BEEN STOPPED OR ADDED SINCE THE LAST FOLLOW-UP?
(Consider every class and category of drugs - not iust psvchoactive drugs)
MOLECULE* DATE (dd/mm/yy)
0  S T A R T  o f  t r e a t m e n t  
D E N D  o f  t r e a t m e n t
□  S T A R T  o f  t r e a t m e n t  
D  E N D  o f  t r e a t m e n t
D  S T A R T  o f  t r e a t m e n t  
D  E N D  o f  t r e a t m e n t
D  S T A R T  o f  t r e a t m e n t  
0  E N D  o f  t r e a t m e n t
□  S T A R T  o f  t r e a t m e n t  
D  E N D  o f  t r e a t m e n t
* The use of L IT H IU M  or other mood stabilisers is permitted only if it was started a t  least 3  m onths p rio r to recruitm ent.
B M 3 Q  DISCONTINUATION MODULE
DISCONTINUATION Date: 1 1 1 1 1 1 j
dd mm yy
[ o ]  LACK OF EFFICACY © clinician's decision 
(D patient's decision 
© shared decision
Please specify:
[T] POOR TOLERABILITY © clinician's decision 
© patient's decision 
© shared decision
Please specify: lijliliillllS sig iiii!iiiiiiiii||||g |||||ii|g !i||i|||ii;ii||i||i
[2} PATIENT'S OWN INITIATIVE
Please specify: --------- -
[3 ] CLINICAL REMISSION -> ©  clinician's decision 
©  patient's decision 
© shared decision
Please specify:
C om pleted on I i | i | i_38 mm yy
By ____________________________________  S ig nature
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Site code I I I I Patient code
FOLLOW-UP FORM (FF)
(Please answer the following questions by marking the appropriate reply with a cross)
FOLLOW -UP DEADLINE □ DISCONTINUATION OF AP DRUG
DATE: | | J 1 1 1 1
□
dd mm  yy
MONTH 12
WAS THE FOLLOW-UP EXAMINATION POSSIBLE*? , 1
-n c'J , YE
I f  NOT, state the reason:
[~0~| The patient has died
f l l  The patient has withdrawn his/her consent
RT| The patient cannot be traced
|~3~| The time limits have expired* V
* The examination and sampling must take place not more than 21 days after discontinuing the assigned AP treatment or following the end of the 12-month treatment period.
I f  the  p a tie n t is s t i l l  ta k in g  the  ass igned AP d rug  ONE YEAR LATER, h e /she  w ill be  
asked the  fo llow ing  que s tion :
Has th e  drug you have been tak in g  fo r th e  last y e a r (s ta te  th e  n a m e)
(a )  helped to  m ake you feel better?
fo l  NO, my ailments have worsened
n i l  NO, the effect was insufficient
|~2~1 I  did not feel any effect
f~3~l YES, there has been some improvement
PH YES, there has been a considerable improvement
(b )  caused you any problem s? jo] YES, I  found it very difficult to tolerate
fT I  YES, it caused me several problems
{~2~| NO, it simply caused me some discomfort, but which I  found
tolerable
|~3~) NO, it did not cause me any discomfort
PHARMACOLOGICAL TREATMENT 
Is the patient taking ANTTHYPERTENSIN TREATMENT?
Is the patient taking INSULIN or HYPOGLYCAEMIC TREATMENT?
YES
YES
NO
NO
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Site code Patient code
CLINICAL EXAMINATION
H eight cm Body w e ig h t
I i i I , L
kg
j i
A bdom inal c ircum ference  
Hip c ircum ference
B P |___ |___|___ | /  |___ |___|___| m m H g
Report the presence of any of the fo llo w in g  disorders
cm
cm
Akathisia
Parkinsonian state 
Dystonia
Tardive dsykinesia 
ECG FIN D IN G * |
J I.
[y e s ! [n o ] 
Iy e s I [n o ] 
Iy e s I I n o | 
Iy e s I [n o !
Gynaecomastia 
Galactorrhea 
Dysmenorrhea 
Irregular menstruation
Iy e s I I n o  I ' 
Iy e s I I n o  I 
Iy e s I I n o  I 
Iy e s I [n o ]
HR bpm
Date
QTC
dd mm yy
msec
A ssessm ent o f ECG:
I f  ABNORMAL, specify:
Atrial fibrillation/flutter 
PM-induced rhythm  
Pathological Q waves
□  Other. Specify:_____________
[o] ABNORMAL [T] NORMAL
I n o  I Right Bundle Branch Block IyesI I n o  I
I n o  I Left Bundle Branch Block IyesI I n o  I
I n o  I LEFT ventricular hypertrophy IyesI I n o  I
GAF s c o re ** LUNSERS s c o re **  I | |
BLOOD SAMPLES FOR THE CENTRALISED LABORATORY
(glucose, triglycerides, HDL cholesterol, prolactin)
Taken on mfh J_yy Stick the adhesive label from  the sampling k it here
*  Keep copies of the electrocardiogram and of the finding in the GiSAS folder 
* *  Indicate the overall score of the scales and keep copies of them in the GiSAS folder
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Site code | _|___|___ | Patient code
BLOOD C H E M IS TR Y  TESTS
HAEMOCHROME W IT H  FORM ULA Sampling date | _ | _ | _ U _ | _ |
dd mm yy
Haemochromocytometric tests Leukocyte form ula
While blood cells (/m m 3) I I I I I
 ^ Neutrophils (% ) I I I I
Red blood cells (/m m 3) | | , | | million
Lymphocytes (% ) 1 1 1 1
Platelets (/m m 3) 1 1 1 1 1 1 Electrolytes
Haemoglobin (g /dl) | | | , | | Na+ (m Eq/l) I I I I
Haematocrit (% ) | | | K+ (m Eq/l) | | | | 
Mg++ (m g/dl) 1 1 1 1
LIFESTYLES  
f N.B. R efer ONLY to the period  fo llow ing recruitm ent)
CONSUM PTION OF
ALCOHOL [ y e s ]  [ n o ] CIGARETTES I y e s I  i n o i COFFEE I y e s I I n o  1
I f  YES, ind ica te  the  average d a ily  co n su m p tio n :
wine (125-m l glasses ) n° | | | Cigarettes n° | | | coffee-cups nc L _ l _I
beer (33-cl cans) n° | | |
hard drinks (small glass) n° | | |
PHYSICAL A C T IV IT Y
AT W ORK IN  FREE T IM E
Sedentary (e.g. derical worker, student) I 0 | Little, Sedentary (e.g. reading, watching TV)
m Standing (e.g. shop assistant housewife, teacher) I 1 | Mild exercise (e.g. short walks, yoga, riding a bicyde)
m Average (eg. maid /  manservant; deaning) |2~| Moderate exercise (e.g. regular sports or open-air activity)
a Heavy (eg. gardener, farmer, industrial worker) |~3~1 Intense activity (e.g. intense sports)
s Very heavy (e.g. builder, demolition worker, sports)
a Not working
Has the patent attended psycho-educational weight management or diet improvement 
courses or activities?
YES NO
Has the patient controlled or changed his/her diet, even only partly, 
for reasons of weight or health (e.g. low-sodium or low-calorie diet)?
NO, never YES,
©  < 
several tim es YES,
2 )
always
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Site code I I I I Patient code
Has the patient been hospitalised after recruitment in a non-psychiatric wand? YES NO
I f  SO: a) due to what disease:
b) Was the patient subsequently transferred to a non-psychiatric 
long-stay ward or residential facility? YES NO
T A K IN G  T H E  P A T IE N T  IN T O  P S Y C H IA T R IC  CARE  
f N.B. Report events occurring AFTER RECRUITMENT)
Has the patient been hospitalised in a psychiatric ward, day hospital or 24-h r Mental
Health Unit or other service for acute patents? YES NO
Has the patient been admitted to a RESIDENTIAL FACILITY?
YES NO
Has the patient attended a DAYCARE CENTRE?
YES NO
I f  th e  an sw er to  any  o f th e  foregoing  questions is in th e  a ffirm a tiv e , specify;
(0=Psychiatric ward; l= D a y  hospital; 2=  24-hr Mental Health Unit; 3 =  Other service for acute patients; 4 =  Residential 
facility; 5=  Day-care centre)
S ite P eriod S ite P eriod
(dd/mm/yy) (dd/mm/yy)
i i 1 1 1 1 1 1 1 -» 1 1 1 1 1 1 1 i i 1 1 1 1 1 1 1 -» 1 1 1 1 1 1 1
i i 1 1 1 1 1 1 1 "> 1 1 1 1 1 1 1 i i 1 i 1 i 1 i 1 -M  i 1 i 1 i 1
i i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 i i 1 i 1 i 1 i 1 -M  i 1 i 1 i 1
i i 1 1 1 1 1 1 1 ^ 1  1 1 1 1 1 1 i i 1 i 1 i 1 i 1 -> 1 i 1 i 1 i 1
How many times has the patient been seen by the TREATING PSYCHIATRIST? n °
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[no] IF  SO,: ® occasionally
® regularly
[Non IF  SO,: ® occasionally
® regularly
InoI IF  SO,: ® occasionally
® regularly
[no] IF  SO,: ® occasionally
® regularly
[no] IF  SO,: ® occasionally
® regularly
[no] IF  SO,: ® occasionally
® regularly
[no] IF  SO,: ® occasionally
® regularly
[no] IF  SO,: ® occasionally
® regularly
Has the patient had contacts with OTHER PROFILES?
(N.B. DO not consider any periods spent in hospital or in residential faalities)
IF SO, which? (always mark one of the two possible replies with a cross)
1) Psychologist [yes] [ ] i f s o    | specify:
2 ) A n o th e r p sych ia trist iyesi In i i f s o    | specify:
3 ) Nurse
4 ) E d u c a to r/re h a b  personnel
5 ) O th e r h ea lth care  professional
6 ) O th e r social care  professional
7 ) Social w o rke r
8 )  GP
A C T IV IT IE S  (always m ark one o f  the two possible replies with a cross)
YES NO
®  private specialist 
®  health service 
®  private specialist 
®  health service
3.
4.
5.
6. 
7.
Psychiatric interviews 
Psychological support interviews
IF  SO, specify: ®  occasionally 
®  regularly
Individual psychotherapy
Group psychotherapy
Interviews with family members 
IF  SO, specify:
YES NO
o o 
o o
®  occasionally 
®  regularly
Specific family support activities
IF  SO, specify: Psycho-educational activities
Family therapy
Job introduction/support
YES NO
IF  SO, specify: Preparatory courses or training o o
Job support o o
Other rehab activities
Multi-family groups 
Other
Job introduction 
Other
YES NO
IF  SO, specify: Expressive activity groups o o Discussion groups
Social skills o o Daily life skills
Structured recreational activities o o Supported housing
I Y E S  | I N O  |
I Y E S  | I N O  |
| Y E S |  [ N O |  
| Y E S |  I N O |  
I Y E S  | I N O  |
l Y E S l  I N O j
YES NO
o o 
o o
I y e s I I n o  I
YES NO
o o 
o o
| y e s | | n o |
YES NO
o o 
o o 
o o
9.
10.
Attendance of self-help groups
Home visits or activities 
IF  SO, how many times? n° I I I I
I Y E S  I I N O  | 
| Y E S |  I N O  |
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Site code I I I I Patient code
A C T IV IT IE S  FOR PROM OTING PA TIEN T COMPLIANCE W IT H  
THE ASSIGNED TREATMENT, AFTER RECRUITMENT
(always mark one of the two possible replies with a cross and refer only to SPECIFIC NOT OCCASIONAL 
ACTM7IES):
1. STRATEGIES FOR IMPROVING THE THERAPEUTIC ALLIANCE
Has the patient's personal experience and his/her subjective perception of both the
beneficial and undesired effects of the AP treatment been investigated? 1 Y E S  I 1 NO 1
Have the goals of the AP treatment been shared with the patient? | Y E S  | pNO~l
Has the patient been involved in planning and monitoring the AP therapy? 
2. BEHAVIOURAL INTERVENTIONS
| Y E S  | fNOl
a) for improving attendance of foilow-up examinations
Has the patient received regular telephone or mailed reminders? 1 Y E S  | I noI
Has the patient been permitted to come for visits even without an appointment? j Y E S  | fNOl
Has the patient been provided with guidance brochures? I Y E S  | l~NOl
Have the procedures for accessing the service been negotiated with the patient? 
(e.g. appointments always at the same time and on the same day of the week)
1 Y E S  | l~NOl
b) for improving daily compliance with the prescribed treatment
Has the dosage been optimised and the manner of taking the doses simplified? I y e s I [no]
Has the treatment been delivered to the patient in a loose form or in a customised pack? 1 y e s  | fNOl
Has the treatment been administered directly to the patient by a staff member? 1 Y E S  | fNOl
Has administration of the treatment been entrusted to a family member? 1 Y E S  I l~NOl
3. PSYCHO-EDUCATIONAL INTERVENTIONS
Has a psycho-educational activity been conducted with regard to compliance with AP treatment? 
I f  so: □ individual □ group
| y e s | fNOl
4. PSYCHOTHERAPY
Has a psychotherapeutic activity been conducted to improve the patient's motivation and insight? 
I f  so: o  cognitive □ short psychodynamic □ motivational therapy
| y e s | l~NOl
5. SOCIAL AND FAMILY SUPPORT INTERVENTIONS
Have the patient's family been involved in planning and monitoring the AP treatment? | Y E S  | [NOl
Have the goals of the pharmacological treatment been shared with the patient's family? I y e s I l~NOl
Has a family psycho-educational activity been conducted? | y e s | l~NOl
Have specific activities been conducted to improve the patient's social network? 
6. ORGANISATIONAL STRATEGIES
1 y e s | fNOl
When the patient was discharged from hospital or residential facility, was he/she placed in contact with
the community mental health team?
Has an integrated treatment for both the schizophrenia and the substance abuse been
| Y E S  | l~NOl
implemented? I y e s ! l~NOl
Com pleted on I I I I I I I
- 3cT "nlrh yy
by __________ S ig nature
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S u rv e y  o n  ra n d o m iz e d  c l i n i c a l  t r i a l s  (RC T) in  s c h iz o p h r e n ia
The p resen t su rvey is addressed to a ll the c lin ic ians w ork ing in the centers where GiSAS 
tr ia l has been activa ted , n o t  o n ly  t o  t h o s e  w h o  a r e  c u r r e n t l y  in v o lv e d  i n  t h e  s t u d y
Code |___|___|___| Date | _ i_ | _ i_ | _ i_ |  Age |__|__|
Gender [m] [F] Years of psychiatric clinical activity |__|__|
1. Setting of your clinical activity:
□  In p atien ts  acute w ard
□  O utp atien t clinic
□  Residential fac ility
2. Are official guidelines for the treatm ent of 
schizophrenia adopted in your Department?
□  YES
□  NO
3. Did you ever take part to a RCT on schizophrenia?
Do not consider participation in the GiSAS trial.
□  YES
□  NO
I f  YES, please specify the number of RCT you took 
part to:
independent Studies I ndustry-sponsored S tudies
n° I I I n° |___ |__ |
I f  NOT, why? Please check ju s t 1 box
□  I  don 't have tim e
□  No one ever ask m e to participate
□  I  don't think that casual assignment of
treatm ent (randomization) is appropriate
□  I  don't think participation could lead to an 
improvement of my clinical practice
□  IVe never received interesting proposals
4. Did you ever take part to RCTs on non-
pharmacological interventions in schizophrenia?
□  YES
□  NO
5. In  your opinion, which are the main 
problems with subjects recruitm ent in a 
pharmacological RCT on schizophrenia?
Please number 3  answers from 1 to 3 in order of decreased 
importance
Difficulties in obtaining patient's informed consent 
Poor patient's cooperation 
The fear of recurrence 
Time constraints
The study protocol limits clinical choiches 
Fear of losing therapeutic alliance 
Ethical doubts about randomization
Fear of legal consequences
The colleagues are not well disposed 
towards participation
Inclusion/exclusion criteria 
To change current medication
6. In  your opinion, why are currently being 
implemented RCT on schizophrenia?
Please check ju s t 1 box
□ To objectively evaluate drugs' effectiveness and 
tolerability
□ To let the drugs being prescribed regardless of 
the final results
□ To develop scientific evidence with the aim to 
improve clinical practice
□ to get results that promote the new drugs
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7. Have you been adequately informed about (SSAS trial?
Please check ju s t 1 box
□  YES, I  received much inform ation
□  YES, I  received sufficient inform ation
□  NO, I  did not receive sufficient inform ation
□  NO, I  did not receive inform ation a t all
8. In  your opinion, which is the main difficulty that 
faces the clinician taking part to the GiSAS trial?
Please check ju s t 1 box
□  I 'm  not aw are  of th e  study
□  Problems w ith  th e  prescription of an 
antipsychotic m onotherapy
□  The 3 study drugs are hardly considered 
smilar
□  To have no choice in regard to  the  
antipsychotic prescribed
□  The com plex ity  of study protocol and  
procedures
□  The only inclusion o f schizophrenic patients
□  previous negative experiences w ith  the  
study drugs
□  I t  is hard to im p lem ent a RCT in the  
rountine o f Ita lia n  m ental health services
9. Are you currently involved in the 
recruitment for GiSAS trial?
□  Yes
□  NO
I f  Yes, did you succeed in including a t least 1 
subject?
□  YES
□  NO
10. Based on your knowledge and experience, 
please number the following 3 drugs both in 
order of better efficacy and of better tolerability.
Please indicate with number 1 the best medication and go ahead 
with 2 and 3. I f  you consider two or more of them to be equivalent 
assign them the same number.
EFFICACY TOLERABILITY
HALOPERIDOL HALOPERIDOL
OLANZAPINE OLANZAPINE
ARIPIPRAZOLE ARIPIPRAZOLE
11. Based on your experience, which is the best 
antipsychotic drug?
Please consider a ll the drugs a t your disposal
1 2 .  Not taking into account dazapiney do you think 
there are differences in terms of effectiveness 
between first- and second-generation antipsydiotics?
Please check ju s t 1 box
□  YES, first-generation antipsychotics are more effective
□  YES, serond-generation antipsychotics are more effective
□  NO, there are no differences in terms of effectiveness
13. Not taking into account dozapine, do you think 
there are differences in terms of tolerability between 
first- and second-generation antipsychotics?
Please check ju s t 1 box
□  YES, first-generation antipsydiotics are more tolerable
□  YES, seoond-generation antipsychotics are more tolerable
□  NO, there are no differences interns of tolerability
14. What does mainly influence you in the choice of the 
antipsychotic cfrug fora patient affected by schizophrenia?
Please number 3 answers from 1 to 3  in order of decreased importance
Evidence based efficacy 
Patient's medication adherence
Drug tolerability 
Patient's preference  
Drug dosage and fo rm ulations  
My personal evaluation of drug effects
15. Which is your main source of knowledge 
and information on the use of antipsychotic 
medication?
Please number 3 answers from 1 to 3 in order of decreased importance 
Personal reading of scientific publications
Attending conferences
Information by drug-company representatives
Personal clinical experience and sharing 
information with colleagues
Label indications and AIFA warnings
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TREATMENT RETENTION W ITH REBOXETINE IN  YEARS 2000^2006: A 
PHARMACO-EPIDEMIOLOGICAL COMPARATIVE STUDY.
Reboxetine has been used since 1997 for the treatment of depression in many 
European countries. It  is supposed to act by binding to the noradrenaline transporter 
and blocking the reuptake of extracellular noradrenaline. Although reboxetine has been 
claimed to show superior efficacy than placebo and similar efficacy to SSRIs, its clinical 
relevance was questioned, and its preliminary approval was declined by US Food and 
Drug Administration (FDA) in 2001 [1].
In a recent report on newer antidepressants of the German Institute for Quality and 
Efficiency in Health Care (IQWiG), while mirtazapine and bupropion proved to be 
effective in alleviating symptoms, reboxetine resulted ineffective and potentially 
harmful [2]. The main findings of the meta-analysis on reboxetine were recently 
published on the British Medical Journal [3]. This paper by Edyng and colleagues 
provides an emblematic example of publication bias, in which the previously favourable 
evidence on the risk-benefit profile of reboxetine was overturned by the addition of 
unpublished data. Thirteen short-term randomised clinical trials (RCTs) of reboxetine 
against placebo or selective serotonin reuptake inhibitors (SSRIs), comprising a total of 
4098 patients, were analysed, of these, data on 3033 subjects were unpublished. In 
the reboxetine versus placebo comparison no significant differences in remission rates 
were shown, but reboxetine was inferior for harm outcomes. Moreover, reboxetine was 
inferior to SSRIs, and, in particular, it was inferior to paroxetine for response and 
remission rates and to fluoxetine for withdrawals owing to adverse events. The authors 
included an additional analysis showing that published evidence overestimated 
reboxetine efficacy while underestimating harm [3]. This typical effect of publication 
bias was highlighted in other recent research on antidepressants [4, 5]. Turner and
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colleagues (2008) reported that among 74 FDA-registered RCTs on antidepressants 
31%, accounting for 3449 study participants, were not published [4]. According to the 
published literature 94% of the trials on antidepressants were positive, but only 51% 
were positive when unpublished studies were included. Separate meta-analyses of the 
published and unpublished data sets showed that the increase in effect size ranged 
from 11 to 69% for individual drugs and that was 32% overall [4].
In most European countries, including Italy, antidepressant prescribing doubled from 
1993 to 2002, and within this rise, the use of selective serotonin reuptake inhibitors 
(SSRIs) increased tenfold [6]. Had clinicians known for the past two decades that the 
evidence for effectiveness was inflated perhaps they would have been more judicious 
in their use of antidepressants [7]. The case of reboxetine, however, seems to 
represent an exception. As was already pointed out by Edyng and colleagues (2010), in 
fact, reboxetine has a very small market share in Europe [8, 9]. Thus, it would appear 
that over the last decade the prescribing clinicians have voted against its use. Market 
success can be influenced by a number of factors other than drug's efficacy. 
Nevertheless, we can hypothesize that reboxetine poor effectiveness may have played 
a role in its commercial failure. In particular, a lower prescription trend might be 
associated with a higher rate of drug discontinuation which in turn could be interpreted 
as an indicator of ineffectiveness. The case of reboxetine represented therefore a 
singular and unique occasion to test out if a lack of efficacy would have been reflected 
over the years by a higher proportion of premature drug discontinuations.
The present analysis aimed to compare the use of reboxetine with that of fluoxetine 
and paroxetine in a large population sample in northern Italy. Trends of 
antidepressants' utilization from 2000 to 2006 and rates of prolonged and persistent 
use were compared. A secondary aim was to compare reboxetine prescribing trends 
with those of mirtazapine, another newer antidepressant with a very similar history in
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terms of approval for marketing and admission to reimbursement by the Italian 
National Health Service (SSN). -
In Italy, only between 1999 and 2001 were most second-generation antidepressants 
(including SSRIs and reboxetine) admitted for full reimbursement by NHS without 
restrictions. Thus, only since year 2000 are regional drug administrative data free from 
bias related to reimbursement restrictions and can be reliably used to evaluate and 
compare antidepressants' utilization in primary and secondary healthcare [10].
An analysis of the prescriptions of reboxetine, fluoxetine, paroxetine and mirtazapine to 
the adult population (18-65 years) of three Italian administrative provinces was 
performed. The study catchment area includes both rural and urban contexts and 
comprises nearly 30% of the population of Lombardy. In particular, the present study 
employed a population-based dataset containing prescribing records for 1 704 923 
inhabitants from January 1, 2000 to December 31, 2007. It is part of a pharmaco- 
epidemiological collaborative project on drug prescription in Lombardy (the EPIFARM- 
Elderly Project). The structure of this database, routinely updated for administrative 
reasons, has been described in details elsewhere [11]. Briefly, for a drugs to be 
reimbursed by the NHS patients need a prescription from their general practitioner 
(GP) or a specialist and then get the medicines free of charge from retail pharmacies. 
Each local pharmacy provides these prescriptions to the Regional Health Authority to 
get reimbursed. Finally, the Regional Health Authority electronically stores these 
prescriptions into the Regional Drug Administrative Database.
We defined antidepressant "use" as the proportion of those who had at least one 
recorded prescription. We then distinguished those who were prescribed at least four 
drug packages ("prolonged use") from the rest of the group ("occasional use").
Since the premature discontinuation of the prescribed antidepressant can be 
considered a direct consequence of treatment failure related to adverse events or lack 
of therapeutic effect, persistence was adopted as a proxy indicator of effectiveness. To
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identify the annual rates of persistence, we selected those who had (a) at least one 
recorded prescription, (b) no prescriptions in the previous year and (c) a treatment 
duration of at least six months. Since information on the individual dosage regimen 
was missing, we considered adequate the consecutive prescription of at least 6 drug 
packages within 8 months from the first dispensing which for reboxetine corresponded 
to a trial of 180 consecutive defined daily doses [12].
To analyse changes over time of the proportion of prolonged to occasional use and of 
persistence to non-persistence a Cochran-Armitage test for trend was used, splitting 
the Chi-squared value to obtain a test for the presence of a linear trend and a test for 
the deviation from linearity [13]. We then calculated the mean yearly rate of change in 
the proportion of prolonged to occasional use [14].
Differences in terms of prolonged and persistent use between reboxetine, fluoxetine 
and paroxetine were calculated through Chi-square tests; odds ratios (ORs) and 
confidence intervals (CIs) were calculated. A Hochberg adjustment was used to take 
into account the presence of multiple comparisons.
Logistic regression analyses were used to study the evolution of the incidence of 
antidepressant using calendar year as a continuous variable. The different 
antidepressants were compared in terms of mean annual incidence and slope of annual 
incidence. ORs are reported taking paroxetine as the reference category. Tests were 
done using JMP version 9.0, SAS Institute Inc.
Across the study period, the mean number of subjects per year who were prescribed 
and dispensed at least one of the study drug was 211 883. Figure 1 shows the annual 
prevalence rates of the use and of the prolonged use of the four study drugs from 
2000 to 2006. The use of paroxetine and fluoxetine peaked in 2002 and then slightly 
decreased. On the whole, however, the growth of the prescriptions of both SSRIs was 
dramatic: from 0.42% to 1.16% for paroxetine, and from 0.18% to 0.39% for
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fluoxetine. The prescripition rates of mirtazapine gradually increased all through the 
study period: from 0.07% in 2000 to 0.13% in 2006. On the contrary, the prescription 
rates of reboxetine showed a different trend and progressively decreased from 0.20%  
in 2000 to 0.04% in 2006.
Table 1 shows the annual rates of prolonged and persistent use for reboxetine, 
fluoxetine and paroxetine from 2000 to 2006. The overall proportion of prolonged to 
occasional use was significantly lower for reboxetine (42%) than for paroxetine (57%; 
OR 0.55, 95% Cl 0.53/0.57, Chi-square, p<0.001, Hochberg adjusted) and fluoxetine 
(58%; OR 0.53, 95% Cl 0.51/0.55, Chi-square, p<0.001, Hochberg adjusted). The 
annual rates of the prolonged use of paroxetine and fluoxetine were very similar and 
showed comparable changes. For both drugs, rates significantly increased over time: 
from 58% in 2000 to 63% in 2006 (test for trend, p<0.001). These annual changes, 
however, were characterised by a highly significant heterogeneity (deviation from 
linearity, p<0.001). Also reboxetine prolonged use showed a statistically significant 
growth: from 33% in 2000 to 52% in 2006 (test for trend, p<0.001). It  increased by 
4% per year with no significant deviation from linearity (deviation from linearity, 
p=0.98). The overall proportion of persistence to non-persistence was significantly 
lower for reboxetine (23%) than for paroxetine (34%; OR 0.60, 95% Cl 0.56/0.64, 
p<0.001, Hochberg adjusted) and fluoxetine (36%; OR 0.53, 95% Cl 0.49/0.57, 
p<0.001, Hochberg adjusted). The annual rates of persistence ranged 21-27% for 
reboxetine, 28-43% for paroxetine and 30-46% for fluoxetine. There was a certain 
fluctuation in annual rates of non-persistence and no significant time trends were 
evident. As shown in Figure 2, incident use of reboxetine, fluoxetine and paroxetine 
significantly decreased from 2000 to 2006 (p<0.001 for each of the three drugs). Both 
reboxetine and fluoxetine had lower mean incidence rates than paroxetine (fluoxetine: 
OR 0.40, 95% IC 0.40-0.41; reboxetine: OR 0.07, 95% IC 0.07-0.07). Similarly, more 
pronounced decreasing trends were observed for reboxetine and fluoxetine if
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compared with paroxetine (fluoxetine: OR 0.96, 95% IC 0.95-0.97; reboxetine: OR
0.81, 95% IC 0.080-0.83). In particularfTeboxetine showed the most relevant decrease 
in incident use: from 0.97%o in 2001 to 0.19%o in 2006.
Our results showed, for reboxetine, a progressive fall of the prescriptions in years 
2000-2006 and higher treatment discontinuation rates than for fluoxetine and 
paroxetine. Reboxetine was the only antidepressant showing a decrease of the 
absolute number of users. Compared with fluoxetine and paroxetine, moreover, 
reboxetine had the most significant annual decrease of new prescriptions and the 
lowest rates of prolonged and persistent use. Thus, the use of reboxetine showed a 
decline in terms of prevalence and incidence and was associated with higher 
discontinuation rates at both the initiation and the maintenance phase of treatment. 
The major strength of the present study is the reliability of the prescription data. The 
study dataset, in fact, included all the reimbursable prescriptions which were issued by 
GPs and specialists and were subsequently collected by patients in local pharmacies. A 
first study limitation is the absence of clinical data that did not allow to detect those 
who received antidepressant prescription properly. Moreover, although our records 
reflect both drug prescription and dispensing, no information on whether the study 
subjects eventually took the prescribed drugs was available. Finally, data are 
observational and we were not able to control for confounder at the patient level.
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Fluoxetine and paroxetine showed an increase in their prescriptions from 2000 to 2006. The 
increase of their prevalent use, however, was not,mirrored by incident use, which significantly 
decreased. The discordance observed between prevalent and incident use is consistent with 
previous studies and has been explained by the persistence of antidepressant treatment [15, 16]. 
Namely, it is not that more people are being prescribed antidepressants but that treatment periods 
have became longer. Furthermore, the decrease in rates of new prescriptions can be interpreted 
as a consequence of the burst of growth observed for fluoxetine and paroxetine between 2000 and 
2001.
In year 2000 the prescription rates of reboxetine and fluoxetine were very similar, but afterwards 
something changed. As was pointed out in previous work, the change of drug reimbursement 
policies could reliably explain the peak of SSRIs' prescriptions between 2001 and 2002 [10]. The 
same effect, however, was not evident for reboxetine. Moreover, while reboxetine is still an 
expensive brand-name antidepressant both paroxetine and fluoxetine went off patent during the 
study period and it is unlikely that the drug companies had incentive to promote them [17]. The 
comparison between reboxetine and mirtazapine gave unexpected results. The prescription rates 
of the two drugs had completely reversed trends, and again this can hardly be ascribed to 
marketing factors. What lies, then, behind the decline of reboxetine prescriptions?
Our findings, although being observational, are consistent with those of Eyding et al. (2010) [3]. 
In their meta-analysis, outpatient setting was highlighted as the strongest negative effect modifier 
for reboxetine. This could partly explain our results since virtually all subjects were 
community-dwelling adults and GPs accounted for more than 90% of antidepressant prescriptions. 
Moreover, we can hypothesize that the higher discontinuation rates of reboxetine have affected its 
perception as a poorly effective antidepressant and that this resulted in the decline of its 
prescriptions.
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